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The Council of Canadian Academies
Science Advice in the Public Interest
The Council of Canadian Academies (the Council) is an independent, not-for-profit 
organization that supports independent, science-based, authoritative expert 
assessments to inform public policy development in Canada. Led by a 12-member 
Board of Governors and advised by a 16-member Scientific Advisory Committee, 
the Council’s work encompasses a broad definition of science, incorporating the 
natural, social, and health sciences as well as engineering and the humanities. 
Council assessments are conducted by independent, multidisciplinary panels of 
experts from across Canada and abroad. Assessments strive to identify emerging 
issues, gaps in knowledge, Canadian strengths, and international trends and 
practices. Upon completion, assessments provide government decision-makers, 
researchers, and stakeholders with high-quality information required to develop 
informed and innovative public policy. 
All Council assessments undergo a formal report review and are published and 
made available to the public free of charge in English and French. Assessments 
can be referred to the Council by foundations, non-governmental organizations, 
the private sector, or any level of government. 
The Council is also supported by its three founding Member Academies: 
The Royal Society of Canada (RSC) is the senior national body of distinguished 
Canadian scholars, artists, and scientists. The primary objective of the RSC is 
to promote learning and research in the arts and sciences. The RSC consists 
of nearly 2,000 Fellows — men and women who are selected by their peers 
for outstanding contributions to the natural and social sciences, the arts, and 
the humanities. The RSC exists to recognize academic excellence, to advise 
governments and organizations, and to promote Canadian culture.
The Canadian Academy of Engineering (CAE) is the national institution 
through which Canada’s most distinguished and experienced engineers provide 
strategic advice on matters of critical importance to Canada. The Academy 
is an independent, self-governing, and non-profit organization established 
in 1987. Fellows are nominated and elected by their peers in recognition of 
their distinguished achievements and career-long service to the engineering 
profession. Fellows of the Academy, who number approximately 600, are 
committed to ensuring that Canada’s engineering expertise is applied to the 
benefit of all Canadians.
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The Canadian Academy of Health Sciences (CAHS) recognizes individuals of 
great achievement in the academic health sciences in Canada. Founded in 2004, 
CAHS has approximately 400 Fellows and appoints new Fellows on an annual 
basis. The organization is managed by a voluntary Board of Directors and a 
Board Executive. The main function of CAHS is to provide timely, informed, 
and unbiased assessments of urgent issues affecting the health of Canadians. The 
Academy also monitors global health-related events to enhance Canada’s state 
of readiness for the future, and provides a Canadian voice for health sciences 
internationally. CAHS provides a collective, authoritative, multidisciplinary 
voice on behalf of the health sciences community.
www.scienceadvice.ca
@scienceadvice
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Message from the Chair
Regulators have a responsibility to warn individuals about the potential harms of 
drugs and other health products. Although they use several tools to communicate 
risks, we know little about whether their messages are reaching and influencing 
the views and behaviours of various populations. Without evaluative information 
on who is paying attention, what they are learning, and what impacts are 
occurring, mistakes may be repeated and opportunities to demonstrate success 
may be lost. The evidence is clear regarding the positive value in undertaking 
evaluation of risk communication. With dedicated commitment and resources, 
there is an opportunity for Canada to take international leadership in this 
field. This assessment is intended to inform the continuing dialogue across 
Canada and internationally on the evaluation of the effectiveness of health 
risk communication.
The Expert Panel on the Effectiveness of Health Product Risk Communication 
is deeply appreciative of the opportunity to explore this important question 
and of the input and assistance it received throughout the course of its work. 
Several individuals provided helpful advice and assistance early in the process. In 
particular, Matthew LeBrun, Scientific Evaluator, and Lisa Lange, Director, at the 
Health Products and Food Branch at Health Canada provided background on 
the work of the Therapeutic Effectiveness and Policy Bureau as well as guidance 
on the impetus for the report and scope of the assessment questions. The Panel 
also wishes to thank the report reviewers for making valuable suggestions for 
improving the quality and comprehensiveness of its work. The final report 
would not have been the same without their sage advice.
Finally, the Panel is most grateful for the outstanding support that it received 
from staff members of the Council of Canadian Academies.
Annette M. Cormier O’Connor, FRSC, FCAHS  
Chair, Expert Panel on the Effectiveness of Health Product Risk Communication 
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Executive Summary
Risk communication is an important component of improving the health 
and safety of Canadians. For numerous departments and agencies at all levels 
of government, as well as public and private organizations, effective risk 
communication can protect Canadians from preventable hazards. The Minister 
of Health, on behalf of Health Canada (the Sponsor), asked the Council of 
Canadian Academies (the Council) to provide an evidence-based and authoritative 
assessment of the state of knowledge on measurement and evaluation of health 
risk communication. This assessment focuses on identifying tools, evaluation 
methods, gaps in the literature, and barriers and facilitators to carrying out 
successful communication and evaluation activities. Specifically, this assessment 
examines the following questions:
How can the effectiveness of health risk communications be measured 
and evaluated?
• What types of instruments/tools are currently available for health 
risk communication? 
• What methodological best practices can be used to evaluate the reach, use 
and benefit of health risk communication? 
• What research could be done to inform the measurement of the effectiveness 
of risk communications? 
• What are the existing barriers to effective risk communications and what best 
practices exist to address these challenges? 
To address the charge, the Council assembled a multi-disciplinary panel of 
11 experts (the Panel) from Canada and abroad. The Panel’s composition 
reflected a balance of expertise, experience, and demonstrated leadership in 
academic, clinical, and regulatory fields. Each member served as an informed 
individual, rather than as a representative of a particular discipline, patron, 
organization, or region.
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The focus, as specified by the Sponsor, is risk communication for health 
products, which includes pharmaceuticals, biologics and vaccines, medical 
devices, and natural health products. Consumer products, other products, 
and general health promotion communications were considered out of scope. 
Health product risks generally involve known side effects, medication and 
medical device errors, product defects, and uncertainty in information. From 
its discussions and review of the current state of the evidence, the Panel 
identified four key findings that serve to answer the charge put forward by 
Health Canada. The following executive summary presents those findings; a 
more detailed discussion continues in the Panel’s full report. The Panel also 
created a report roadmap to guide the reader through each chapter of the full 
report (Figure 1). It summarizes the discussion of the context of health product 
risk communication, related tools, and the role evaluation plays throughout 
the entire communication process.
Recognition of the importance of dialogue and ongoing relationships is 
prompting a paradigm shift for risk communication.
Risk can be defined in a number ways, but ultimately refers to probabilities of 
different possible outcomes and the severity of those outcomes. Risk cannot 
always be quantified and often involves a range of uncertainties. It evolves 
with changing awareness and views of hazard and safety and is influenced by 
social and cultural factors. Communicating about health risk can therefore not 
be reduced to a simple formula. The process includes analysis of a potential 
threat, understanding what is important to the populations meant to receive 
a risk communication, and disseminating the message in an understandable 
and appropriate way. Risk communication is also fundamentally a socially and 
politically interactive process in which individuals are informed of real or 
potential risks and are expected to use this information to undertake personal 
strategies to manage that risk.  Although often approached as a simple one-
way transfer of information from an organization (e.g., government body, 
pharmaceutical company) to an individual, risk communication is a complex 
process of ongoing relations that involve multiple stakeholders and interactions 
at many different levels and points in time (i.e., multi-way and multi-level 
transfer of information). 
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 New Paradigm for Risk Communication
Governance  •  Complexity  •  Uncertainty  •  Empowerment  •  Timeliness  •  Transparency
Goals of Risk 
Communication
• Development
• Reach
• Use
• Impact
Risk Communication
• Characterizing and 
    Managing Risk
• Creating Messaging
• Ongoing Partnership 
    and Exchange
Health Product Risk 
Communication Tools
• Ongoing
• Incident(s)-Based
• Defect-Error
Stages
Needs Assessment  •  Pre-Testing  •  Process/Implementation  •  Outcome
Evaluation Questions and Approaches
Synthesis  •  Records-Based  •  Self-Reported  •  Experimental  •  Mixed Methods
Institutional Commitment and Resources
Figure 1 
Evaluation of Health Product Risk Communication – A Report Roadmap 
Chapter 2 (represented in blue) describes the context of risk communication. A paradigm shift shapes 
contemporary risk communication by building on the learning from the past to address new communication 
challenges related to building strong and meaningful relationships. This new paradigm also reframes 
the goals of risk communication to broaden potential outcomes related to development, reach, use, and 
impact. In this context specific health product risk communication tools are created and implemented to 
fulfill regulatory responsibilities. Chapter 3 (represented in grey) examines both established and emerging 
tools used to communicate ongoing, incident(s)-based, and error-related health product risk information. 
Chapter 4 (represented in red) explores how such communication tools can be evaluated to ensure they 
are achieving their goals. However, evaluation is an integral component to the entire risk communication 
process and not simply an end-stage task carried out after the communication is completed. There is 
no universal evaluation approach; rather selecting the most appropriate approach is a function of the 
evidence required and resources available to answer specific evaluation questions. These questions stem 
from identifying and integrating information needs and motivations as well as the attributes of a risk 
communication including type of risk communication tool, stage (needs assessment, pre-testing, process/
implementation, and outcome), and communication goals. Chapter 4 also explores how to ensure the 
foundation for evaluation — institutional commitment and sufficient resources — is secured.
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The understanding of, and approach to, risk communication has evolved. 
Contemporary risk communication typically comprises the following:
• Characterizing and managing risk: using accurate science and data analysis to 
establish risk assessment and management strategies, including identifying 
what scientific information and uncertainty need to be communicated and 
understanding the larger context and population needs inherent to a given 
risk communication. 
• Creating messaging: applying multidisciplinary knowledge of how individuals 
interpret, process, and respond to risk-related information, and how socio-
cultural factors shape those activities, to create messages that are understood 
and meaningful. A large body of research specific to health risk and the 
science of science communication can inform this process.
• Ongoing partnership and exchange: recognizing the influence and importance 
of broader societal factors to focus on communicating messages in a way 
that respects dialogue, exchange, and relationship-building. This can be 
fostered by understanding and appreciating the senders and receivers of 
information and other stakeholders, and ensuring meaningful dialogue in 
which all parties learn from the experience.
These activities will ultimately lead to the development of specific communication 
products that should be assessed for their reach, how they are being used, and 
whether they are having an impact. However, evaluation is more than an end-
stage task carried out after the risk communication is completed. To ensure 
that communications are meeting their goals, getting through to people, and 
avoiding any adverse or unintentional effects, evaluation is needed throughout 
the entire risk communication process, starting with planning and development.
Recognition of the importance of multi-way dialogue and the need to build, 
foster, and maintain strong relationships over time is prompting a paradigm 
shift for risk communication. This emerging paradigm builds on the learning 
from the past to address new challenges relevant for evaluation of health 
product risk communication: 
• Governance: addressing the challenges that stem from shared responsibility 
within the risk management and communication environment by establishing 
who is responsible for what and ensuring coordination, exchange, and flow 
of data and information across organizations and jurisdictional boundaries.
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• Complexity: navigating the inherent complexities of the risk and the 
communication environment that comprises multiple stakeholders through 
recognition of shared responsibility, potentially competing priorities, and 
the need for coordination and collaboration.
• Uncertainty: communicating uncertainty and multiple interpretations of the 
evidence in a manner that is clear, understandable, proactive, and central 
to the risk communication at hand as well as communicating what is being 
done to minimize or reduce uncertainty over time.
• Empowerment: moving from providing prescriptive statements to enabling 
solutions and empowerment by creating messaging that is appropriate 
for understanding, comprehension, and action; involving the receivers of 
information and other stakeholders in the decision-making process; and 
focusing on long-term relationships. 
• Timeliness: ensuring timely and proactive responses that build trust over time 
through having communication guidelines, using new enabling communication 
sources, and establishing relationships. 
• Transparency: ensuring reasoned transparency that increases the public’s 
access to and ability to understand health information, through striking a 
balance between openness, urgency, and confidentiality.
These dimensions are variable depending on the nature and context of the 
risk and may evolve. They do not exist in isolation, and elements of one can 
affect another.  A common theme that cuts across dimensions is the role of 
trust in building relationships over time. 
Regulators around the world use similar health product risk communication 
tools that are not systematically evaluated.
The Canadian regulatory context for health product risk communication is similar 
to that in other jurisdictions, including the United States, the United Kingdom, 
Australia, and Europe. Although regulatory authority to require further studies, 
issue recalls or label changes, or withdraw a drug from the market is variable, most 
regulators have such authority. Passive systems for monitoring health product 
risks are also common, affecting the post-marketing identification of health 
product risks. In addition, all regulators have or are developing frameworks that 
guide the communication of health product risks. The frameworks generally 
emphasize two-way communication, engagement with affected populations, and 
meaningful and accessible messaging for a range of groups. However, while 
recognizing the importance of evaluating risk communication, most frameworks 
do not provide any detail or guidance on how it should be defined, how it is 
to be carried out, or if it is actually being done. 
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Regulators from the jurisdictions examined use similar tools to communicate 
health product risk information. The Panel classified them as ongoing 
communication, incident(s)-based communication, and defect and error 
communication. A lack of readily available information on the use of some tools 
made them difficult to characterize. Despite this challenge, the Panel found 
important similarities across established tools, many of which do not align with 
evidence-informed communication practices. Many tools, for example, were 
primarily text-based with few visuals and sparse colour. Images used were generally 
illustrations or pictures rather than graphic risk presentations. Posting online 
was the most common method of dissemination (with the notable exception 
of leaflets), although some of the tools aimed at healthcare professionals 
were also disseminated by other methods such as mail. Most of the tools that 
targeted the public often did not quantify risk, instead using vague terms such 
as “increased risk,” “rare,” or “chance of.” Detailed information about risk was 
available in some comprehensive ongoing communication documents, which 
were also longer and written in more technical language.
The Panel identified several emerging communication tools that use new 
technologies, platforms, and multi-media approaches to expand the reach 
of communications, change the conditions that shape behaviour to support 
informed decision-making, or change how messages are framed and presented 
to improve use and impact. For example, drug fact boxes present the risk and 
benefit information for prescription drugs in a manner similar to nutrition 
labels. Although more research is needed on their real-world applicability for 
varying populations, the Panel identified drug fact boxes as the most promising 
innovation in health product risk communication.
There are few publicly available and publicly conducted evaluations of established 
health product risk communication tools in any jurisdiction. Regulators have 
either not evaluated their effectiveness or used the results of external evaluations, 
and in any case not made results public or easily accessible. This gap could 
have implications for the quality of risk communication. The majority of the 
evaluations identified for ongoing communication focused primarily on indicators 
of understandability (e.g., readability) and user surveys, expert analysis, and 
public consultations. Those identified for incident(s)-based communication 
examined effectiveness in terms of use and impact after implementation and 
completion of the communication. These studies most often used medical or 
pharmacy claims (e.g., prescribing rates) as indicators. 
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Given the similarities in regulatory contexts and communication tools, it is 
not surprising that Health Canada’s challenges in evaluating and enhancing 
health product risk communication are common. Health Canada can benefit 
from the lessons learned by other regulators and from innovations that they 
have adopted. Canada also has the opportunity to lead globally in aligning its 
communication tools with evidence-informed communication practices and 
implementing effective evaluations.
Evaluation is an integral part of risk communication and can be supported 
with institutional commitment and sufficient resources.
Proper evaluation is integral to risk communication activities and can aid in 
fulfilling regulatory and fiduciary obligations, demonstrating a commitment 
to transparency and accountability, and attaining an understanding of the 
strengths and weaknesses of risk communication efforts. Evaluation activities 
can improve decision-making and real-world applications of a communication 
and ultimately help to ensure the health and safety of the population. Evaluation 
can also improve content and processes, build trust and relationships, assess 
whether communications have achieved their objectives, and identify who 
is paying attention, what they are learning, and what impacts are occurring 
across a range of different groups. Without adequate evaluation, not only is 
there potential for mistakes, but there is also the risk of missing opportunities 
to continue or build on proven successes. 
Ensuring that evaluation evidence is meaningful and useful demands institutional 
commitment and sufficient resources — the biggest challenge to evaluation 
overall. This challenge can be addressed by:
• fostering a learning culture that encourages and facilitates continuous 
learning and values evaluation;
• demonstrating the value of evaluation relative to other spending priorities 
to establish its sufficient and stable funding as an integral part of 
risk communication;
• standardizing communication appraisal tools and checklists, which include 
evidence-informed communication practices, so that risk communications 
meet certain minimum standards and reduce constraints on time, money, 
and human resources; and
• encouraging peer learning and sharing of experiences from other jurisdictions 
by bringing together evaluation experts, risk communication researchers, 
regulators, and affected populations to identify examples of strong evaluations 
and leading evaluation practices.  
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Careful planning determines relevant evaluation questions, which guide 
evaluation methods.  
Evaluation methods are sometimes selected without properly understanding the 
context of a risk communication and the information needs and motivations 
of regulators and government institutions communicating risk, receivers of 
risk information, and other stakeholders. Since different evaluation methods 
produce different knowledge and have varying strengths and weaknesses, they 
may be more or less applicable. There is also no universal way to evaluate a 
communication; different methods may be applied in different ways to address 
various situations, needs, and goals. It follows that careful planning efforts 
are needed to first determine the most relevant evaluation questions before 
choosing evaluation methods. The best questions result from identifying and 
integrating information needs and the attributes of a risk communication 
tool, including the communication goals. Selecting an evaluation method 
then becomes a function of the evidence required to answer an evaluation 
question and the level of available resources. Evaluation conducted on this 
premise and involving relevant stakeholders will reveal the most relevant and 
meaningful information.
Information Needs and Motivations
Regulators and other government institutions communicating health product 
risks (the senders of information) may be interested in accountability, program 
improvement, or transparency. Receivers of information, however, may need 
to determine credibility and who to trust, feel engaged in the communication 
process, and feel empowered to use the information. Each of these needs and 
motivations will shape evaluation questions and subsequent choices around 
appropriate methods.
Communication Attributes
Evaluation questions should also take into account the three main attributes 
of a risk communication tool: its type, stage, and goal.   
Evaluations are influenced by the type of tool involved. For ongoing communication 
there is potential to conduct more systematic and comprehensive evaluation 
and engage affected populations before, during, and after the evaluation. The 
time sensitivity of incident(s)-based communication implies that evaluation is 
often undertaken with less planning, uses less comprehensive methods, and 
faces additional challenges in engaging different groups. Since it is delivered 
at a fixed point in time, there is a clear baseline from which to measure various 
goals and to use before and after comparison groups. Evaluation is more likely 
to be demanded for high-profile incident(s)-based communication. In these 
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cases, regulators and other government institutions may be more interested 
in demonstrating that proper processes were followed than in measuring 
long-term impacts. 
Four types of evaluation highlight certain stages of risk communication and 
link to information needs and communication goals:
• Needs assessment: undertaken to identify the information needs of the 
senders and receivers of information and other stakeholders. Its findings can 
increase the likelihood that a risk communication will be effective.
• Pre-testing: undertaken before the full implementation of a risk communication 
to preliminarily test the feasibility, appropriateness, and effectiveness of 
the identified communication tool in sub-groups. Its findings can lead to 
changes to the communication, which will further increase the likelihood 
that it will be effective. 
• Process/Implementation: typically undertaken during the implementation of 
a risk communication to provide evidence that it is progressing as planned. Its 
findings provide insight into potential revisions to implementation strategies, 
the need for reassessing goals and potential outcomes, and the potential 
value in conducting outcome evaluations in the future. 
• Outcome: conducted after a risk communication has been disseminated and 
completed to link meaningful short-, medium-, and long-term outcomes to 
the tool in question. Although considered end-stage efforts, more rigorous 
evaluations usually establish a baseline prior to the implementation of the 
communication followed by ongoing measurement. 
Different types of evaluation should be undertaken for different risk 
communication goals. These goals will ultimately align with information needs 
and motivations as well as other communication attributes to shape evaluation 
questions and determine appropriate methods. Goals are defined here and 
dimensions for each are described in Table 1: 
• Development – incorporating evaluation methods and learning into the steps 
involved in designing risk communications, including when characterizing 
and managing risk, creating messaging, and ensuring ongoing partnership 
and exchange;
• Reach – how and when the communication is sent and received and by whom; 
• Use – how the information is considered, its timeliness, and the reactions 
and actions taken as a result of the communication, thus exploring 
understandability, timeliness, informed decision-making, and behaviour; and
• Impact – achieving a desired result with respect to various outcomes related to 
the senders and receivers of information and the relationship between them. 
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Choosing Evaluation Methods
Once evaluation questions have been established, methods can be chosen that 
best provide the required evidence to answer the questions. This increases 
the likelihood that an evaluation will produce meaningful results. The Panel 
organized the numerous available methods into five broad approaches that 
are feasible for regulators and other government institutions and relevant for 
health product risk communication:
• Synthesis: Methods include literature reviews, systematic reviews, 
and meta-analyses.
• Records-based: Methods include textual, archival, and administrative 
data analysis.
• Self-reported data: Methods include interviews, focus groups, and 
population-based surveys.  
• Experimental: Methods include quasi-experimental methods, natural 
experiments, and randomized controlled trials. 
• Mixed methods: This involves combining quantitative and qualitative methods 
from different approaches in the same evaluation.
These approaches vary in complexity and in how data is collected and used 
(i.e., employing qualitative and quantitative methods). They also vary in the 
extent to which receivers of information and other stakeholders participate 
in data collection (e.g., self-reporting the effects of risk communication or 
acting as participants in a controlled RCT). Table 1 summarizes the relevant 
evaluation questions and methods across the four goals of risk communication. 
Methods are ordered from simple to more complex. Taken together, they can 
help design and re-design communications that are aligned with the needs of 
various affected populations, to account for and learn from past mistakes, and 
to continue or build on identified successes.
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Table 1 
Key Points for Matching Evaluation Questions and Methods
Goal Dimensions Evaluation Questions Methods
Development: 
incorporating 
evaluation methods 
and learning into 
the steps involved 
in designing risk 
communications
Characterizing 
and Managing 
Risk
 • Who needs to receive  
the risk communication?
 • Who wants to receive  
the risk communication?
 • What needs to be communicated?
 • Who is the source of  
the risk information?
 • What is the accuracy and 
credibility of the evidence base?
 • Literature 
review/
Systematic 
review/
Meta-analysis
 • Textual 
analysis
 • Interviews and 
focus groups
 • Randomized 
controlled 
trials
 • Mixed methods
Creating 
Messaging
 • What are the communication 
wants and needs of the 
receivers of information?
 • How do the receivers of 
information make sense of risk?
 • Will they understand the content?
 • What will the content look like 
(e.g., text, images, colour)?
 • Does the content address wants 
and needs?
 • How will the risk communication 
be disseminated?
 • Are the communication channels 
appropriate for all groups 
receiving the information?
Ongoing 
Partnership  
and Exchange
 • What is the relationship 
between the sender and receiver 
of information?
 • How could that relationship 
change, stay the same, or  
be strengthened?
 • What is the best way to engage 
the receivers of information  
in the evaluation process?
 • How can the senders and 
receivers of information  
and other stakeholders be 
involved in the implementation 
of evaluation?
Reach:
how and when  
the communication 
is sent and received 
and by whom
Delivery  • Was the risk communication 
sent and to whom specifically?
 • Administrative 
data analysis
 • Interviews and 
focus groups
 • Population-
based surveys
Receipt  • Did those groups receive the risk 
communication?
 • Are those groups aware of the 
risk communication?
continued on next page
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Goal Dimensions Evaluation Questions Methods
Use:
how the 
information is 
considered, its 
timeliness, and  
the reactions and 
actions taken as  
a result of the 
communication
Understandability  • What are the barriers (facilitators) 
that might prevent (support) 
understanding the message? 
 • Was information sent in  
a way that overcomes barriers 
and leverages facilitators  
to understanding?
 • How does the information  
align with evidence-informed 
practices in communication  
and health literacy?
 • Is the information understood by 
those receiving the information?
 • Was awareness of the risk 
increased in the receivers  
of information?
 • Textual 
analysis
 • Interviews and 
focus groups
 • Population-
based surveys
 • Quasi-
experiments
Timeliness  • How much time has elapsed 
between identification and 
dissemination?
 • What is the justification for this 
amount of time and is it based  
on reasonable grounds?
 • Did the senders and receivers  
of information and other 
stakeholder groups consider  
the risk communication timely to 
inform their decision-making and 
behaviour? How do expectations 
compare across these groups?
Informed 
Decision-Making
 • Did the receivers of information, 
both among the public and 
among healthcare professionals, 
seek the risk communication out?
 • Did the receivers of information 
feel that the communication 
provided meaningful information? 
 • Did the risk communication 
contain messages that the 
receivers of information believe 
they can successfully carry out 
and were those messages 
believed to be successful for 
averting any harm?
 • Did the risk communication 
influence shared decision-making 
between healthcare professionals 
and the receivers of information?
continued on next page
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Goal Dimensions Evaluation Questions Methods
Behaviour  • Did the risk communication 
change the risk perceptions of  
the receivers of information?
 • Were there any changes in the 
preferences of the receivers of 
information (e.g., patients,  
healthcare professionals)?
 • Was information used by 
healthcare professionals and the 
groups that they work with?
 • Did the receivers of information 
change their behaviour or 
continue recommended  
desirable behaviour?
 • Was the risk minimized by 
actions based on specific 
recommendations from  
the risk communication?
Impact: 
achieving a  
desired result with 
respect to various 
outcomes related  
to the senders  
and receivers of 
information and  
the relationship 
between them
Outcomes for 
Receivers of 
Information
 • What individual and population 
health outcomes have  
improved as a result of  
the risk communication in the 
groups receiving the information 
and other stakeholders?
 • What individual and population 
health outcomes have worsened 
(i.e., unintended impacts) as a 
result of the risk communication 
in those same groups?
 • Have knowledge, attitudes,  
and perceptions advanced  
or changed as a result of  
the risk communication?
 • Archival and 
administrative 
data analysis
 • Population-
based surveys
 • Interviews and 
focus groups
 • Quasi-
experiments
 • Natural 
experiments
 • Mixed methods
continued on next page
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Goal Dimensions Evaluation Questions Methods
Outcomes for 
Senders of 
Information
 • What organizational constraints 
hindered the risk communication? 
Did the risk communication make 
efficient use of financial and 
human resources? How did  
the organization overcome  
these constraints?
 • Did the receivers of information 
and other stakeholders trust  
the risk communication and  
how has it affected general 
perceptions of trust?
 • What was the effect of the risk 
communication on the credibility 
of the organization?
 • Did the receivers of information 
and other stakeholders view  
the risk communication as 
transparent and how has it 
affected general perceptions  
of transparency?
Outcomes 
Related to 
Relationships 
Between Senders 
and Receivers
 • Were there opportunities for 
those receiving information and 
other stakeholders to provide  
feedback? How were affected 
populations and other 
stakeholders engaged?
 • Did the sender of information 
receive that feedback and  
make use of it to improve  
the risk communication?
 • Did receivers of information  
feel empowered by the  
risk communication?
 • How has the risk  
communication contributed  
to future communications and 
opportunities for cooperation?
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Final Reflections
The Panel found no clear best methodological practices to evaluate health 
product risk communication. There are, however, many promising evaluation 
methods, which if tailored to the type, stage, and goal of a risk communication, 
can provide strong evidence of effectiveness. While this assessment has outlined 
a range of methods, some of which require significant time and resources, 
the Panel firmly believes that even a minimal evaluation can provide benefits. 
With commitment and sufficient resources, however, there are opportunities 
for regulators and other government institutions around the world to become 
leaders in this area, conducting relevant, well-planned, comprehensive, systematic, 
and rigorous evaluations. 
Overall, the Panel believes there is significant room for improvement in the 
volume and quality of evaluations on health product risk communication, 
conducted both in Canada and elsewhere. While there are numerous challenges, 
even when taken together, they are far from insurmountable. Since evaluation 
can fundamentally improve the health of Canadians, now and in the future, the 
Panel concluded that engaging in the challenges is therefore worth the effort.
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1 Introduction
1.1 BACKGROUND AND PURPOSE
Risk communication is an important component of improving the health 
and safety of Canadians. For numerous departments and agencies at all levels 
of government, as well as public and private organizations, effective risk 
communication can protect Canadians from preventable hazards associated with 
medicine, food, and various consumer products. These communication efforts 
exist in a complex environment involving many stakeholders with varying levels 
of expertise and multiple sources of information. In Canada, communication 
must also span large and complex geographic, social, and cultural settings, in 
which varied communicators and audiences play dual roles of both senders 
and receivers of information.
Pressures on government for greater openness and transparency have also 
increased. A 2011 Auditor General’s report recommends that Health Canada 
assess its communication efforts about medical device risks to ensure that 
they are effectively reaching affected populations in a timely manner (Office 
of the Auditor General of Canada, 2011). A similar report from the Auditor 
General in 2013 on Canada’s Food Recall System finds that, although public 
warnings were issued in a timely manner, few follow-up activities were completed 
to confirm that products were removed from shelves (Office of the Auditor 
General of Canada, 2013). There have also been a number of reviews of public 
health incidents — including the H1N1 pandemic, the listeriosis outbreak, 
and numerous drug recalls and related inquests — all of which recommend 
improving timeliness, outreach, and plain language approaches, particularly for 
vulnerable populations. For example, the five-member coroner’s jury looking 
into the suicide of 18-year-old Sara Carlin (who was taking an antidepressant) 
recommended that Health Canada seek to “maximize the effect” of health 
product advisories by considering that they “be succinct; clearly set out the 
warning; clearly set out the body of evidence giving rise to the warning; 
be specific; [and] be profiled in a way to attract physician’s attention” 
(Chief Coroner Province of Ontario, 2010). 
These pressures have been met with several government commitments. In its 
Regulatory Transparency and Openness Framework, Health Canada commits to 
addressing criticisms by “making information easier to understand…making 
more information available…[and] making the decision-making process more 
open” (Health Canada, 2014a). This framework is an extension of a broader 
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federal government effort committing to Canada’s Action Plan on Open Government, 
which sets out similar principles involving availability of information and citizen 
participation (GOC, 2014). These larger policy directions have created new 
realities for all government departments and agencies in terms of openness 
and transparency. It follows that better evaluation and quality improvement 
efforts, and the communication of the results of those activities, will become 
that much more important. However, in this environment, although there is 
general guidance for evaluating the effectiveness of programs and interventions, 
there is no clear consensus on appropriate practices and strategies for risk 
communication efforts specifically. While this lack of guidance and consensus 
does not diminish the need for evaluations using available principles and 
knowledge, it does contribute to gaps in understanding whether the risk 
communication activities of regulators are achieving the goals of improving 
and protecting the health of Canadians. 
Evaluating health risk communication can aid in fulfilling regulatory 
and fiduciary obligations, demonstrating commitment to transparency and 
accountability, and attaining an understanding of the strengths and weaknesses 
of risk communication efforts. Evaluation also helps to improve their content, 
processes, and outcomes. Without formal evaluation, it is difficult to assess 
whether a communication has reached its objectives or made the situation worse, 
to identify its impacts on different audiences, or to determine who is paying 
attention and what they are learning from the communication (Kreps, 2014). 
Without this feedback, not only is there potential for mistakes, but there is also 
the risk of missing opportunities to continue or build on success.
In this context, this assessment comprehensively examines the state of knowledge 
on the evaluation of health product risk communication, including methods and 
barriers to evaluation, as well as lessons learned from international experiences. 
The report fills a distinctive niche in the effort to advance the evaluation of 
health product risk communication in Canada and abroad.
1.2 CHARGE TO THE PANEL
Recognizing the importance of successfully evaluating health risk communication, 
the Minister of Health, on behalf of Health Canada (the Sponsor), asked the 
Council of Canadian Academies (the Council) to provide an evidence-based 
and authoritative assessment of the state of knowledge on measurement and 
evaluation of health risk communication. This assessment focuses on identifying 
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risk communication tools, evaluation methods, gaps in the literature, and 
barriers and facilitators to carrying out successful communication and evaluation 
activities. Specifically, this assessment examines the following questions:
• How can the effectiveness of health risk communications be measured and evaluated?
 – What types of instruments/tools are currently available for health risk communication? 
 – What methodological best practices can be used to evaluate the reach, use and benefit 
of health risk communication? 
 – What research could be done to inform the measurement of the effectiveness of 
risk communications? 
 – What are the existing barriers to effective risk communications and what best practices 
exist to address these challenges? 
To address the charge, the Council assembled a multi-disciplinary panel of 
11 experts (the Panel) from Canada and abroad. The Panel’s composition 
reflects a balance of expertise, experience, and demonstrated leadership in 
academic, clinical, and regulatory fields. Panel members brought knowledge 
from the disciplines of healthcare, behaviour and decision-making science, 
environmental and health risk communication and management, population 
health, and research and evaluation. Each member served on the Panel as an 
informed individual, rather than as a representative of a particular discipline, 
patron, organization, or region.
Over 12 months, the Panel met in person four times to refine its assessment of 
the issue at hand. At the beginning of the assessment process, the Panel met 
with the Sponsor to acquire a full understanding of the charge and receive 
additional direction:
• The report was to focus specifically on risk communication for health products, 
which may include pharmaceuticals, biologics and vaccines, medical devices, 
and natural health products. Consumer products, other products, and general 
health promotion communications were considered out of scope. 
• The Panel agreed to focus broadly on a range of tools/instruments 
(e.g., public warnings, recall notices, product monographs) used in health 
product risk communication (i.e., all aspects of specific actions taken to deal 
with a particular hazard).
• The Sponsor confirmed they were open to the Panel’s assessment of appropriate 
approaches to effectiveness as well as to alternative dimensions of effectiveness 
that can realistically be measured. Although reach, use, and impact were the 
primary focus, the Panel also set out to explore timeliness, informed refusal/
choice, multi-way dialogue, trust, and credibility.
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• Based on Sponsor interest and clarification, the report was to focus more 
heavily on barriers to evaluating risk communication activities. As a result, 
the Panel placed less emphasis on practices for addressing challenges that 
constrain health risk communication more generally.
1.2.1 Scope 
The report examines: 
• the role of health product risk communication, and its evaluation, 
in decision-making;
• activities for health product risk communication, especially the varying types 
of tools used to communicate risk to a range of different populations;
• approaches to evaluation from a variety of disciplines, sectors, jurisdictions, 
and organizations in Canada and internationally, which could be used to 
assess the effectiveness of health product risk communication; 
• knowledge gaps in the state of evidence; and
• barriers and facilitators to evaluating the effectiveness of health product risk 
communication, and potential strategies to address these factors.
The report does not:
• evaluate actual risk communication initiatives or make judgments on 
their effectiveness;
• address cost-effectiveness of risk communication initiatives; 
• specifically explore issues related to consumer products, other products, and 
general health promotion communication, although lessons from health 
product risk communication may apply to these areas; or
• provide formal recommendations.
1.3 PANEL’S APPROACH AND METHODOLOGY
The Panel’s assessment of the state of the literature is based on various sources 
of evidence. Primary evidence-gathering activities included a review of:
• academic literature from peer-reviewed publications exploring risk 
communication, risk perception and decision-making, and risk management, 
as well as approaches for evaluating health risk communication and 
population-based intervention; 
• publicly available government information that describes regulatory context 
and specific policy and communication initiatives; and
• other grey literature1 relating to risk communication and evaluation planning 
and implementation. 
1 Grey literature refers to various types of documents produced by government, academics, industry, 
and other organizations that are not published commercially/formally. 
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In seeking the most relevant evidence, the Panel conducted keyword-based 
searches of published literature and explored websites of various regulatory 
agencies in Canada and internationally. The search strategies varied across 
different topics in the report, and evolved as the Panel assessed the availability 
of the most recent information. The report underwent a formal peer review 
process to assure quality and objectivity; all comments from the reviewers were 
considered by the Panel, although not all comments resulted in revisions to the 
report. This process also contributed to the identification of new evidence for 
the Panel’s deliberations. The report is the result of the Panel’s deliberations 
on the charge and the available evidence. The Panel’s discussions generated 
original interpretations of the evidence and provided insight into the state of 
the evidence and how it could be strengthened or improved.
1.3.1 Key Terms
The Panel has defined terms central to the charge, based on its interpretation 
of the Sponsor’s interest. These definitions, defined below, differ in some cases 
from traditional understandings of the concepts. The Panel’s choices reflect a 
careful reading of the questions and, in some instances, a blend of definitions 
put forward in other sources.
The Panel adopted the U.S. National Research Council (NRC) definition of risk 
communication: “an interactive process of exchange of information and opinion 
among individuals, groups and institutions. It involves multiple messages about 
the nature of risk and other messages, not strictly about risk, that express 
concerns, opinions or reactions to risk messages or to legal and institutional 
arrangements for risk management” (NRC, 1989). Risk communication, it 
follows, is an ongoing process meant to improve individual and population 
health over time.
Health products are defined broadly in the context of this report and include 
over-the-counter and prescription pharmaceuticals (small-molecule drugs, 
mainly consisting of chemical compounds); biologics (drugs derived from 
biotechnology or living sources, including vaccines, blood, and blood products); 
medical devices and combination products (devices used for diagnosis, treatment, 
mitigation, or prevention of a disorder or its symptoms or those used to restore, 
correct, or modify body structure or function); and natural health products 
(vitamins, minerals, herbal remedies, homeopathic or traditional medicines, 
or probiotics).
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Effectiveness is defined as producing a desired result and depends largely on 
the goals of the communication in question. Within the context of this report, 
effectiveness is explored across the following goals:
• Development includes incorporating evaluation methods and learning into 
the design of risk communication. 
• Reach includes aspects of how and when the information is sent and received 
and by whom.
• Use involves how the information is considered, its timeliness, and the 
reactions and actions taken as a result of the communication.
• Impact refers to achieving a desired result with respect to various outcomes 
related to the senders and receivers of information and the relationship 
between them.
Best practice is interpreted broadly in this report to include practices that may 
exist across a continuum of established quality. This continuum may range from 
emerging (e.g., based on prior sound evidence and incorporating a process 
for evaluation and continual improvement), to promising (e.g., beginning to 
show evidence of positive outcomes), to best (e.g., shown to improve outcomes 
based on a range of rigorous evaluation methods and is generalizable to a range 
of contexts). The Panel did not formally assess or distinguish practices along 
this continuum, but rather broadly captured all practices to provide a picture 
of the state of the evidence.
Evaluation is defined as an integral component to all stages of the risk 
communication process (i.e., planning, implementation, and assessment) 
and not simply as an end-stage task carried out after the risk communication is 
completed. This assessment therefore looks at evaluation across the full range 
of risk communication and includes needs assessment, pre-testing, process/
implementation, and outcome evaluation. Evaluation is also understood as 
an applied research process that focuses on improving decision-making and 
real-world applications of a communication. 
Traditionally, the terms sender, communicator, audience, and target are used in 
risk communication to capture the distinction between the communicator and 
the target audience of a communication. These terms reflect a simple one-way 
interpretation of risk communication. However, current theory suggests that 
effective communication is two-way, enabling dialogue and back and forth 
exchange between traditional communicators and audiences. The terms 
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audience or target do not capture this deliberative approach. Furthermore, 
many other groups (e.g., media, health professionals, interpersonal networks) 
may influence perceptions and appropriate management of risk. Along with 
audiences, these groups are often called stakeholders. For the sake of clarity, this 
report uses senders of information to denote the authorities who are responsible 
for ongoing risk communication efforts and who originate particular messages, 
receivers of information to denote audiences who become active participants in 
the communication process, and stakeholders to mean the people and groups 
who shape those relationships and the communication process. Receivers of 
information and stakeholders should be seen as active participants in the risk 
communication process.
1.4 ORGANIZATION OF THE REPORT
The final report is an in-depth assessment of the state of scientific knowledge 
on evaluating the effectiveness of health product risk communication. As 
such, it is intended primarily as a tool to inform evaluation and decision-
making within government departments and agencies responsible for risk 
communication and looking to improve their efforts. It may also be relevant 
to stakeholders concerned with public health and safety, including regulatory 
bodies and health authorities that communicate risk to the public, industries 
and manufacturers that evaluate the effectiveness of their communication 
products, non-governmental organizations and associations that advocate 
on behalf of populations, and community-based organizations and research 
institutes that work with populations to mitigate risk. The Panel intends this 
report to inform the continuing dialogue across Canada and internationally, and 
across many sectors, on the broader evaluation of health risk communication 
and population-based intervention.
Chapter 2 provides an overview of risk and risk communication, particularly 
for health and health products. It defines characteristics of effective risk 
communication, outlines the evolving state of the literature, and notes the 
dimensions of a paradigm shift that is influencing the traditional goals of 
health risk communication.
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Chapter 3 discusses health product risk communication in Canada and 
other similar jurisdictions, beginning with an overview of the regulatory 
regimes, including their responsibility and authority for health product 
risk communication. It also provides an overview of the communication 
tools commonly used now, and those that are emerging, in Canada and 
other jurisdictions. 
Chapter 4 explores the evaluation of health product risk communication. It 
considers how specific information needs and motivations and communication 
attributes of health product risk communications, including communication 
goals, can shape evaluation questions and subsequent evaluation methods. 
It demonstrates that there is no one-size-fits-all approach to evaluation. The 
selected examples illustrate the practice and challenge of health product risk 
evaluation across different goals.
Chapter 5 synthesizes gaps in the current evidence on the evaluation of health 
product risk communication, summarizes the Panel’s main findings, and 
provides final reflections.
Ultimately, the Panel summarized these chapters in a report roadmap that 
guides the reader through the report (Figure 1.1). It summarizes the discussion 
of the context of health product risk communication, related tools, and the 
role evaluation plays throughout the entire communication process.
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 New Paradigm for Risk Communication
Governance  •  Complexity  •  Uncertainty  •  Empowerment  •  Timeliness  •  Transparency
Goals of Risk 
Communication
• Development
• Reach
• Use
• Impact
Risk Communication
• Characterizing and 
    Managing Risk
• Creating Messaging
• Ongoing Partnership 
    and Exchange
Health Product Risk 
Communication Tools
• Ongoing
• Incident(s)-Based
• Defect-Error
Stages
Needs Assessment  •  Pre-Testing  •  Process/Implementation  •  Outcome
Evaluation Questions and Approaches
Synthesis  •  Records-Based  •  Self-Reported  •  Experimental  •  Mixed Methods
Institutional Commitment and Resources
Figure 1.1 
Evaluation of Health Product Risk Communication – A Report Roadmap
Chapter 2 (represented in blue) describes the context of risk communication. A paradigm shift shapes 
contemporary risk communication by building on the learning from the past to address new communication 
challenges related to building strong and meaningful relationships. This new paradigm also reframes 
the goals of risk communication to broaden potential outcomes related to development, reach, use, and 
impact. In this context specific health product risk communication tools are created and implemented to 
fulfill regulatory responsibilities. Chapter 3 (represented in grey) examines both established and emerging 
tools used to communicate ongoing, incident(s)-based, and error-related health product risk information. 
Chapter 4 (represented in red) explores how such communication tools can be evaluated to ensure they 
are achieving their goals. However, evaluation is an integral component to the entire risk communication 
process and not simply an end-stage task carried out after the communication is completed. There is 
no universal evaluation approach; rather selecting the most appropriate approach is a function of the 
evidence required and resources available to answer specific evaluation questions. These questions stem 
from identifying and integrating information needs and motivations as well as the attributes of a risk 
communication including type of risk communication tool, stage (needs assessment, pre-testing, process/
implementation, and outcome), and communication goals. Chapter 4 also explores how to ensure the 
foundation for evaluation — institutional commitment and sufficient resources — is secured.
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2 Context and Overview of Health Product  
Risk Communication
Communicating about risk cannot be reduced to a simple formula. There are a 
range of potential hazards that can pose risks to health, and these risks can vary 
in severity, certainty, probability, and complexity. The communication of these 
issues takes place in a complex environment with many stakeholders and sources 
of information, which vary in their reliability and importance. Risk communication 
therefore involves a combination of complex processes, including scientific 
appraisal and characterization of risk, application of knowledge concerning 
people’s values, perception and management of risk, and ongoing partnership 
and information exchange. In this chapter, the Panel examines established and 
evolving approaches to risk communication. It also looks at how this evolution 
creates specific challenges for health product risk communication and helps 
shape communication goals. 
2.1 DEFINING AND UNDERSTANDING RISK
Risk is defined in a number of ways, from colloquial usage to expert 
understandings, and can have many different meanings. A broad definition of 
risk considers “the possibility of physical and/or social and/or financial harm/
detriment/loss due to a hazard within a particular time frame” (Rohrmann, 2008). 
Although in most contexts risk refers to negative outcomes, in some fields it 
is used to describe probabilistic outcomes that can be positive or negative 
(Rohrmann, 1998; Slovic, 2000; Kahneman, 2011). The International Risk 
Governance Council (IRGC) definition of risk refers to “an uncertain (generally 
adverse) consequence of an event or activity with respect to something that 
humans value,” but also explains that risk can have positive or negative 
consequences depending on the values that individuals or groups associate 
with them (IRGC, 2008). 
Key Findings
• Risk can be defined in a number ways but ultimately refers to probabilities of 
different possible outcomes and the severity of those outcomes. Risk cannot always 
be quantified and often involves a range of uncertainties.
• Risk evolves with changing awareness and views of hazard and safety, and 
is influenced by social and cultural factors. 
• Health product risks generally involve known side effects, medication/medical 
device errors, product defects, and uncertainty in information.
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Quantifying a risk can be challenging because many effects cannot easily be 
measured or described in quantitative terms. For instance, certain outcomes, 
such as effects on mental health or disrupted family ties, may be observable but 
hard to put a number on (Rohrmann, 2008). In some cases (e.g., the monetary 
value of the environment), quantification may even be controversial and 
equivocal (Fischhoff & Kadvany, 2011). Quantification can also be complicated 
by uncertainties, including those related to lack of information, differences 
in interpretation, or inherent unknowns (see Table 2.3 and Section 2.2.3).
Because of varying interpretations and values, as well as the challenges associated 
with quantification, risks must be understood as dynamic, rather than static. 
As more information becomes known about a hazard, a situation previously 
viewed as safe may be perceived as risky (e.g., hormone replacement therapy 
for menopausal women (Watkins, 2007)) or the understanding of what is 
safe may swing back and forth over time (e.g., sleeping position for an infant 
(Gilbert et al., 2005)). In some cases, this evolution may give rise to awareness 
of new risks that must be addressed (e.g., the dangers of second-hand smoke 
(U.S. Department of Health and Human Services, 2006)) or new ways of thinking 
about risk (e.g., viewing health as something dependent not solely on individual 
genetics and behaviour but also on socio-economic, demographic, and cultural 
considerations (Kasperson et al., 1988; Mikkonen & Raphael, 2010)). The 
perception of risk is dependent on context, socially and culturally mediated, 
and influenced by emotional responses such as trust in institutions and sources 
of information.
2.1.1 Health and Health Product Risk
Risks to health and risks from health products are a subset of risks. Health 
Canada (2000) formally defines health risk as “a measure of both the harm to 
human health that results from being exposed to a hazardous agent, together 
with the likelihood that the harm will occur.”
Since characterizing, managing, and communicating potential risks varies 
greatly depending on the agent, it is important to clearly define the nature of 
the hazard involved (IRGC, 2005). This report focuses on risks associated with 
health products: over-the-counter and prescription drugs; biologics (including 
blood, blood products, and vaccines); medical devices and combination products; 
and natural health products (recall Section 1.3.1). While noting that risks and 
benefits are often communicated together, the Panel concentrates on potential 
negative outcomes associated with the use of these products, rather than their 
potential therapeutic benefits. For example, although the effectiveness of vaccines 
and the potential risks due to lack of vaccination are considered beyond the 
scope of this assessment, the risks associated with receiving particular vaccines 
14 Health Product Risk Communication: Is the Message Getting Through?
(e.g., risks arising from a manufacturing error) are in scope. Although this 
report does not explicitly focus on hazards associated with consumer products 
or food, it may provide insight into risk communication concerning those 
comparable hazards.
The risks associated with health products are variable, but can be broadly 
classified into four categories:
• Known side effects: risks associated with health products that were detected 
before they were approved for sale (identified in the approval process) or 
after they have been on the market for some time through post-marketing 
monitoring and surveillance (identified through pharmacovigilance). 
• Medication/medical device errors: risks associated with inadvertent misuse 
of a health product (e.g., accidental overdose) or from interactions between 
different health products (e.g., between two drugs). 
• Product defects: risks resulting from an error in the production process or 
from incorrect or incomplete labelling of health products (e.g., a natural 
health product that contains allergens not included in the ingredient list). 
This category does not refer to labelling that is incomplete because of new 
knowledge that has only emerged recently. 
• Remaining uncertainties: risks associated with uncertainty (e.g., the effect 
of a new drug on a population that has not been studied in clinical trials, 
such as infants). 
(Task Force on Risk Management, 1999)
All of the above risk categories could lead to negative consequences that 
are known or mild (e.g., headache or nausea) or more severe or unknown 
(e.g., adverse drug reactions (ADRs)2 such as increased risk of heart attack 
that may result from the use of certain non-steroidal anti-inflammatory drugs 
(Health Canada, 2014b)). In cases of highly likely risks or serious ADRs, a 
medicine may be taken off the market. There may also be risks stemming 
from intentional misuse of a health product (e.g., self-medication, overdose, 
self-harm); however, this topic is beyond the scope of the Panel’s assessment. 
2 An ADR is defined by Health Canada (2012a) as a “noxious and unintended response to a drug 
which occurs at doses normally used or tested for the diagnosis, treatment or prevention of a 
disease or the modification of an organic function.”
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2.2 DEFINING AND UNDERSTANDING  
RISK COMMUNICATION
2.2.1 Definition and Traditional Goals of Health Risk Communication
Health risk communication is part of the responsibilities of several regulatory 
agencies around the world. Each of these agencies defines health risk 
communication in a different way, but each definition includes the concept of 
exchange of information to improve or maintain health (Health Canada, 2006; 
FDA, 2009; EMA, 2010; MHRA, 2010; enHealth, 2012). Taking into account 
these definitions, the Panel adopted the U.S. NRC definition, one of the more 
progressive because it captures the importance of ongoing and evolving dialogue 
involving all stakeholders:
Risk communication is an interactive process of exchange of information 
and opinion among individuals, groups and institutions. It involves 
multiple messages about the nature of risk and other messages, not 
strictly about risk, that express concerns, opinions or reactions to risk 
messages or to legal and institutional arrangements for risk management.
(NRC, 1989)
Meeting all dimensions of this definition is challenging and is seldom achieved 
in practice. Many organizations adopt a more general definition of risk 
communication and develop a set of discrete goals to guide their efforts. In 
the charge to the Council, the Sponsor discusses its risk communication goals 
in terms of reach, use, and impact (as introduced in Chapter 1). Table 2.1 
defines these goals along with examples of desired outcomes, as they were 
presented by the Sponsor to the Panel (this table will be re-examined and 
broadened in Section 2.4).
Key Findings
• Risk characterization involves quantifying and understanding the probability and 
potential damage of a hazard as well as the larger context and needs of affected 
populations.
• Understanding how individuals make decisions under risk, as well as socio-economic 
and cultural factors that shape those decisions, are central to effective messaging. 
• Ongoing partnership and exchange among all relevant stakeholders allow 
communication to evolve to meet changing needs and perceptions.
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Table 2.1 
Goals of Risk Communication as Provided by Sponsor
Goal Definition Potential Desired Outcome
Reach How the information is 
sent and received and 
by whom.
 • sent/directed at the appropriate target receivers
 • received by the target receivers
 • considered timely 
Use How the information  
is considered by the 
target receivers and 
what action is taken.
 • sought out by the target populations
 • the target receivers can make informed choices  
based on the risk information provided
 • action taken based on the opinions, perceptions,  
and/or beliefs of the recipient
 • risk minimized by actions based on specific 
instructions/recommendations 
Impact What effects the 
information has 
immediately and  
over time.
 • appropriate change in behaviour observed
 • risk of serious harm reduced (minimized)
 • awareness of the risk increased in target receivers
2.2.2 Process of Risk Communication
Communicating health risks entails several stages, including analysis of a potential 
threat, understanding the perceptions of relevant populations, and disseminating 
the message in an appropriate manner (Fischhoff et al., 2011). This process allows 
a risk to be communicated based on evidence and in a manner that ensures 
that those most likely to be affected by it will receive the message. However, 
risk communication is also fundamentally a socially and politically interactive 
process in which individuals are informed of real or potential risks and are 
expected to use this information to undertake personal strategies to manage 
that risk. Risk communication requires the identification of the most important 
facts and information related to a risk, often from large amounts of technical 
information, by experts in health-related fields (Fischhoff & Kadvany, 2011). It 
also involves communication specialists conveying information in a manner that 
is comprehensible to various populations with a wide variety of life experiences 
and values. Therefore, although risk communication may be seen as a simple 
one-way transfer of information from an organization (e.g., government body, 
pharmaceutical manufacturer) to an individual, it is a more complex process of 
ongoing relations that involve multiple stakeholders and interactions at many 
levels (i.e., multi-way and multi-level transfer of information). The ongoing and 
dynamic nature of risk communication and the importance of life experiences 
and values are incorporated in the IRGC risk governance framework, which, 
in identifying several stages in risk governance, notes risk communication as 
central to all (IRGC, 2008). 
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While this broadened view of risk communication is now widely accepted, this 
was not always the case. How regulators view and approach risk communication 
has changed dramatically over time. Table 2.2 synthesizes the learning from 
three key phases of this evolution. 
Table 2.2 
Phases in Risk Communication and Management
Synthesis Fischhoff’s (1995) 
Developmental 
Stages in Risk 
Management
Leiss’s (1996) Risk 
Communication 
Phases (as 
summarized by 
Bouder (2011))
Krimsky’s (2007) 
Stages in the 
Evolution of Risk 
Communication
Phase 1: Establish 
accurate science  
and data analysis  
to educate.
Key Learning:
Need to properly 
identify the science 
that needs to be 
communicated. 
“All we have to do is 
get the numbers right
All we have to do is 
tell them the numbers
All we have to do is 
explain what we mean 
by the numbers.”
“The first phase 
focused on the 
necessity of conveying 
probabilistic thinking 
to the general public 
and to educated  
lay audiences.”
Communications are 
delivered from the  
top down in a linear 
process to address  
“the public’s potentially 
irrational or unrealistic 
response to a risk.”
Phase 2: Focus on 
persuasion and 
paternalistic 
messaging.
Key Learning:  
Need to be clear  
and address the  
needs and perceived 
reality of stakeholders 
involved.
“All we have to do  
is show them that 
they’ve accepted 
similar risk in the past
All we have to do is 
show them that it’s a 
good deal for them
All we have to do is 
treat them nice.”
“The second phase 
focused on the 
persuasion of audiences 
and the management  
of public relations to 
convince people that 
some of their behaviour 
is inappropriate.”
Communicating  
about risk emphasized 
scientific uncertainty, 
and the cultural and 
subjective aspects  
of risk.
Phase 3: Move  
from persuasion  
to partnership.
Key Learning:  
Risk is socially 
constructed, and 
therefore ongoing 
partnership and 
interactive exchange 
are needed.
“All we have to do is 
make them partners
All of the above.”
“In the third phase,  
the aim has been to 
develop a two-way 
communication process 
in which scientists,  
risk managers, and 
various laypersons 
engage in a social 
learning process.”
Risk estimates and 
perceptions in the 
post-modernist social 
constructionist view 
include scientific bias 
and hazards that are 
socially constructed.
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Contemporary risk communication is influenced by the legacy of these three 
phases and typically consists of:
• Characterizing and managing risk: using accurate science and data analysis to 
establish risk assessment and management strategies, including identifying 
what scientific information and uncertainty need to be communicated and 
understanding the larger context and population needs inherent to a given 
risk communication.
• Creating messaging: applying multidisciplinary knowledge of how individuals 
interpret, process, and respond to risk-related information, and how 
socio-cultural factors shape those activities, to create messages that are 
understood and meaningful. 
• Ongoing partnership and exchange: recognizing the influence and importance 
of broader societal factors to focus on communicating messages in ways that 
respect dialogue, exchange, and relationship-building.
These activities will ultimately lead to the development of specific communication 
products that should be assessed for their reach, how they are being used, 
and whether they are having an impact. However, evaluation is more than an 
end-stage task carried out after the risk communication is completed. To ensure 
that communications are meeting their goals, getting through to people, and 
avoiding any adverse or unintentional effects, evaluation is needed throughout 
the entire risk communication process, starting with planning and development. 
Evaluation of health product risk communication is explored in more depth 
in Chapters 3 and 4.
2.2.3 Characterizing and Managing Risk
Establishing what is known and not known about a given risk is the first step 
in risk management and communication. Risk characterization synthesizes 
knowledge in two areas: (i) quantifying and understanding the probability of 
a hazard and potential for (and extent of) damage; and (ii) understanding 
the larger context and stakeholder needs at multiple levels.
Establishing the probability of a hazard and outcomes may seem straightforward, 
but the multi-faceted nature of risk and uncertainty in the data can make it 
challenging. The U.S. NRC states that quantifying and understanding potential 
adverse health effects consists of four major steps:
• Hazard identification: assessing the nature and strength of the evidence for 
causal association between a hazard and negative health outcome(s).
• Dose-response assessment: assessing the incidence of an adverse effect, the 
intensity of exposure, and the various factors that may affect response. 
• Exposure assessment: assessing the intensity, frequency, and duration of 
exposures and any uncertainties that may be involved. 
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• Risk characterization: estimating the incidence of adverse events in a 
given population, combining the dose-response and exposure assessments 
described above.
(NRC, 1983)
Similarly, considering health product risks, Bouder (2011) proposes five 
key dimensions to assess when characterizing risks and benefits for a 
particular situation:
• Seriousness: level of threat to human health, regardless of exposure factors 
(e.g., intake quantity). Key question: will this lead to negative outcomes 
(e.g., fatalities)?
• Uncertainty: how much is known and not known. Key question: what is the 
state and quality of the evidence and what can it really tell us?
• Complexity: challenges associated with dealing with multiple causes and a 
range of possible consequences. Key question: will a coordinated response 
be required and what factors need to be addressed beyond the hazard itself?
• Ambiguity: variability of the explanations stemming from a fixed data set. 
Key question: what does that evidence actually show (e.g., does a rise in 
reported outcomes stem from better monitoring and awareness or actual 
increases in incidence)? 
• Confidence: the degree of uncertainty surrounding efficacy. Key question: 
does the health product really do what it claims and is it worth the risk?
(Bouder, 2011)
Ideally, the magnitude and likelihood of a risk and any associated uncertainty 
can be identified from dimensions such as these; however, this depends on 
the quantity and quality of the evidence available (Paté-Cornell & Cox, 2014). 
There is therefore no single approach to quantifying risk. The approach that 
is most relevant depends on the information available and the level and type 
of uncertainty in the data.
In general, uncertainty arises in the four situations listed in Table 2.3.
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Table 2.3 
Descriptions of the Types of Risk Uncertainty
Name and Definition Effect of New 
Information
Method for Analysis Example
Variability (aleatoric 
uncertainty) involves 
risks that are inherently 
complex that can “behave 
in different ways or…
[be] valued differently.”
Not modified by 
new or additional 
information.
Traditional methods for 
analyzing medical data 
(frequentist statistics) 
are most relevant, 
providing objective 
measures of the 
strength of evidence 
and the probability  
of obtaining a  
given result.* 
A drug is effective at 
relieving symptoms  
in 50% of patients 
(regardless of age, 
gender, etc.).
Limited knowledge 
(epistemic uncertainty) 
involves situations  
when there is little or no 
information (i.e., there is 
scientific uncertainty) 
about a particular risk.
Decreases as new 
information and 
data are collected.
Bayesian techniques** 
are often most 
relevant, enabling  
the integration of all 
known information, 
even from different 
experiments, as it 
becomes available.
If a certain population 
is not included in  
the clinical trials for  
a particular drug, 
ongoing surveillance 
activities following 
wider distribution of 
the drug may reveal 
new information for 
that population.
Interpretative 
ambiguity involves 
situations where 
knowledge about a  
risk allows different 
interpretations of  
its seriousness or 
likelihood.
New information 
can reduce 
ambiguity by 
lending support  
to one (or  
more) particular 
interpretation.
Will depend on the 
amount of knowledge 
and variability.
Two experts come to 
different conclusions 
about the likelihood of 
a risk (e.g., a particular 
adverse effect) despite 
having the same 
evidence base to  
draw from.
Socio-cultural  
or normative 
ambiguity involves 
situations where there 
are variable beliefs 
about what is tolerable 
or acceptable as a risk.
Acceptability of 
pre-natal genetic 
screening or 
amniocentesis varies 
across parents and 
medical professionals.
Source: (Paté-Cornell, 1996; Goodman, 1999; Van Asselt & Rotmans, 2002; Walker, 2003; IRGC, 2008; 
Klinke & Renn, 2012; Markon et al., 2013; Gregory & Dieckmann, 2014)
* Probability is based on independent and identically distributed observations, and background 
information is combined with significance tests to interpret any results.
** Bayesian methods define probability as a degree of belief that can be supported by data, models, 
and expert opinions, allowing different types of information to be combined to produce a new 
probability distribution.
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Getting the numbers right can therefore be a complicated process. When the 
evidence is less clear, it becomes more important to understand the larger 
context and varying stakeholder needs, interpretations, and perspectives (Krewski 
et al., 2007). In these situations it is also important that risk characterization 
be an iterative process that involves participation of the interested and 
affected parties and incorporates their feedback as appropriate. Further, 
while risk characterization requires considering a wide variety of outcomes and 
consequences, in practice the appropriate level of effort for a risk characterization 
is specific to each situation (NRC, 1996).
Once a risk is characterized, this information can be used to determine activities 
to manage the risk. There are several definitions of risk management, and the 
Panel decided to adapt the definition developed by NRC (1983) by expanding 
it beyond regulatory decision-making:
The process of individuals, families, and/or other groups weighing 
alternatives and selecting the most appropriate action, integrating the 
results of risk assessment with multiple forms of evidence and social, 
economic, and political concerns to reach a decision. 
Inherent in this definition is that risk management policy includes judgments 
(specific to each case) concerning the public perception of risk and the benefits 
and costs of control strategies. Risk management can relate to the hazard itself 
or to the consequences it produces; depending on the risk involved (including 
any associated uncertainty), the management process will differ (Rohrmann, 
2008; Klinke & Renn, 2012). To be effective, risk management needs to be 
tailored based on the nature of the risk in question. One approach to tailoring 
management is outlined in the IRGC (2005) risk governance framework, which 
uses different classifications of risks to guide management (Table 2.4).
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Table 2.4 
Linking Risk Management Strategies and Knowledge Characteristics
Knowledge 
Characteristics
Management Strategy Example 
Simple (or linear)  
risk problems.
Routine-based strategies (e.g., 
introducing a law or regulation).
Known health risks (e.g., known side 
effects of a given prescription drug).
Complexity-induced 
risk problems.
Robust strategies developed by 
accessing and acting on the best 
available scientific evidence.
Risks of critical loads (e.g., of fertilizer 
contaminants) to ecosystems.
Uncertainty-induced 
risk problems.
Strategies that are focused on 
resilience and are precaution-based, 
with the capacity to cope  
with surprises and reverse  
critical decisions.
Health effects of pollutants  
below the threshold of statistical 
significance (e.g., below the limit  
of detection).
Ambiguity-induced 
risk problems.
Dialogue-based strategies to  
enable a mutual understanding  
of conflicting views with the aim  
to eventually reconcile them.
Interpretive ambiguity: low-dose 
radiation. Normative ambiguity: 
pre-natal genetic screening.
Summarized and adapted from: (IRGC, 2005, 2007)
2.2.4 Creating Messaging 
Understanding how individuals interpret, process, and respond to risk and 
risk information is important for creating appropriate messaging that will be 
understood and accepted. Research on individual risk perception explores how 
psychological and other processes filter and modify technical risk information, 
amplifying or attenuating public responses to risk (Slovic, 1987, 2000). A set 
of key risk characteristics have been found to affect public perception of risk 
acceptability: voluntariness, controllability, equity, time period/delay effect, 
and dread (described in Table 2.5). Because these factors are correlated with 
each other in varying ways, Slovic (1987) simplifies these perceptions into 
two general factors: dread risk, involving “a perceived lack of control, dread, 
catastrophic potential, fatal consequences, and the inequitable distribution 
of risks and benefits;” and unknown risk, involving “hazards judging to be 
unobservable, unknown, new, and delayed in their manifestations of harm.”3 
Linked to these ideas are cognitive biases, such as loss aversion, which affect 
how people view probability of risk (Table 2.5) information (Tversky & 
Kahneman, 1979, 1992; Fox & Poldrack, 2008; Kahneman, 2011). Research 
also suggests that individuals use heuristics -— quick decision factors or 
3 These terms may be understood differently in the case of health products (e.g., an adverse 
reaction that has a known delayed onset will be a known risk for medicine safety assessors — not 
an unknown one).
23Chapter 2 Context and Overview of Health Product Risk Communication
rules of thumb — to process, filter, and modify risk information (Tversky & 
Kahneman, 1979, 1981; Kahneman & Tversky, 2000; Kahneman, 2011). They 
thus simplify risk information and often make very rapid decisions in situations 
involving risk (Kahneman & Tversky, 2000; Kahneman, 2011). Four important 
heuristics are introduced in Table 2.5: representativeness, availability, anchoring, 
and affect. 
Many demographic and social characteristics may influence an individual’s risk 
perception, including age, gender, ethnicity, income, and education (Slovic, 2000; 
Morgan et al., 2002; Bennett et al., 2011). Socio-economic and cultural factors 
therefore also play an important role in shaping risk perception. Vulnerable 
populations, those groups that cannot be reached with timely risk information 
because of cultural or socio-economic reasons, face “increased potential for 
loss in a hazardous situation” (Vaughan & Tinker, 2009). As Fothergill and 
Peek (2004) argue, in addition to actually facing greater risks, low-income 
populations experience heightened perceptions of risk because they typically 
have less control over their lives and tend to normalize everyday exposure to 
hazards. Many groups cannot be reached effectively with general risk messages 
because of linguistic or socio-economic factors, or cultural experiences that 
may lead them to mistrust health officials and government authorities. For this 
reason, risk communicators must be able to determine for which segments of 
the population specialized communication may be required and to evaluate 
whether the risk information that they are providing is being understood by 
vulnerable groups. 
As Kasperson et al. (1988) argue, “the investigation of risk is at once a scientific 
activity and an expression of culture.” Indeed, the role of culture in shaping 
risk perceptions has been an active area of research for several decades 
(Kahan, 2012). Successful risk communication depends on understanding 
differences in cultural practices and beliefs. In some contexts, a pervasive media 
environment plays a strong role in shaping public responses to risk events, 
including their assessment of the performance of health regulators or other 
government agencies in managing risk exposure. In other contexts, the role 
of community elders, peer groups, or religious and spiritual beliefs may play 
a more powerful role in shaping risk perceptions. As Abraham (2009) argues, 
“[d]ifferent cultures ascribe different meanings to illness, sickness and disease 
and biomedical explanations of disease are not universally accepted.” Yet, 
within a given culture, there may also be variability that risk communicators 
need to understand. In Canada this includes addressing the multicultural 
dynamics of diverse urban populations and the differences in risk perception 
and health behaviour between Aboriginal and non-Aboriginal populations 
(NAHO, 2007; Vukic et al., 2011). Research has led to the identification of 
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several processes (described in Table 2.5) whereby cultural world views and risk 
perception interact such as identity-protective thinking (Finucane et al., 2000; 
Slovic, 2000; Kahan et al., 2010a), culturally biased assimilation (Kahan, 2012), 
and the social amplification of risk (Kasperson et al., 1988).
Table 2.5
Risk Characteristics, Mental Heuristics, and Socio-Cultural Factors  
that Affect Risk Perception
Risk Characteristic Description Example 
Voluntariness Imposed risks are less acceptable 
than voluntary risks (i.e., risk is 
amplified if the risk is imposed  
and attenuated if it is voluntary). 
Individuals will accept voluntary 
risks that are much more risky  
than involuntary risks.
Taking natural health products  
is seen as voluntary while being 
prescribed a medication is seen  
as imposed. This leads people  
to believe that natural health 
products may carry less risk.
Controllability Risks that individuals cannot  
control are less acceptable than  
risks perceived to be under  
individual control. Perceived  
control is not necessarily the same  
as actual control. Individuals often 
overestimate their ability to control  
a situation/risk (i.e., over-confidence).
Chronic diseases such as type II 
diabetes or heart disease are viewed 
as less risky or fear-inducing because 
they often relate to lifestyle choices 
within an individual’s control 
compared with being exposed to 
outbreaks of a severe virus, which  
is seen as less controllable. 
Equity Distribution of risk impacts is 
perceived as more important than the 
overall impact of risk. Risks that are 
perceived to be unfairly distributed 
are less acceptable than risks 
perceived to be fairly distributed.
Flu outbreaks in the community are 
perceived to be fairly distributed 
across the population while hospital 
infections are seen to be unfairly 
distributed in particular cases, and 
are therefore less acceptable.
Time Period/Delay 
Effect
The time period between an initial 
risk event or risk behaviour and  
the eventual impact influences the 
perceived level of risk. Generally, 
risks with delayed impacts are 
perceived as lower risk no matter 
how severe their consequences.
There is a long delay between poor 
eating habits and the onset of heart 
disease and a short delay between 
exposure to a virus and the onset  
of symptoms.
Dread Risks that evoke fear/great 
apprehension are perceived to be less 
acceptable than those that do not.
The risk of Ebola evokes dread while 
the risk of heart disease does not.
Cognitive Bias Description Example
Loss Aversion Individuals have a tendency to 
strongly prefer avoiding losses  
to acquiring gains.
An individual may fear the negative 
outcomes associated with taking a 
drug over the potential benefits of that 
product even if the benefits are greater.
continued on next page
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Individual Heuristic Description Example 
Representativeness Leads individuals to evaluate the 
probability of a risk event by how 
similar it is to a stereotype or other 
pre-existing knowledge structure. Can 
lead to biases because the fact that 
something is more representative 
does not make it more likely.
Individuals using a stereotype of  
the “typical woman who gets breast 
cancer” when considering their risk  
of getting the disease.
Availability Leads individuals to evaluate  
the probability of a risk event  
by whether similar occurrences  
can be brought to mind.
Someone underestimating the risks  
of genetic testing for cancer because 
they cannot recall risks associated  
with the testing. 
Anchoring Leads individuals to estimate 
probabilities by starting from an 
initial piece of information that  
may be unrelated to the risk.
Women who overestimate their  
risk of breast cancer pre-genetic 
counselling may continue to 
significantly overestimate their  
risk post-counselling.
Affect Leads individuals to estimate  
risk based on their subjective 
impression of the goodness/badness 
of the situation. 
Someone overestimating their risk of 
cancer because he/she has personal 
experience with the disease through 
friends or family.
Socio-Cultural 
Factor
Description Example 
Cultural Identity-
Protective Cognition
People tend to align their  
views with others with whom  
they share some important  
cultural characteristic.
Tendency for white men to view 
environmental risks as less serious  
than they are viewed by women  
and minorities.
Culturally Biased 
Assimilation
Leads individuals to reinforce those 
arguments that reinforce their cultural 
viewpoint while dismissing those that 
do not, leading to polarization of 
groups even when they are exposed 
to the same information.
Tendency for those with egalitarian 
and communitarianism world views to 
be less fearful of the risks associated 
with the HPV vaccine compared  
with those with hierarchical and 
individualistic world views.
Social Amplification 
of Risk
An original real-world event creates  
a signal whose magnitude (i.e., the 
perceived threat) is changed as it 
moves through a given society. Every 
person who receives the risk signal 
also engages in amplification or 
attenuation processes and therefore 
has an effect on the risk signal.  
Initially, social amplification of risk 
encompasses only those who are 
directly impacted by a risk (or the first 
group made aware of it). But over time 
the impacts extend to other groups. 
The magnitude of fear associated 
with the Ebola virus has been 
amplified by discussions in media, 
social media, and personal networks 
of peers. Other groups that impact 
the Ebola risk signal include domestic 
and international governance groups.
Source: (Tversky & Kahneman, 1979, 1981; Kasperson et al., 1988; Cull et al., 1999; Finucane et al., 2000; 
Kahneman & Tversky, 2000; Slovic, 2000; Gerend et al., 2004; Peters et al., 2006; 
Kahan et al., 2010a, 2010b; Kahneman, 2011; Kahan, 2012; Roeser et al., 2012)
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While there is strong evidence for the described risk perception factors, they may 
not be true in all cases. Furthermore, the research on individual decision-making 
is not specific to health product risks. Therefore, targeted research on these 
relationships for health product risks is needed to better understand how they 
affect communication. For a more thorough and in-depth discussion of these 
research areas, the reader is directed to more comprehensive sources such as 
Kahneman & Tversky (2000), Slovic (2000), Kahneman (2011), Kahan (2012), 
Roeser et al. (2012).
Risk Communication Practices Supported by Scientific Research
Research into how people interpret and respond to health risk communication 
specifically could be used to guide communication development and to ensure 
that people understand and use information. For example, when communicating 
health-related probabilities and uncertainties, research has shown that numbers 
are more effective than words in conveying probabilistic information to 
patients (Marteau et al., 2000; Man-Son-Hing et al., 2002; Trevena et al., 2004; 
West et al., 2013). Furthermore, numeric information (over words) about 
adverse events increases risk comprehension across numeracy levels (i.e., 
those who are less numerate benefit along with those with high numeracy) 
(Peters et al., 2013). Research also indicates that illustrations should be used 
to complement the presentation of probabilities when possible, and that there 
are advantages and disadvantages of the many different types of illustrations 
available (Lipkus, 2007; Fagerlin & Peters, 2011; Mt-Isa et al., 2013a, 2013b). 
The emotional response to a communication is also an important dimension 
in understanding how an individual reacts to recommendations. Emotions 
(or affect) can be induced either integrally or incidentally. Integral affect 
describes feelings that result from an explicit part of the communication, 
whereas incidental affect refers to feelings that are only indirectly induced by the 
communication or independent of the communication (Lerner & Keltner, 2000; 
Visschers et al., 2012). The emotions induced incidentally depend on the unique 
context of that individual and may result from social amplification (e.g., media) 
or past experiences (e.g., a previous hospitalization) (Lerner & Keltner, 2000). 
While the sender has greater control over integral affect, negative incidental 
affect requires careful consideration and planning to mitigate, when possible 
(Visschers et al., 2012). 
Linked to this idea is the use of fear in communication efforts. Although not 
appropriate for risk communication in general, a meta-analysis demonstrates 
that it can be effective to invoke fear in public health campaigns when messaging 
depicts a “significant and relevant threat,” when recipients feel the advice will be 
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successful in averting the threat, and when recipients believe they can successfully 
implement the advice. Fear appeals, however, need to be used cautiously as 
they can backfire when these conditions are not met (Witte & Allen, 2000).
These examples are only a small sample of the relevant research studies that 
have yielded useful information on how individuals interpret/respond to risk 
information. For example, a comprehensive review of evidence supporting 
patient decision-aids (a type of risk communication tool) in clinical care have 
been summarized and a set of communication appraisal standards have been 
developed (Volk et al., 2013). For government agencies and health regulators 
there are several publications that provide guidance based on research into 
health risk communication (Fischhoff et al., 2011; Mt-Isa et al., 2013a, 2013b). 
The Panel has identified Communicating Risks and Benefits: An Evidence-Based 
User’s Guide, a publication prepared for the U.S. Food and Drug Administration 
(FDA), as providing the most thorough discussion of evidence-informed 
communication practices for health regulators (summarized in Table 2.6). 
Table 2.6
Risk Communication Practices Supported by Scientific Evidence
Category Evidence-Informed Communication Practices
Definitions of 
Outcomes
Use standard definitions for risks with multiple outcomes.
Use standard definitions for risks with multiple features.
Use standard definitions for outcomes that occur over time.
Quantitative 
Information
Provide numeric likelihoods of risks and benefits. 
Provide absolute risks, not just relative risks.
Keep denominators constant for comparisons.
Keep timeframes constant. 
Use pictographs and other visual aids when possible.
Make the differences between baseline and treatment risks and benefits clear. 
Reduce the amount of information shown as much as possible. 
Provide both positive and negative frames. 
Use interpretive labels or symbols with care to convey the meaning of  
important information. 
Test communications prior to use.
continued on next page
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Category Evidence-Informed Communication Practices
Qualitative 
Information
Identify the main factors determining the risks and benefits of a choice, along 
with the relationships among them.
Characterize existing beliefs in terms comparable to the formal model.
Draft, test, and redraft communications, addressing the critical differences 
between what people know and what they need to know.
Health Literacy (e.g., 
Treatment Labelling)
Organize components to reflect how people process instructions.
Emphasize critical information.
Simplify language.
Give explicit time periods.
Include purpose for use.
Limit auxiliary information.
Address language proficiency.
Select appropriate font.
Improve readability.
Affect and Emotion Provide risk and benefit information about taking an action.
Consider presenting risks and benefits of not taking an action.
Make the affective meaning of important information easy to access.
When emotions are expected to be high (and potentially harm decisions), 
provide methods to “stop and think” to reduce affective input.
Fight fire with fire (when persuasive communication is needed).
Consider the effects of advertising, brand names, and other promotional efforts 
on perceptions of the risks and benefits of products.
Source: (Downs & Fischhoff, 2011; Fagerlin & Peters, 2011; Fischhoff, 2011; Peters, 2011; Wolf, 2011)
2.2.5 Ongoing Partnership and Exchange 
Given the importance of contextual factors and the needs of various populations 
and stakeholders, risk communication has moved from a model of one-way 
(expert-to-public) dissemination of information to multi-level and multi-way 
exchange among all relevant populations and stakeholder groups (Leiss, 1996). 
This new communication practice involves more than simply monitoring what 
particular groups are saying with the goal of changing their behaviour. Rather, 
it focuses on understanding and appreciating the concerns of those involved to 
establish a meaningful dialogue in which all parties learn from the experience 
and remain open to adjusting their positions accordingly. 
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Importantly, the nature of each risk situation will dictate the level of dialogue 
appropriate for different receivers of information and stakeholders. For example, 
while in many cases communications are improved through coordination with 
industry stakeholders, there may be situations for health products where it is 
most appropriate for the regulator to issue communications independently 
and without consulting those groups. While stakeholder engagement and 
multi-way exchange are important, there may be instances where command 
and control communications that focus on one-way exchange could still be 
useful. For instance, in emergency situations where the risk of harm is great 
or imminent, there may not be time for detailed and lengthy consultation 
with all relevant groups. These situations are often predictable, however, and 
communications can be tailored to the specific situation at hand through 
pre-testing with experts knowledgeable about affected populations but not 
involved in content development (Fischhoff, 2005). 
The necessity of command and control communications in some situations 
illustrates the importance of ensuring continuous dialogue between the 
senders and receivers of information, and other stakeholders, so that there is 
a foundation on which communications can rely. Ongoing dialogue is needed 
to find out what different groups already know about a risk and where there 
are gaps and information needs. Communicators also need to understand 
the concerns of particular affected groups. Because people actively seek out 
(or avoid) risk information and evaluate a given risk based on their own set of 
criteria (Alaszewski, 2005), communicators need to recognize and understand 
a group’s broader social context, needs, and cultural factors (Frewer, 2004). 
Multi-way communication involves understandable, decision-relevant information 
and the incorporation of meaningful feedback to policy and planning. The 
exchange requires the receivers of information to be respected and viewed 
as legitimate partners whose input is valued and heard (Covello, 2010). 
A commitment to active listening with the intention of dealing openly with 
concerns is crucial for meaningful, ongoing dialogue. 
There are several benefits to ensuring that dialogue starts early, is ongoing, 
and does not end once a particular risk communication is released. Any 
communication may cause a risk to evolve as needs change or perceptions are 
modified. Continued dialogue is needed to monitor, and adequately respond, 
to the changing context (Veil et al., 2008). Ongoing communication can help 
ensure that all stakeholders feel listened to, provided communication is done 
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in good faith. This includes responding to specific concerns or comments 
and clarifying what action will follow as a result. This type of engagement at 
multiple levels may help establish and build trust, foster credibility, and develop 
common understanding over time, which provides the foundation for future 
risk communications and events. Having established positive relationships 
with a variety of groups will be especially important in those cases where only 
one-way communications are possible due to time or other constraints.
2.2.6 Moving Forward
While the literature recognizes the importance of many different communication 
practices, they may not always be incorporated in practice. In fact, some research 
suggests that risk communication by government agencies has, in many ways, 
changed little in the past several decades (Kasperson, 2014). Notably, while 
the importance of ongoing exchange and relationships with all stakeholders is 
recognized in theory, the broader steps needed to develop these relationships 
are rarely considered. Recognition that relationships with stakeholders need to 
be fostered and managed will bring risk communication into a new paradigm 
with broader goals and new ways of communicating (discussed in the next 
section). At the same time, the lessons and practices of the past should not be 
forgotten: sound risk characterization, clear and appropriate messaging, and 
ongoing partnerships and exchange will continue to be very important for 
effective health product risk communication in the future. 
2.3 THE NEW PARADIGM OF RISK COMMUNICATION
Key Findings
• The complex environment for health product risk communication demands shared 
responsibility, coordination, and collaboration among several different groups. 
• Communicators better meet the needs of various populations when communicating 
uncertainty clearly and proactively and making it a central component of any risk 
communication message.
• Communicators can increase the public’s access to and ability to understand 
health information as well as empower and build trust by involving the public 
in decision-making and by valuing transparency efforts. These efforts can lay 
the groundwork for meaningful risk communication dialogue over the long term.
• Established relationships with various affected populations and stakeholders 
can enable timeliness and acting proactively in the face of new risks.
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Recognition of multi-way dialogue, and the need to build strong relationships 
over time, is prompting a paradigm shift for risk communication. This emerging 
paradigm builds on the learning from the past to address new challenges 
relevant for evaluation of health product risk communication: 
• Governance: addressing the challenges that stem from shared responsibility 
within the risk management and communication environment.
• Complexity: navigating the inherent complexities of the risk and the 
communication environment that comprises multiple stakeholders 
and priorities.
• Uncertainty: communicating uncertainty and multiple interpretations of 
the evidence.
• Empowerment: moving from providing prescriptive statements to enabling 
solutions and empowerment. 
• Timeliness: ensuring timely and proactive responses that build trust over time. 
• Transparency: ensuring reasoned transparency that increases the public’s 
access to and ability to understand health information.
These challenges vary depending on the nature and context of the risk. 
They also do not exist in isolation, and elements of one affect another. For 
example, uncertainty can be influenced by the complexity of the communication 
environment, and both of these challenges may affect the timeliness of a 
communication and empowerment. There are also common themes that 
cut across challenges, most notably the role of trust in building relationships 
over time. 
2.3.1 Governance
The complicated governance structures for health in Canada create challenges 
for the communication of health product risks. At the federal level, Health 
Canada is responsible for the regulation of health products, approving drugs 
and medical devices for sale, and carrying out post-marketing evaluation to 
ensure these products are safe (regulatory responsibilities are described further 
in Chapter 3). However, industry (or market authorization holders, MAHs) 
plays a critical role in health product risk communication and is responsible 
for the identification of risks. For example, some risks (e.g., known side effects) 
are detected during clinical trials and included in the materials submitted by 
industry to seek market approval. In many cases, the MAHs actually produce 
and distribute the health product risk communication tools also distributed 
by Health Canada (e.g., public advisories). For communications such as drug 
labels, dear doctor letters, and public advisories, Health Canada provides detailed 
guidance documents and templates outlining the format and content to be 
included in risk communications, and approves the final product. Health Canada 
does, however, distribute its own communication tools when an MAH refuses 
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or is unable to do so (Health Canada, 2008). It is clear that regulators and 
health product manufacturers and distributors have a shared responsibility 
that must be coordinated in any communication effort on health product risk. 
This can be challenging to navigate given that regulators and industry groups 
may have competing goals.
Adding to this governance structure is the segmentation of different health 
communication activities across different orders of government. As Driedger 
et al. (2013) explains, “the nature of the Canadian confederation, with its 
federal-provincial-territorial division of powers and responsibilities makes it 
ripe for risk communication quagmires.” In the case of health products, Health 
Canada acts as the regulator; provincial health ministries are responsible for 
the administration and delivery of health services (except for First Nations and 
Inuit, military personnel, veterans, and members of the Royal Canadian Mounted 
Police, who are under federal jurisdiction); and local authorities provide public 
health services in their jurisdiction such as influenza immunization clinics, 
sexual health clinics, outbreak investigation, and food establishment inspection. 
This shared responsibility can lead to a lack of clarity on the responsibilities of 
each level of government for communication and evaluation, particularly when 
different communication programs in different jurisdictions are designed to 
influence similar health outcomes. 
During the H1N1 pandemic of 2009, for example, several government agencies 
had a role to play in managing the outbreak (PHAC, 2010). These included 
two federal players, Health Canada (e.g., ensure vaccine safety) and the Public 
Health Agency of Canada (e.g., analyze and interpret surveillance information); 
provincial health departments (e.g., cover the costs and provide vaccines); 
Aboriginal leaders (e.g., arrange for the delivery of vaccinations); and city/
regional public health departments (e.g., deliver vaccinations through clinics, 
monitor local health events). Furthermore, given the global nature of the 
outbreak, international organizations like the World Health Organization 
(WHO) coordinated international responses and made recommendations on 
when to start vaccine production. Cooperation and coordination during the 
crisis was identified as one of the factors that worked well and helped manage 
the pandemic in Canada (PHAC, 2010). 
Depending on the nature of a health risk, the affected populations receiving 
information, and other stakeholders, responsibilities for risk management 
may also involve non-health government departments and agencies. For 
example, in Canada, for certain risks, communication may need to involve 
the Canadian Food Inspection Agency, Environment Canada, or Aboriginal 
Affairs and Northern Development Canada at the federal level. Similarly, 
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there may need to be coordination with non-health departments at provincial 
or municipal levels. In some cases, risk governance may also include groups 
outside formal government structures, such as interest and advocacy groups 
or individuals on social media. A Canadian event in the 1980s demonstrated 
the severe consequences of poor coordination and collaboration among 
these groups. Contaminated blood resulted in infection of at least 30,000 and 
2,000 individuals with hepatitis C and HIV, respectively. In response to the crisis, 
a commission of inquiry was established, which found the contamination of the 
blood supply was inevitable, but that failures by all organizations responsible 
for regulating blood made the problem worse (Krever, 1997). These failures 
included an absence of communication of risk among different agencies and 
organizations, and among doctors and patients, as well as unclear mandates 
of key organizations such as the Canadian Red Cross Society (Norris, 2008; 
GOC, 2013b). 
Moving Forward
Establishing who is responsible for what and exchanging data and information 
can be difficult when multiple authorities or jurisdictions are involved in risk 
communication and its evaluation. Ensuring coordination and flow of information 
in these cases is essential for success (WHO, 2001). Strong relationships and 
cooperation among the different governance bodies, along with good planning 
that considers complicated governance structures, can support the development 
and dissemination of effective risk communications and their evaluation.
2.3.2 Complexity
The communication of health product risk does not take place in a vacuum: 
beyond the levels of government and industry there are multiple stakeholders 
involved who add their own interpretive dimension to any communication. 
Further, complexity may arise from the nature of the risk, the knowledge 
about that risk, or any resulting discourse. Complexity stems from the hazards 
causing a risk, the knowledge and uncertainty in the effects, the interactions 
between effects, and other political, ethical, economic, and social dimensions.
Multiple Players
Although the regulator often develops or approves strategies for communicating 
health product risk, several other groups influence how that information will 
reach, or be interpreted by, various populations. Many of these groups are 
responsible for disseminating risk information to consumers directly. They 
may change the original message entirely or influence what information 
people see as relevant, important, or credible, thus supporting or hindering 
the dissemination of accurate information. For example, a study of vaccination 
seeking behaviours during the H1N1 outbreak found that media coverage 
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as well as messages from authority groups competed to shape and frame 
people’s view of the pandemic (Boerner et al., 2013). Study participants were 
also far more likely to mention the media stories (rather than government 
communications) during focus groups (Boerner et al., 2013). Non-governmental 
health organizations (e.g., counselling services for pregnant women) and 
health professionals were also trusted sources of information that shaped 
how people viewed the pandemic and vaccinations (Lynch et al., 2011; 
Sakaguchi et al., 2011). How these different sources of information may agree 
with or challenge the recommendations communicated by regulators can 
increase the complexity of the overall communication environment.
Health Professionals
In communicating about health products, health professionals (e.g., paramedics, 
nurses, pharmacists, physicians) often interact most directly with the public 
and are among one of the most trusted groups in Canada (Ipsos, 2012). 
Health professionals are expected to be up to date on the nature of the risks 
associated with health products and provide the information needed to work 
with the public. The public assumes that health professionals will disclose all of 
the safety information available. It is therefore essential to engage and involve 
these professionals in any communication effort. 
Organizations
In Canada a wide variety of health-based organizations have a role in creating or 
disseminating health product risk communications, and each organization has 
access to its own unique group of people. Disease-based support or fundraising 
organizations (e.g., the Canadian Cancer Society) communicate with patients 
and interested members of the general public. Organizations that accredit, 
regulate, license, or advocate for health professionals may provide guidance 
to their members on how to use health product risk information and on the 
treatment of patients, in general or in cases of identified risks. For example, 
the Canadian Association of Gastroenterology issued a position statement 
with recommendations on prescriptions of proton pump inhibitor drugs in 
response to emerging concerns about their effect on risk of bacterial infections 
(The Canadian Association of Gastroenterology, 2005).
Media
Often much of the information that the general public receives about a health 
product risk comes through the media (e.g., newspaper, radio, television). 
According to the WHO, “the media may merely transmit a message, or they 
may create or interpret a message. They are not limited to official sources of 
information and their messages often reflect the concerns of the public and other 
sectors of society” (WHO, 1998). Journalists may act as partners (particularly 
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during periods of crisis or emergency) and as key players who can contribute or 
enhance outrage and/or the social amplification of risk. News media therefore 
not only reflect what risks mean to different groups and actors, but actively 
shape the discursive environment through which risks emerge as problematic 
and in need of action (Greenberg, 2012). In some cases, the success or failure 
of a risk communication may be influenced by media coverage. For example, a 
communication on the risks associated with co-dispensing cisapride with other 
medications issued in the United States in 1998 was found to have an impact 
on co-prescriptions when earlier warnings did not, partly because it was more 
widely publicized in the media (Weatherby et al., 2002). In contrast, in 2009 the 
U.S. Preventive Services Task Force recommended that routine mammograms 
should start at age 50, while women in their forties should decide whether 
to undergo the test only after discussing their risk factors with their doctor 
(Schwitzer, 2011). Many news stories discussing these recommendations focused 
on anecdotes and overstated the benefits of mammography, while downplaying 
potential harms, thus contradicting the recommendations (Schwitzer, 2011). 
Examples such as these seem to be a widespread problem; in an analysis of 
1,400 news articles related to health, about 70% failed to adequately mention 
the harms and benefits of interventions being discussed (Brainard, 2011; 
Schwitzer, 2011).
Individuals, Communities, and the Influence of Social Media
The critical role of the public must also be considered. Individuals are generally 
responsible for decision-making on their own health, and in many cases have 
significant influence on decisions about the health of their friends and family. 
Health decision-making is informed by the risk information an individual or 
group accesses, and how they interpret it. Social media provide new platforms 
that can be exploited to spread messages quickly, effectively, and in different 
ways (e.g., Instagram for photos, Facebook for personal connections and 
engagement) as part of an overall risk communication strategy. Participatory 
media like Twitter and Facebook can potentially amplify the demands for 
greater accountability and transparency and can challenge the nature of the 
relationship between communicator and receiver by facilitating discussions and 
building trust among these groups. They can also provide potential sources of 
intelligence for issue surveillance. These changes move the internet beyond 
a new medium to disseminate risk information to a social movement that can 
accelerate behaviours and challenge authority. By contrast, the wide availability 
of counter-information online can be spread quickly through social media and 
influence how people interpret and react to risk. Social media are therefore 
not a panacea and should be used as part of an overall risk communication 
strategy that recognizes that different platforms are appropriate for different 
communication goals. 
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Complex Risks and Hazards
Risk decision-making must account for a myriad of demographic, socio-economic, 
environmental, political, and organizational factors, which may interact in 
largely unpredictable ways to produce the outcomes associated with a risk 
communication. These relationships are themselves complex, non-linear, 
and dynamic. Even in cases where there is a clear hazard leading to a risk 
(e.g., smoking and lung cancer), the factors comprising the risk context influence 
risk management activities among various groups, making the situation and 
behaviour difficult to understand. Situational complexity consists of multiple 
factors: the impact of the risk (actual, perceived, and potential); the vulnerability 
or resilience of those affected by the risk; and the uncertainties associated with 
the evidence surrounding the risk (Lemyre et al., 2011). 
Furthermore, the many, and often competing, interests, values, expectations, 
and needs of the interdisciplinary players involved with any particular risk 
situation go well beyond their role in communicating about risk. Each player 
exists in its own context and sees risk through a unique lens (Stame, 2004). These 
contexts are not independent of one another, however, given the social and 
power dynamics that exist across all risk communication players (Stame, 2004). 
Health product risks also have material, economic, political, social, and other 
dimensions that add to their complexity. This wide range of competing interests 
and needs make it challenging to link any one input to another because so 
many factors can interact with and affect one another, sometimes producing 
largely unexpected outcomes (Pawson & Tilley, 1997; Weiss, 1998).
Moving Forward
The complex environment for health product risk communication can be 
addressed through consideration of a range of relevant interests and coordination 
of key players. Coordination and collaboration with all relevant stakeholders, 
including health professionals, organizations, media, and the public, can help 
regulators in the integration and communication of available information on a 
given risk. These relationships can foster a greater understanding of the range of 
complexities associated with a risky situation. This is especially important when 
there are competing interests, perspectives, and interpretations. An absence 
of coordination can increase uncertainty among the receivers of information 
and, in some cases, increase risk. 
2.3.3 Uncertainty
While uncertainty is inherent in all types of risk (see Section 2.2.3), it is very 
relevant in the context of health product risk. Risks of recently approved health 
products are based on limited evidence from controlled trials, and information 
from long-term real-world use is lacking. If drugs were approved through 
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accelerated processes and/or processes with surrogate outcomes, this adds to 
uncertainty (IOM, 2014). Uncertainty may diminish as real-world experience 
accumulates; however, socio-cultural ambiguity may increase if there are differing 
interpretations of whether benefits outweigh known side effects and other risks. 
Communicating uncertainty in the context of health products is also complicated 
for both the senders and receivers of information (Kasperson, 2014). Experts may 
be reluctant to communicate uncertainty because of perception that uncertainty 
is “misplaced imprecision” that provides unnecessary complication or doubt; 
poor opinion of “lay audiences” or decision-makers and the expectation that 
information will be misunderstood; fear of being punished for being candid 
about the presence of uncertainty; or their own inability to properly express 
uncertainty in a clear and succinct way (Fischhoff, 2012; IOM, 2014). Experts 
may also have concerns that the public cannot conceptualize the uncertainties 
associated with risk estimates (Frewer, 2004), leading to misunderstanding of 
risk information, or that they will view scientific uncertainty as incompetence 
(Frewer et al., 2003; Wynne, 2008; Markon et al., 2013). 
Reluctance to explain uncertainty can stem from a view of risk communication 
as a tool for persuasion rather than empowerment, as it does not take into 
account the views and desires of those receiving risk information. Open 
discussion with the public about the multiple sources of uncertainty is believed 
to improve risk communication and encourage trust in the senders of 
information (Palenchar & Heath, 2007; Wynne, 2008), although there 
has been limited research in this area to provide empirical support 
(Johnson, 2003; Markon et al., 2013). There is evidence, however, that the ability of 
non-experts to understand uncertainty has been underestimated, and that the 
public can recognize and distinguish between different types of uncertainty 
(Markon & Lemyre, 2013). In addition, research has found that individuals 
often want information about the uncertainties associated with risk information 
(Frewer, 2004). 
As an example, during the H1N1 outbreak, health agencies around the world 
strongly recommended that pregnant women get vaccinated as they were at 
higher risk from the illness (PHAC, 2010). Pregnant women, however, had 
concerns about the uncertainty associated with effects of the vaccine on 
themselves and their babies (Lynch et al., 2011; Sakaguchi et al., 2011). They are 
taught to be selective about medicines and are therefore generally hesitant to 
take any medication during pregnancy because of fears of harming their babies 
and affecting breast feeding after birth (Bonari et al., 2005; Lynch et al., 2011). 
However, research suggested that pregnant women were willing to reassess their 
previous views “after exposure to engaged discussion” (Lynch et al., 2011). 
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Poor communication around uncertainty has been shown to have negative 
outcomes. These include needless hesitation or, conversely, unwarranted 
confidence, inappropriate choices, personal regret, or interpersonal resentment 
(IOM, 2014). For example, conflicting messaging about which vaccine pregnant 
women should take caused further confusion during the H1N1 outbreak 
(Babbage, 2009; Smith, 2009). Failure to communicate known ambiguity may 
also have negative implications: conflict among different sources has been 
found to lead to more alarmist perceptions than conflicting data presented 
from the same source (Viscusi, 1997). 
The context and nature of the risk information may affect how much uncertainty 
information is needed in communication efforts. Research has found that 
people value an uncertainty discussion, using that conversation to inform their 
choices about a given health risk, but do not need to know all of the known 
uncertainties (Fischhoff, 2013; Kasperson, 2014). Furthermore, they generally 
do not want uncertainty information about risks outside of their personal 
control (Frewer et al., 2002). People may be more comfortable with uncertainty 
stemming from divergent data than with uncertainty stemming from divergent 
interpretations by experts (Markon et al., 2013). For example, in the case of 
vaccines, people in focus groups in Edmonton, Winnipeg, and Toronto felt 
that the messaging from alternative communicators was more credible than 
provincial/federal health agencies because these alternative sources presented 
both pro- and anti-sides of the vaccine debate for their consideration while 
health agencies presented a one-sided campaign (Boerner et al., 2013).
As with transparency about past failures, openness about uncertainty can decrease 
public confidence in an organization (Kasperson, 2008). In fact, research 
has demonstrated that uncertainty information may lead people to view the 
institution responsible for the communication as more honest but less competent 
(Johnson & Slovic, 1995). In contrast, while communication of uncertainty is 
often associated with greater perceived risk (Slovic, 1987; Löfstedt, 2003), this 
is not always the case. For example, Frewer (2004) found that, while disclosing 
uncertainty does increase perceived risk for those people who were previously 
indifferent to the issue, it can actually reduce the perceived level of risk of 
those people who were previously very concerned. Despite the potentially 
negative trade-offs, building trust through communicating uncertainty in an 
appropriate manner can result in a strong relationship between the senders 
and receivers of information.
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Moving Forward
There is potential benefit to accounting for uncertainty in risk communications, 
but how to present that information depends on the type of uncertainty, the 
objectives of the communication, and evidence-based communication practices 
(Table 2.6). Although there is sometimes debate about the best way to present 
uncertainty, appropriate communication practices will help. Such practices 
aid not only in getting the message through but also in building the trust and 
relationships needed for ongoing exchange. Further research is needed on 
promising ways to communicate uncertainty, when it matters, and when it can 
be harmful. 
2.3.4 Empowerment
Empowerment of individuals to make informed decisions (i.e., to change 
behaviour or make an informed refusal) is one of the shifts in the evolving 
risk communication paradigm and is an important way to mitigate or avoid 
negative responses among populations receiving information. Aiming for 
empowerment recognizes that regardless of how effective risk communication is, 
reasonable people may disagree about the best path forward (Fischhoff, 2013). 
Empowerment thus requires that communication considers and respects the 
values, desires, and knowledge gaps of various populations. 
Risk communication must make sense to those affected, and empowerment 
strategies can help in this regard. For example, when developing a sexual 
health intervention aimed at empowering young women, one study focused 
on a suite of factors that might affect decisions on sex (including pleasure and 
personal relations) (Bruine de Bruin et al., 2007). An interactive DVD was then 
developed to fill the knowledge gaps identified and to present both positive and 
negative outcomes. This format allowed for the presentation of information 
“more easily seen than explained” (e.g., how to put on a condom), helped teens 
to select the material most relevant to them, and avoided the awkwardness 
associated with discussions on sex between teens and educators (Bruine de 
Bruin et al., 2007). By considering the knowledge needs of young women, the 
tool avoided the pitfalls of many sexual health education programs (e.g., not 
emphasizing the risk of ongoing unprotected sex) (Downs et al., 2004a, 2004b; 
Bruine de Bruin et al., 2007). Overall, the DVD was found to reduce condom 
failures and increase abstinence while also decreasing incidence of sexually 
transmitted infections when compared with other interventions (Bruine de 
Bruin et al., 2007). 
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The importance of empowerment through shared decision-making has been 
recognized in the health risk communication literature, most notably in 
patient-physician joint decision-making to choose treatment plans for very 
serious health issues (Charles et al., 1999; O’Connor et al., 2003; Jardine & 
Driedger, 2014). This approach recognizes patients as part of the decision-making 
team, rather than simply as a target for risk information, and considers their 
values and preferences in the decision-making process, aspects of which could 
be extrapolated to broader health product communication efforts by regulators 
(Jardine & Driedger, 2014). Interventions like this have been linked to positive 
health outcomes. For example, Greene and Hibbard (2011) demonstrates the 
strong links between patient activation (“having the knowledge, skills, and 
confidence to manage one’s health”) and a range of positive health outcomes, 
including systolic blood pressure in the normal range, lower rates of obesity, and 
fewer hospitalizations. Engaging affected populations in the decision-making 
process includes sharing in a way that is both available and appropriate (Jardine & 
Driedger, 2014). This means using effective presentation methods to ensure risk 
information can be understood (see Table 2.6) and including an appropriate 
amount of information. Providing too little can leave people feeling ill informed 
while too much can make it difficult to identify what information is important 
and make the process feel overwhelming. Similarly, messaging is more effective 
if it provides accessible solutions that are considered realistic by those receiving 
the information (O’Carroll et al., 2013). 
Trust and empowerment efforts are greatly linked. People who do not have 
core values on a given issue look towards credible communications to make 
decisions in the face of uncertainty (Bostrom, 1997; Downs et al., 2008). Much 
of this group’s responsiveness to what is communicated is related to their trust 
in the agency doing the communication, and how complete they believe that 
information to be. Empowerment helps build trust, while communications 
that do not address population needs risk losing it. For example, sexual 
health programs often fail to consider that teens and adults may view the same 
decisions about sexual intercourse differently and educators may attribute the 
risky behaviour of teens to their acting irrationally or underestimating the risks 
(Bruine de Bruin et al., 2007). Communications based on these misconceptions 
may lead to teens “draw[ing] erroneous inferences” and “resent[ing] adults 
who seem to be wasting their time with simplistic, incomplete, and repetitious 
messages.” Teens may start to mistrust the source if their real-life experiences 
contradict the sexual health messages that they are being told (Bruine de 
Bruin et al., 2007). Likewise, health product regulators may lose public trust 
as a result of specific crises (e.g., Vioxx®) where communications are reactive. 
This exacerbates the loss of trust, whereas proactive communication can 
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rebuild public trust (Morgan et al., 2002; Löfstedt, 2010). The importance of 
the participation of health product users in the entire risk management process 
(including communication), and its role in building trust, has been recognized 
(Bahri, 2010). A lack of trust makes empowerment of those who are exposed 
to a given risk all the more important. 
Moving Forward
Messaging that does not meet the needs of groups receiving the information 
is typically not effective in changing behaviours and can cause people to avoid 
risk information or ignore messaging. Empowerment efforts can be effective in 
creating meaningful dialogue that better meets people’s needs. These efforts 
include creating appropriate messaging for understanding, comprehension, 
and action; engaging populations receiving information as members of the 
decision-making process; and focusing on long-term relationships and informed 
change. In an empowerment context, communicators must respect informed 
individual decisions that may go against risk communication messaging. In 
practice, ensuring that populations receiving information are empowered is a 
long-term process that is achieved incrementally (Jardine & Driedger, 2014).
2.3.5 Timeliness 
Balancing Trade-Offs and Expectations
An organization should communicate relevant information within a suitable 
timeframe after it becomes aware of a risk. This is particularly true for 
regulators that become aware of health product risks because the regulator 
has a responsibility to ensure that people have the necessary information to 
make informed decisions about their health. The definition of timely will vary 
for each risk situation and depend on the severity, probability, and uncertainty 
associated with a given risk. There are also important trade-offs to be considered, 
including balancing the time needed for proper risk assessment with getting 
information out to the public quickly. If inaccurate information is released 
too early, it can cause unnecessary anxiety or, conversely, a false reassurance 
concerning a product. It can also lead to a need to correct information that 
has already been disseminated. On the other hand, waiting too long to release 
important information may put patients at risk. If risk information is not 
communicated in a timely manner, public opinion may have already started to 
take shape on the nature of the risk and blame for the problem (Greenberg, 2012; 
RSI, 2013). Even in cases where there is limited information, communicating 
early may not be harmful if done honestly, humbly, and cautiously. Ensuring 
risk communication is done early can have long-term benefits, setting the stage 
for the next hazard by building trust over time.
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Many stakeholders can impact the public’s perception of timeliness, particularly 
the media. For example, during the 2011 Ottawa endoscopy scare,4 the news 
media received limited information before Ottawa Public Health (OPH) was ready 
to make a formal public announcement about the breach in infection control 
measures at a local, non-hospital medical clinic. The public health unit was 
therefore forced to accelerate the timeline for public disclosure under pressure 
from the media. Initially, OPH released only general information about the 
event (e.g., the specific source not released) for a variety of reasons, including 
concerns over patient privacy, doctor-patient confidentiality, and the ability of 
the public health department to deal with increased demand for testing and 
information expected to result from a full announcement (Greenberg, 2012). 
Detailed information about the nature of the risk was released two days later. 
The media were highly critical of the health unit’s risk communication strategy, 
and journalists reported that the decision initially to release only partial details 
led to increased public anxiety and a loss of confidence in the public health 
system (Greenberg, 2012).
Social media and the internet have changed expectations around timeliness. 
Information available online can spread quickly through social networks, making 
the challenges of establishing message control once risk information becomes 
known even more difficult (Greenberg, 2012). The strengths and challenges 
associated with social media only confirm what has been recognized for decades: 
that “audiences are not passive recipients of information, that calculations 
of risk that ignore social components are worthless and that controversies 
over risk are often surrogates for concern over process, values, and identity” 
(Neeley, 2014). The above example illustrates these issues further. After the 
partial release of information by OPH on the Ottawa endoscopy scare, social 
media discussion about the incident initially involved “unsubstantiated claims 
[that] attributed the infection lapse to tattoo parlours, dentist offices, and flu 
clinics, among other locations” (Greenberg, 2012). OPH could not correct this 
misinformation, as it was not active on social media during the 36 to 48 hours 
following the initial media release (Greenberg, 2012). 
Moving Forward
While what is considered timely will be different for each risk communication 
situation, communicators can lay the groundwork to ensure that they are able 
to respond to risks quickly. Having clear risk communication guidelines and 
established relationships with various populations and stakeholders can enable 
organizations to act proactively in the face of new risks. In addition, using 
4 A non-hospital medical clinic did not carry out the proper safety and sterilization procedures 
on endoscopes over a 10-year period, potentially exposing thousands of patients to HIV and 
hepatitis (Ottawa Public Health, 2011).
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new communication sources such as social media to strengthen relationships 
and engage with affected populations and stakeholders can help set a strong 
foundation to deal with future risk situations. 
2.3.6 Transparency
Transparency can build empowerment, trust, and quality relationships between 
the senders and receivers of information. It lays the groundwork for proactive 
and timely communication efforts over the long term. “[T]ransparency is 
crucial to effective risk communication because it is the bedrock on which 
public trust is based” (Greenberg, 2012), and it is the foundation for turning 
the populations that receive information into partners in risk communication 
(Markon et al., 2013). Calls for transparency have increased in recent years, 
generally following a scandal or signal of lack of trust in governments, regulators, 
or communicators (Löfstedt & Bouder, 2014). For example, Health Canada 
has been criticized for the perceived lack of openness in releasing confidential 
business information submitted to it for licensure, which some observers say 
is needed to identify where there are weaknesses in the evidence, maintain 
public trust, and protect the health of the general public (Turner et al., 2008; 
Hébert et al., 2011; Herder, 2012). 
In response to these concerns, transparency has become a focus for many 
governments. Canada’s Action Plan on Open Government sets out four principles 
for the federal government: availability of information, citizen participation, 
professional integrity, and new technologies for openness and accountability 
(GOC, 2014). As part of this action plan, the government promises to issue a 
policy directive that will provide guidance to all federal departments on “what 
they must do to maximize the availability of online information and data, identify 
the nature of information to be published, as well as the timing, formats, and 
standards that departments will be required to adopt” (GOC, 2014). Health 
Canada’s Regulatory Transparency and Openness Framework, released in 2014 
(Health Canada, 2014a), recognizes the importance of openness, defined as 
“inviting, hearing, considering and sharing information with the public as Health 
Canada makes its regulatory decisions.” The framework refers to three goals 
for risk communications: “Making information easier to understand,” “Making 
more information available,” and “Making the decision-making process more 
open” (Health Canada, 2014a). The Framework website highlights the availability 
of existing documents (e.g., summary basis of decision documents and recent 
plain language efforts that seek to make drug labels more comprehensible) 
(see Chapter 3 for more detail). 
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Internationally, calls for transparency have been prominent for health products 
(Löfstedt & Bouder, 2014). In response to drug scares (e.g., withdrawal of 
Vioxx® from the market), there have been demands that regulators improve 
the transparency of their decision-making processes. The European Medicines 
Agency (EMA) has recently announced its intention to release all clinical 
trial information accompanying market authorization applications for new 
medicines (EMA, 2014d), later broadening to trial information accompanying 
applications for extension of indication and line extension for existing medicines 
(EMA, 2014e). The policy change came after consultations with a variety of 
stakeholders, including patients, healthcare providers, and academics. The 
information provided will not be without limits, however. MAHs will be able to 
redact information that is considered commercially confidential, and none of 
the information released can be used for commercial purposes (EMA, 2014d). 
Eventually, the EMA also plans to make individual patient data available but 
acknowledges the need to first address the privacy, legal, and technical issues 
that would accompany such a release (EMA, 2014d). Global policy shifts such 
as this will have far-reaching effects for other jurisdictions, including Canada, 
and point to a need for proactive response.
Transparency is often poorly defined, and establishing transparency is not a 
cut-and-dry process. Measures to increase transparency are not a panacea in 
terms of establishing trust, and in some cases initiatives can have no effect 
or the opposite effect (Löfstedt & Bouder, 2014). Ensuring transparency is 
challenging, as it requires trade-offs with urgency and confidentiality, and 
measures intended to enhance transparency may have counterintuitive impacts 
(Löfstedt & Bouder, 2014). In some cases, notably the health field, there will 
be limitations to the degree to which some information can legally be released 
(e.g., in cases of individual health data). Making promises in terms of transparency 
that cannot be met because of these privacy and/or legal limitations can be 
destructive overall. Research has demonstrated that measures to increase 
transparency need to be well planned, and consider the information needs of all 
relevant groups and all potential impacts. A data dump, in which large amounts 
of data are released online without explanatory or contextual information, does 
not increase the public’s access to, or ability to understand, health information 
(Chakraborty & Löfstedt, 2012). It may even result in confusion. An approach 
that recognizes the impacts of disclosure of information on the audience 
and takes the science of risk communication into account is termed reasoned 
transparency (Löfstedt & Bouder, 2014).
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Moving Forward
Transparency can build empowerment, trust, and relationships between the 
senders and receivers of information. Reasoned transparency can lay the 
groundwork for timely communication efforts by striking a balance between 
openness, urgency, and confidentiality. This type of approach can also support 
the application of good risk communication science and the provision of 
appropriate information that is meaningful for dialogue.
2.4 REFRAMING THE GOALS OF RISK COMMUNICATION
As discussed earlier in the chapter, the goals of health risk communication are 
often classified as reach, use, and impact. While these goals are useful, they 
need to capture the evolving knowledge of risk communication. Focus should 
also include the less tangible, but no less important, goals of comprehensibility, 
trust, empowerment, engagement, and transparency. Table 2.7 reintroduces 
the definitions of reach, use, and impact first introduced in Table 2.1, along 
with modified examples of desired outcomes for each. 
Setting risk communication goals implies careful and thorough evaluation to 
determine whether these goals have been met. As Fischhoff (2009) explains, 
“one should no more release untested communications than untested 
pharmaceuticals.” While reach, use, and impact are key, evaluation can also 
be helpful during the important steps that occur before a communication is 
issued. For this reason, the Panel expands reach, use, and impact to include a 
fourth goal, development (see Table 2.7). This additional goal captures how 
evaluation can support the formal and informal processes that lead to the 
development of specific risk communications. The processes of assessing specific 
needs and developing specific communications can best be described by the 
risk communication dimensions discussed in Section 2.2: characterizing and 
managing risk, creating messaging, and ongoing partnership and exchange. 
Further discussion of how evaluation can be carried out and inform the 
communication goals of development, reach, use, and impact across varying 
health product risk communications is explored in depth in Chapter 4.
This expanded view of communication goals recognizes that risk communication 
has moved beyond the paternalistic view of the past that the public chose 
not to follow public health advice because of ignorance (see references from 
Löfstedt & 6 (2008)). In the emerging risk communication paradigm, this view 
is challenged by many experts who “argue that the public are not generally 
stupid, but distrusting for explicable reasons” (Löfstedt & 6, 2008). Clear 
evidence demonstrates that, in general, people are not acting groundlessly 
when they respond to risk in ways that are inconsistent with the expectations 
of health agencies (Alaszewski, 2005). Instead, they are evaluating risks in the 
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context of their personal criteria and values. Risk communication that seeks 
to empower people and that uses evaluation approaches to help incorporate 
their values, beliefs, and views throughout planning, implementation, and 
assessment therefore has greater potential to have widespread benefits.
Table 2.7
Reframed Goals of Risk Communication 
Goals Broadened Definitions Potential Desired Outcomes
Development Incorporating evaluation 
methods and learning  
into the steps involved  
in designing risk 
communications, including 
when characterizing and 
managing risk, creating 
messaging, and ensuring 
ongoing partnership  
and exchange.
 • needs and wants of affected populations and 
stakeholders have been identified during risk 
characterization efforts
 • preliminary messages use evidence-informed 
communication practices (Table 2.6) and have 
been tested with identified populations to  
ensure meaningful communication content, 
design, and channel
 • efforts have been made to understand the  
best way to engage various populations 
 • affected populations have been engaged in  
risk communication and evaluation planning  
and implementation
Reach How and when the 
communication is  
sent and received  
and by whom.
 • information sent/directed to the  
appropriate populations
 • information received by those populations
 • affected populations aware of the communication
Use How the information is 
considered, its timeliness, 
and the reactions and 
actions taken as a result  
of the communication.
 • information understood by affected populations
 • information sent in a way that overcomes  
barriers to understanding 
 • affected populations aware of the specific  
risk information from the communication 
 • information considered timely (based on  
urgency, severity, probability, and uncertainty 
associated with risk)
 • information sought out by populations
 • these populations are able to make informed 
choices based on the risk information provided 
including informed refusal of risk taking advice
 • action taken based on the opinions, perceptions, 
and/or beliefs of the recipient
 • risk minimized by actions based on specific 
instructions/recommendations
 • when relevant, information in communication 
used by health professionals and the groups  
with whom they work
 • continuing of desired behaviour or  
changing behaviour
 • changing preferences in affected groups  
(e.g., patients, healthcare practitioners)
continued on next page
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Goals Broadened Definitions Potential Desired Outcomes
Impact Achieving a desired  
result with respect to 
various outcomes related  
to the senders and 
receivers of information 
and the relationship 
between them.
 • individual and population health outcomes 
improved (e.g., reduce incidence of disease) and 
mechanisms in place to monitor unintended effects
 • knowledge, attitudes, and perceptions advanced 
or changed
 • organization characteristics (e.g., efficiency, 
responsiveness) improved 
 • trust and credibility built over time
 • communication seen as transparent by those 
receiving the information and other stakeholders
 • feedback on the communication provided by  
the recipients 
 • feedback used by the sender to modify the process
 • affected groups trust message and feel 
empowered to act
 • communication facilitates cooperation, exchange, 
and empowerment
2.5 CONCLUSION
Risk can be defined as the probabilities of different possible outcomes and the 
severity of those outcomes. It is dependent on context, evolves, and is socially 
and culturally mediated. Risks often cannot be fully quantified and may involve 
a range of uncertainty. In the case of health products, risks generally fall into 
one of four categories: known side effects, medication/medical device errors, 
product defects, and remaining uncertainties. All of these categories could 
lead to negative consequences that are known or mild or to more severe or 
unknown adverse events that result in hospitalization or death.
Communicating risks has evolved, moving from a sole emphasis on accurate risk 
characterization, to a focus on understanding how individuals respond to risk and 
risk information, and finally to recognition of the broader social and collective 
context. Each offers important lessons: (i) risk communication is a process, 
during which the risk must be characterized and managed; (ii) messaging needs 
to be created for particular receivers of information and with evidence-informed 
communication practices in mind; and (iii) relationships need to be built and 
managed with multiple stakeholder groups, including organizations, media, 
health professionals, and the public.
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Risk communication has undergone a paradigm shift over the last 20 years, from 
one-way messaging between the senders and receivers of information, towards 
multi-way dialogue in which all parties learn and grow from the communication 
experience. The current context includes five key challenges that will continue to 
shape and reshape future communication efforts: cooperation and coordination 
in multi-level governance structures; navigating the complexities and shared 
responsibilities of the risk communication environment; addressing the presence 
of uncertainty and multiple interpretations of the evidence; focusing on 
communications that help empower populations receiving information; and 
ensuring timeliness, transparency, and proactive responses that build trust in 
the long term. These challenges are unique for every risk situation and may 
also continue to evolve.
Setting out clear goals at the beginning of the risk communication process 
helps to guide design, dissemination, and evaluation activities. To ensure 
effective communication in the future, the goals of risk communication need 
to be broad and include development, reach, use, and impact, but also less 
tangible goals like understandability, trust, empowerment, engagement, and 
transparency as well as relationship-building more generally.
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3 Health Product Risk Communication in Practice
To help set additional context for evaluation and to address the charge to the 
Panel, this chapter explores how health risk communication is carried out in 
Canada and other similar jurisdictions around the world and the extent to which 
it is evaluated. It first reviews the responsibilities and approaches of regulators 
that focus on health products. The chapter then goes on to identify established 
health product risk communication tools and some examples of emerging tools 
that could be considered when communicating risks in the future. For each of 
these areas, the Panel also considers the current state of evaluation.
3.1 REGULATORY CONTEXT 
In Canada, regulation of health products is the responsibility of Canada’s 
federal department of health, Health Canada, as part of its larger task of 
protecting and promoting the health of Canadians. A part of this task includes 
health product risk communication. Examining the various principles and 
frameworks that guide risk communication activities can help explain how 
and why communication tools are created, disseminated, and evaluated. Canada 
is not alone in facing challenges associated with health product regulation and 
risk communication, and international agencies around the world have also 
developed principles and frameworks. Exploring the similarities and differences 
between these activities and the resulting communication strategies provides 
further insight into tools for health product risk communication and their 
subsequent evaluation.
Key Findings
• Passive systems for monitoring health product risks are common across jurisdictions, 
affecting post-marketing identification of risks.
• Authority to require further studies, issue recalls or label changes, or withdraw 
a drug from the market is variable across jurisdictions although most regulators 
have such authority.
• All jurisdictions examined have communication frameworks (or are developing them), 
and subsequently emphasize two-way communication, population engagement, 
and meaningful and accessible messages. While evaluation is mentioned, most 
frameworks do not state how it is defined, how it is to be carried out, or if it is 
actually being done.
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3.1.1 Health Canada 
One of the core objectives of Health Canada is “provid[ing] health information 
to help Canadians make informed decisions” (Health Canada, 2011b). In 
addition to regulating health products, Health Canada also regulates natural 
health products (e.g., vitamins, homeopathic medicines) under the Natural 
Health Products Regulations (Health Canada, 2012b). Health Canada’s pre- and 
post-marketing powers are laid out in the Food and Drugs Act (GOC, 2013a). 
Before a drug is authorized for sale in Canada, it must undergo a drug review 
process, during which an application is reviewed to assess its efficacy and 
safety (Health Canada, 2001). This assessment is carried out by Health Canada 
scientists and, sometimes, outside experts (Health Canada, 2001). In some cases, 
important health risks will not be detected during the approval process. About 
20% of drugs approved in Canada from 1995 to 2010 were later found to have 
serious safety issues with a higher probability for those drugs that underwent 
a priority review (i.e., fast-tracked) (Lexchin, 2012). Because of cases such as 
these, post-marketing surveillance is important. Health Canada’s authority in 
post-marketing safety issues is limited but evolving. In the past, it could not 
require companies to carry out post-marketing studies, require a label change, 
require a recall, or monitor industry patient registries (Wiktorowicz et al., 2010; 
GOC, 2013a). These limited powers and the extent and nature of its post-
approval drug safety monitoring (pharmacovigilance) have been criticized 
as inadequate and ineffective (Lexchin, 2009; Wiktorowicz et al., 2010). As 
post-marketing testing of drugs was not legally required in Canada (and often 
does not occur), pharmacovigilance activities depended on the reporting of 
ADRs (Wiktorowicz et al., 2010). There are many different mechanisms for 
collecting information about ADRs in Canada. However, overall the system 
is passive, making it likely that only a minority of ADRs are actually reported 
(Environics Research Group, 2007; Wiktorowicz et al., 2010). This lack of 
information about risks subsequently affects the ability to communicate risks 
to the public.
Recently, the federal government received royal assent for new patient safety 
legislation in 2014 (the Protecting Canadians from Unsafe Drugs Act). This led 
to an immediate change in post-marketing authority including giving Health 
Canada the ability to order a recall or a change to the label of a health product, 
to require the provision of information, and to disclose confidential business 
information in certain circumstances. Although the full details on how further 
proposed changes will be incorporated in regulation and amendments to the 
Food and Drugs Act are yet to be determined, it is clear that the new law will 
also enable the government to compel MAHs to carry out further testing on 
a product, apply tougher measures for non-compliance, and make reporting 
of ADRs and medical device incidents by healthcare institutions mandatory 
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(Health Canada, 2013). The Act applies to prescription and over-the-counter 
drugs, vaccines, gene therapies, and medical devices, but does not extend 
to natural health products. Although these changes have implications for 
identification of health product risks and the amount of data that will be available 
for consumption, it is not clear how (or if) the tools used for health product 
risk communication will change nor how an increase in new pharmacovigilance 
data will be communicated. As these changes are leading to a restructuring of 
the pharmacovigilance system, it is an ideal time for Health Canada to examine 
and improve how they communicate safety information. 
Health Canada’s most recent risk management decision-making framework5 
includes several principles that provide a basis for the decisions and actions 
taken by the department (Health Canada, 2000) (Figure 3.1). The primary 
principle is to maintain and improve health. Other principles include, but are 
not limited to, the following: communicate effectively, use a broad perspective 
and collaborate, incorporate sound science in the process, take a precautionary 
5 Health Canada’s framework builds on the one developed by the U.S. Presidential/Congressional 
Commission on Risk Assessment and Risk Management (The Presidential/Congressional Commission 
on Risk Assessment and Risk Management, 1997a, 1997b). 
Identify the Issue and Its Context
Monitor and Evaluate Results
Implement the Strategy
Select a Strategy
Identify and Analyze Options
Assess Risks and Benefits
Involve Interested
and Affected Parties
Source: (Health Canada, 2000)
Figure 3.1 
Health Canada’s Risk Management Decision-Making Framework
The framework illustrates the three phases proposed by Health Canada for risk management decision-
making. As described by Health Canada (2000), these phases are: “issue identification (identify the issue 
and put it into context); risk assessment (assess risks and benefits); and risk management (identify and 
analyze options; select a strategy; implement the strategy; and monitor and evaluate the results).” 
Engagement of various populations is seen as central to each phase.
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approach, and ensure that the process is as transparent as possible. The 
framework is intended to be flexible and dynamic. Fundamental to each 
decision-making phase is the involvement of interested and affected parties, 
including the public, partners, and other stakeholders. Health Canada (2000) 
chose a circular design for the framework as it “reflects an emphasis on an 
integrated decision process, its component steps, and their interrelationships.” 
Risk Communication Framework
Health Canada’s core objectives all encompass some element of risk 
communication. To guide these activities, Health Canada, with the Public 
Health Agency of Canada, established a Strategic Risk Communications Framework 
in 2006 (Health Canada, 2006), which presents an integrated approach to risk 
management and risk communication. Based on Health Canada’s definition of 
risk communication, this framework lays out five guidelines that are informed 
by risk perception, risk communications, and social interaction. Under these 
guidelines, Health Canada stresses that the preparation and implementation of 
risk communications should follow a cyclical process based on this framework: 
• Focus current understanding: review and synthesize scientific knowledge and 
technical information related to all factors surrounding the risks of concern.
• Develop communications strategies sensitive to current understanding, goals, 
and options of affected populations: develop an in-depth understanding 
of affected populations using accepted qualitative research methods and 
subsequently develop strategies, plans, and messages that fit the expectations 
of those receiving information. Begin an iterative drafting process of 
the communication with a team of individuals with backgrounds in risk, 
communication, and organizational issues to ensure all aspects are covered.
• Pre-test strategies, plans, and messages: evaluate approaches to risk 
communication empirically to ensure optimal performance of messages.
• Implement according to risk communication plan: act on the plan to facilitate 
proper processes both internally and externally and to enable the evaluation 
of the risk communication process and outcomes.
• Evaluate the risk communication process and outcomes: measure the 
effectiveness of the risk communication process (including the team) and the 
outcomes to signal how to better address future risk-related challenges. Share 
evaluation results with team and share measurement results with stakeholders.
(Health Canada, 2006)
It is difficult, however, to assess if the principles of the framework are used 
and what they mean, in practice. The framework does not include a clear 
definition of effective risk communication or its evaluation. It mentions the 
need to evaluate the effectiveness of a given approach to communicating risk, 
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but does not offer guidance on risk communication or suggested practices from 
previous experiences. Because evidence of evaluation is difficult to track down 
in the literature (see Section 3.2), this lack of guidance in publicly available 
strategic documents further makes it difficult to assess the effectiveness of actual 
communication practices. Guidance on what is required for a good evaluation 
is provided elsewhere, however, including by the Treasury Board Secretariat 
of Canada (see Box 3.1). 
Health Canada is also undertaking a range of activities related to risk 
communication as a part of the Regulatory Transparency and Openness Framework 
released in 2014 (Health Canada, 2014a). For instance, it has undertaken a 
plain language labelling project to improve the clarity and understandability 
of health product labels for both prescription and non-prescription drugs 
(Health Canada, 2014f). To date, the project is proposing changes to the 
Box 3.1 
Evaluation Standards 
Evaluation standards provide clear guidance for carrying out effective evaluation. 
For example, the Treasury Board Secretariat of Canada has developed best practices 
for all government departments carrying out evaluations (TBS, 2004), and these 
align well with similar standards established or adopted by other key stakeholders 
(CDC, 2006; CES, 2014). Combining the insights of these three sources reveals some 
common characteristics that underlie successful evaluation:
• Evaluations should be credible, objective, and reliable. This requires them to 
be transparent, fair, and open about any conflicts of interests (real or perceived).
• Evaluations should understand the information needs of stakeholders to ensure 
they provide relevant and timely information.
• Evaluations should support the collection of meaningful and valid data to ensure 
that they meet stakeholder needs and that any conclusions reached are justified.
• Evaluation results should be reported in a timely manner to ensure that 
the information needs of affected groups are met and the results can be used in 
decision-making.
• Evaluations should engage all stakeholders affected by the program being 
evaluated, especially those most directly affected by the risk communication, 
making sure to protect their rights and welfare. 
• Evaluation activities should be feasible, given time, human, and financial resources. 
55Chapter 3 Health Product Risk Communication in Practice
way information on labels is organized to make it clearer, improvements to 
documents used by healthcare providers, and more rapid online posting of 
product information. The changes were informed by consultations with relevant 
stakeholders, and further consultations and recommendations are expected 
(Health Canada, 2014f). Health Canada has also committed to a user-friendly 
web portal that will list Health Canada-approved product information and data 
sets linking information from product monographs (see Section 3.2.1) and 
pharmacovigilance systems (Health Canada, 2014a). 
Although Health Canada’s risk communication activities are constantly evolving, 
the Panel did note that there was limited evidence in the guidance documents 
that these activities were being evaluated or that the risk communication 
process was engaging populations, despite the importance of these steps in 
Health Canada’s risk communication framework. However, there was evidence of 
a small number of limited surveys involving the public and health professionals 
carried out between 2003 and 2007 to assess stakeholder awareness and 
understanding (Evaluation Directorate, 2014c).
3.1.2 International Approaches
Looking at similar communication frameworks from outside Canada can 
reveal some of the common challenges associated with health product risk 
communication, provide lessons learned, and help identify areas in which 
Canada could improve and be a leader. The Panel examined four jurisdictions: 
the United States, the United Kingdom, Australia, and the European Union.
United States: Food and Drug Administration 
In the United States, the FDA shares many of the same responsibilities as 
Health Canada. It is responsible for “protecting the public health by assuring 
the safety, effectiveness, quality, and security of human and veterinary drugs, 
vaccines and other biological products, and medical devices” (FDA, 2014a). 
Similar to Health Canada’s past authority, while the FDA can cancel the market 
authorization of a product, it cannot require MAHs to issue a recall, but can 
request one. The FDA’s largely passive post-marketing evaluation of health 
products is also similar to that of Health Canada. In 2007, however, the FDA 
was granted greater powers in post-marketing risk identification (FDA, 2007b; 
Wiktorowicz et al., 2010). It now has the authority to order MAHs to carry out 
post-marketing studies (under certain conditions) or make safety label changes 
(FDA, 2007b). Unlike Health Canada, however, the FDA does not impose 
regulations on natural health products, and manufacturers of these products 
are only required to register with the agency (FDA, 2014c). 
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The FDA’s equivalent to Health Canada’s communication framework is the 
Strategic Plan for Risk Communication (FDA, 2009), which incorporates a multi-
dimensional understanding of risk. Effective risk communication is defined as 
the ability to influence individuals by informing them of both the positive and 
negative consequences of health-related decisions. Unlike Health Canada, the 
FDA explicitly outlines “intermediate outcomes” for assessing the effectiveness 
of risk communications:
• better understanding of both the risks and benefits of regulated products;
• increased public awareness of crisis events;
• increased public view of the FDA as an expert; and
• increased confidence that affected populations are getting information that 
is useful and timely.
(FDA, 2009)
The FDA has also set several goals related to risk communication: 
• increasing the use of plain language so that target audiences can understand 
the message; 
• increasing the quality and timeliness of messages; 
• increasing feedback on communications from the public and healthcare 
professionals; and
• increasing the number of highly credible websites linking to FDA communications. 
(FDA, 2009) 
It is difficult, however, to assess whether the principles of the FDA’s strategic 
plan are used in practice. It is also unclear whether its tools have been evaluated 
against these outcomes and goals because evidence of evaluation is difficult to 
track down or lacking in publicly available strategic and guidance documents. 
United Kingdom: Medicines and Healthcare Products Regulatory Agency 
Each EU member state has an agency that issues market authorizations and 
regulates health products. In the United Kingdom, this responsibility lies 
with the Medicines and Healthcare Products Regulatory Agency (MHRA), 
an executive agency of the Department of Health. The MHRA has many of 
the same responsibilities as Health Canada, regulating medicines (including 
advanced therapies such as somatic cells), medical devices, and blood products. 
Market authorization for most innovative drug products is done through 
the European Union, with the MHRA (along with national authorities for 
EU member states) contributing to the process under the coordination of the 
EMA (EMA, 2015b). Only medicines require market authorization. Industry-
led organizations approve medical devices, and natural health products are 
simply registered with the MHRA. Unlike its counterparts in the United States 
(and until recently Canada), the MHRA has the authority to require a 
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product recall. This power is rarely used, however, and the MAH generally 
issues recalls in the United Kingdom (Wiktorowicz et al., 2010). As is the case 
for Health Canada, the MHRA has a largely passive system for post-marketing 
health product monitoring.
The MHRA’s (2010) Communication Strategy 2010–2015 outlines its current 
approach to communicating health risks, setting out a series of overarching 
priorities and success measures rather than a strict set of policy-oriented goals. 
The Strategy advocates focusing less on reach (e.g., the number of people 
who receive or view communications) and more on use (e.g., the number of 
people who change their behaviour in response to communications), impact 
(e.g., how communications affect public health), and stakeholder engagement. 
Most important is the need for two-way communication with affected groups 
and the ability to adapt communication practices as online media become more 
accessible and effective in reaching a variety of populations. In its strategy, the 
MHRA recognizes the need to rely on its priority groups — health professionals, 
industry, and MHRA staff — to communicate with the public (MHRA, 2010).
The MHRA also recognizes the importance of evaluating risk communication. 
In its communication strategy, the MHRA states that “to measure the effectiveness 
and success [of our risk communication] strategy, evaluation needs to be an 
integral part of the planning process, [and] take place at regular intervals 
throughout implementation.” Furthermore, it recognizes that evaluation has 
not been done consistently in the past, yet is necessary “to ensure maximum 
return on our investment in communication” (MHRA, 2010). To measure 
the effectiveness of its approach to risk communication, the MHRA alludes 
to measureable objectives. It does not, however, provide a clear definition of 
effective communication, and it appears that either little evaluation of its risk 
communication tools has been done or that any such evaluation is not publicly 
available in the guidance documents provided.
Australia: Therapeutics Goods Administration
In Australia, regulation of therapeutic goods (medicines, medical devices, 
biologics, and complementary medicines, the latter of which are called natural 
health products in Canada) is the responsibility of the Therapeutics Goods 
Administration (TGA), part of the Australian Government Department of 
Health. As in Canada and the United States, regulation includes pre-market 
assessment of products, post-marketing monitoring, licensing of domestic 
manufacturers, and verification that overseas manufacturers comply with local 
regulations. As in the United Kingdom, although recalls are generally MAH-led, 
the TGA has the authority to issue mandatory recalls (TGA, 2014c). Similar to 
the other jurisdictions discussed, Australia has a largely passive post-marketing 
monitoring system to detect health product risks.
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In 2011, the TGA carried out a review of how it communicates its regulatory 
methods and decisions related to drug approvals, with the aim of improving 
their transparency (TGA, 2011). The government stated that the review was 
called because “a perception has arisen in the community that the TGA does 
not provide the public with sufficient information about its activities and about 
the therapeutic goods that it regulates” (TGA, 2011). The review led to several 
recommendations, grouped into three areas:
• Raise stakeholder involvement in the TGA: for example, by establishing a 
Australian Therapeutic Goods Advisory Council.
• Improve market authorization process: for example, working with stakeholders 
to improve the requirements for labels and packaging.
• Improve post-marketing activities (monitoring and compliance): for example, 
conducting a feasibility study into an early post-marketing risk communication 
scheme (i.e., similar to the black triangle system in the European Union, 
described in Section 3.2.1). 
(TGA, 2011)
The review also recommended that “the TGA develop and implement a 
comprehensive communication strategy to inform and educate,” as the agency 
does not currently have such a strategy (TGA, 2011). As of publication, no 
such strategy could be found on the TGA website, although the government 
had agreed with the recommendation to develop one (TGA, 2014b). The 
TGA’s review did not include an evaluation of its current health product risk 
communication tools, beyond stating that more effective communication was 
needed. In addition, the review did not mention evaluation of the effectiveness 
of future communication efforts. The agency has carried out, however, some 
qualitative and quantitative market research with consumers, health professionals, 
and industry, to help identify communication gaps and inform the development 
of effective communication strategies (TGA, 2014e, 2014a). 
Europe: European Medicines Agency
For health products in the European Union, the EMA has some of the same 
regulatory roles as Health Canada. It is responsible for evaluating centralized 
procedure applications for medicines, the safety monitoring of these medicines, 
and referrals (scientific assessments of a drug on behalf of the European 
Union). The EMA does not, however, issue market authorizations (providing 
only advice to either the European Commission or the relevant authorities in 
member states), develop laws or policies related to medicines, or evaluate all 
medicines in the European Union (only those that have centralized procedure 
applications). The EMA, the European Commission, and regulatory authorities 
in member states are all involved in pharmacovigilance in the European Union. 
Some pharmacovigilance activities are complicated by jurisdictional issues, 
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as EU and national legislation are not always the same. Patient registries, for 
example, are under national legislation, which can make post-marketing studies 
at the EU level more challenging (Wiktorowicz et al., 2010).
The EMA adopted the European Risk Management Strategy to help mitigate 
health-related risks from medicines (EMA, 2008) and included information 
on risk communication in the guidelines for pharmacovigilance in the Rules 
Governing Medicinal Products in the European Union (European Commission, 2008). 
The EMA updated its risk management initiative in 2010 to increase openness 
and transparency in communicating safety-related issues associated with 
medicines (EMA, 2010). 
The EMA has since released more specific guidance related to health product 
risk communication through its guideline on good pharmacovigilance practices. 
Module XV of the guideline, released in 2013, provides guidance to MAHs, the 
EMA, and authorities in member states on safety communications for medicines 
(EMA, 2013). This includes broad principles on communication and general 
information on several different classes of communication tools (e.g., websites, 
press communications), with detailed material on direct healthcare professional 
communications. The module defines a communication as effective “when 
the message transmitted is received and understood by the target audience in 
the way it was intended, and appropriate action is taken by the target audience” 
and states that effectiveness should be evaluated (EMA, 2013). 
Furthermore, Module XVI on risk minimization efforts (released in 2014) 
provides general guidance on educational tools for risk minimization 
and highlights the importance of both process and outcome evaluation 
(EMA, 2014a). Evaluation and communication will also be a specific focus of 
Module XII, which will provide guidance on continuous pharmacovigilance 
(including communication planning and ongoing evaluation) and is expected 
to be released for public consultation in 2015 (EMA, 2015a). 
3.1.3 Comparison of Regulators
While regulatory systems in all of the jurisdictions examined are similar, with 
comparable authority over prescription medicines and approval processes for 
new medicines, there are also important differences. Regulators in the United 
Kingdom and Australia have the authority to order the recall of a medicine, 
although most recalls continue to be made by the manufacturer. Health Canada 
was recently given similar authority in 2014 but it is unclear how this will take 
place in the future and how that may shape risk communication efforts. Health 
Canada’s authority over natural health products is more extensive than that of 
its counterparts, requiring evidence for any claims made for these products.
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All of the jurisdictions examined have some sort of communication framework or 
guidelines, with the exception of Australia (which has a strategy in development). 
While these frameworks vary greatly in level of detail and guidance, they include 
elements relating to development, reach, use, and impact. In addition, all of 
the strategies call for two-way communication, engagement of groups receiving 
information and other stakeholders, and meaningful and accessible messages. 
Some have gone so far as to establish advisory councils and ongoing consultation 
mechanisms. Finally, all frameworks explicitly or implicitly discuss the importance 
of establishing trust with the public. However, there are some differences in 
emphasis on the goals of risk communication. Canada and the United States 
focus on ensuring that communications meet goals for development and reach, 
through developing communications based on the understandings of affected 
groups or using plain language. The U.K. MHRA emphasizes how many people 
regularly use (and seek out) risk information and how these communications 
influence public health, thus focusing more on use and impact. 
The importance of evaluation is clearly recognized in the communication 
frameworks used by Health Canada, the FDA, and the MHRA, but it is not always 
clear how evaluation is defined. The EMA defines effectiveness and provides 
general guidance on evaluation in its guidelines on good pharmacovigilance 
practices, and is currently in the process of expanding these guidelines further. 
In most cases, frameworks or guidelines explicitly or implicitly refer to outcome 
or impact evaluation (see Chapter 4). While needs assessment or pre-testing 
prior to implementing a communication (see Chapter 4) is not formally 
included in the frameworks or guidelines, some of the activities that would 
make up such an evaluation often are. Despite the guidance available, there 
are limited examples of evaluation in regulatory frameworks and guidance 
documents. Overall, it appears that either real-world evaluation of health 
product risk communication tools is not taking place or, if evaluations have 
been undertaken, the results are not being made public or easily accessible. 
These ideas will be explored more fully in the following section.
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3.2 ESTABLISHED HEALTH PRODUCT  
RISK COMMUNICATION TOOLS 
As part of its charge, the Panel was asked to identify “types of instruments/
tools [that] are currently available for health risk communication,” with a focus 
on health products (see Chapter 1). The Panel carried out a scan of publicly 
available materials to create a catalogue of tools currently used by health 
product regulators in the jurisdictions discussed above. Various characteristics 
of the identified tools are described, including organization, goals, information 
communicated, target population, dissemination methods used, and evaluation. 
If certain characteristics were not explicit, the Panel identified them by looking 
at several direct examples. This section describes established tools, while the 
following section notes less traditional tools that are not in widespread use.
Tools can generally be divided into three categories:
• Ongoing communications: presents what is known about the risks (and 
sometimes benefits) associated with a marketed health product.
• Incident(s)-based communications: presents new information about health 
product risks, which may be updated information about a known risk or 
information about a newly discovered risk. 
• Defect and error communications: presents information about the risks 
associated with an error or deficiency in manufacturing practices in the 
production or packaging of a health product.
Key Findings
• Regulators around the world have adopted similar tools for communicating health 
product risks. Many of these tools have similar formats and make use of online 
dissemination, but it appears that they are subject to few evaluations. 
• Established communication tools often describe risk qualitatively, use text exclusively, 
lack colour or graphics, and/or do not adhere to other aspects of evidence-informed 
risk communication practices.
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3.2.1 Ongoing Communications
Ongoing communications generally relate to health product risks associated 
with known side effects, medication errors, and, in some cases, uncertainty in 
the evidence. These risks are generally communicated to patients in inserts 
included with a new medication and in online documents. The information 
comes from pre-marketing studies, such as side effects detected in randomized 
controlled trials (RCTs), or as a precaution associated with uncertainties in the 
evidence (e.g., no pregnant women included in RCTs). Over time, post-marketing 
monitoring may lead to updates or changes to ongoing communication tools 
(e.g., the addition of a FDA black box warning, as described below, as a result 
of a serious ADR detected through pharmacovigilance). Table 3.1 summarizes 
select examples of these tools.
Table 3.1 
Select Ongoing Communication Tools for Health Product Risks
Drug Approval Documents
Product Monograph – Health Canada
Description Report-style document with three parts: (i) health professional information,  
(ii) scientific information, and (iii) medication information.
May include graphs and tables to present risk information and illustrations  
in selected cases (e.g., images to illustrate where to inject a drug). 
Quantitative risk information presented in natural frequencies and percentages 
(in parts 1 and 2). Qualitative risk information provided in part 3.
Varies in length significantly but is generally about 50 pages.
Purpose To inform on the "properties, claims, indications, and conditions of use for the 
drug, [and] any other information that may be required for optimal, safe, and 
effective use of the drug."
Target Patients, healthcare professionals
Dissemination Posted on the Health Canada Drug Product Database website (drugs from after 
January 2004).
It is recommended that the health professional information is included with 
promotion of the drug, and in any reference manuals distributed.
Examples of 
Evaluation
None identified.
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Summary Basis of Decision (SBD) – Health Canada
Description Report-style document that includes five sections: (i) product and submission 
information, (ii) notice of decision, (iii) scientific and regulatory basis for 
decision (largest section), (iv) benefit/risk assessment, and (v) recommendation, 
submission milestones.
May include graphs and tables to present risk information and illustrations  
in selected cases (e.g., images to illustrate where to inject a drug).
Quantitative risk information presented as frequencies.
Varies in length but is generally about 15–30 pages.
Purpose Scientific and regulatory basis for decision section includes information on the 
clinical and non-clinical basis for the approval or rejection of a drug.
Target Healthcare professionals, general public
Dissemination Posted on the Health Canada website.
Examples of 
Evaluation
Analysis of SBDs found that “significant omissions in the level of clinical trial 
information in SBDs provide little to aid clinicians in their decision-making” 
(Habibi & Lexchin, 2014).
Health Canada evaluation found a little over half of respondents (online 
workbook) found SBDs “useful in helping them make informed treatment 
choices (for themselves or their patients)” (Health Canada, 2010).
Summary of Product Characteristics – EMA (European Union)
Description Report-style document. 
May include tables and illustrations in selected cases (e.g., images to illustrate 
where to inject a drug). 
For side effects qualitative risk information often given using terms such as  
rare, very rare, common, etc. (ranges given for qualitative terms). Quantitative 
information also sometimes given.
Varies in length, but is generally very long (around 100 pages).
Purpose Summarizes all of the information needed to approve a drug (e.g., information 
for doctors, information for patients).
The basis for all information given to healthcare professionals and for the 
package leaflet.
Target Healthcare professionals, general public
Dissemination Documents posted on the EMA website.
Examples of 
Evaluation
Small study concluded that doctors found it challenging to identify the important 
points within a summary. Comments included that summaries are muddled and 
contain considerable repetition (Raynor, 2011; Edwards & Chakraborty, 2012).
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European Public Assessment Reports (EPAR) Summary for the Public –  
EMA (European Union)
Description Text-based document written in a question-and-answer format. 
Qualitative risk information given for most common side effects.
Text provided gives general ranges for qualitative terms (e.g., < 1000).
Generally around 2 to 3 pages.
Purpose To inform the general public what the drug is, how it works, why it was 
approved (i.e., benefits observed in clinical trials), and any associated risks
Target General public
Dissemination Published on the EMA website.
Examples of 
Evaluation
EPARs have been criticized for having irregular and unreliable styles of 
reporting (Barbui et al., 2011).
Consumer/Patient Leaflets
Package Insert – Health Canada
Description Leaflet that presents information on a medicine (e.g., dosage, benefits,  
side effects). 
Generally the same as part (i) (health professional information) of the product 
monograph, but may also include part (iii) (medication information).
May include graphs and tables to present risk information and illustrations  
in selected cases (e.g., images to illustrate where to inject a drug). 
Quantitative risk information presented in natural frequencies and percentages. 
Qualitative risk information also may be included.
Purpose To describe the properties and conditions for use of the drug, including any 
information that may be required for safe and effective use of the drug, and 
potential side effects.
Target Healthcare professionals, patients
Dissemination Included in the package of name-brand prescription drugs.
Not required, but if not included the label must state: “Product monograph, 
package insert or prescribing information available on request.”
Examples of 
Evaluation
None identified.
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Prescribing Information (patient package insert) – FDA (United States)
Description Leaflet that includes information on effectiveness, contraindications,  
and information of the risks (including side effects) and benefits. 
Only needs to be approved for oral contraceptives and estrogen. MHAs often 
submit patient package inserts to FDA for approval voluntarily.
Quantitative risk information presented in a variety of formats. Qualitative 
descriptions of risk also used.
May include graphs and tables to present risk information and illustrations in 
selected cases (e.g., to illustrate the order in which to take birth control pills).
Purpose To enable the safe and effective use of a drug by fully informing patients of the 
benefits and risks associated with the use of drug.
Target Patients
Dissemination Only required for oral contraceptives and estrogen (considered voluntary for  
all other drugs).
Included in the package of a drug.
Examples of 
Evaluation
None identified.
Medication Guide – FDA (United States)
Description Paper document that includes information on the side effects and/or drug 
interactions associated with a medicine. 
Considered part of the labelling process.
Qualitative risk information provided (e.g., using terms such as common, rare).
Tables and illustrations included in selected cases (e.g., images to illustrate 
where to apply a gel).
Varies in length but is generally under 10 pages.
Purpose To inform about issues that are specific to that particular drug (or drug class)  
to help prevent adverse events.
Target Patients
Dissemination Provided with certain prescription medicines (required).
Examples of 
Evaluation
None identified.
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Consumer Medication Information – FDA (United States)
Description Does not need to be approved and can take any form.
Examples examined include only text.
Risks listed provide no qualitative or quantitative information (e.g., “these side 
effects may occur”).
Purpose To provide information for the safe and effective use of a prescription drug or 
specific over-the-counter medicine.
Target Patients
Dissemination Provided voluntarily by pharmacies with prescription drugs.
Usually included inside or stapled to the outside of the bag containing  
the medication.
Written by the pharmacy or an outside company. 
Examples of 
Evaluation
Evaluation (by experts) of CMIs for two drugs found that these documents  
had “very low levels of quality” in terms of meeting communication  
standards/criteria in 14% (drug 1) and 16% (drug 2) of cases  
(Kimberlin & Winterstein, 2008).
Product Information – TGA (Australia)
Description Report-style document that contains information on a prescription medication, 
including pharmacology, indications, precautions, clinical trials, 
contraindications, adverse effects, dosage, and storage. 
Quantitative risk information presented in natural frequencies and percentages.
May include graphs and tables to present risk information.
Generally 10 to 30 pages.
Purpose To “[provide] a summary of the scientific information for the safe and effective 
use of a prescription medicine.”
Target Healthcare professionals
Dissemination Published on the TGA website.
Published in the MIMS Annual and the Prescription Products Guide.
Included in full or abridged form in journal advertisements.
Examples of 
Evaluation
None identified.
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Consumer Medicines Information – TGA (Australia)
Description Brochure-style document that contains information on a prescription 
medication, including dosage, precautions, interactions, how to use the 
medicine, side effects, and how to store the medicine. 
Risks listed but no qualitative or quantitative information given (e.g., tell  
your doctor if you experience these side effects and they worry you).
Generally 5 to 10 pages. 
Purpose To “[provide] information on the safe and effective use of a prescription medicine.”
Target Patients
Dissemination Required to be “made available to consumers either in the pack or in another 
manner that will enable the information to be given to the person to whom the 
medicines are administered or otherwise dispensed.”
Published on the TGA website.
Examples of 
Evaluation
None identified.
Patient Information Leaflet – EMA (European Union)
Description Leaflet that presents written information on the drug (e.g., dosage, benefits, 
side effects). 
May contain illustrations (e.g., images to illustrate where to inject a drug). 
Qualitative risk information provided (e.g., using terms such as common, rare).
Purpose To describe the properties and conditions for use of the drug, including any 
information that may be required for safe and effective use of the drug, and 
potential side effects.
Target Patients
Dissemination Package leaflet must be included with all medicines.
Posted on the EMA website.
Examples of 
Evaluation
Although no specific evaluation was identified in the EU, patient information 
leaflets must be tested to ensure they are effective at conveying information 
(generally use the Australian method) (Edwards & Chakraborty, 2012).
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Warnings
Boxed Warnings (“black box warnings”) – FDA (United States)
Description A black box at the top of documents that provides a summary of serious risk.
The box includes the word WARNING (in upper case).
Appears on the risk communication documents for a given drug  
(e.g., package inserts).
Purpose To inform about “certain contraindications or serious warnings [of a drug], 
particularly those that may lead to death or serious injury.”
Target Healthcare professionals, patients
Dissemination Warning appears in a box at the top of medication insert, entry in the 
Physicians’ Desk Reference, FDA website, website of drug marketing  
companies, and other information on the drug.
Examples of 
Evaluation
Study in Boston found that 0.7% of 324,548 prescriptions issued in 51 outpatient 
practices violated the boxed warning (highest violations for patients over 75) 
(Lasser et al., 2006).
Review of evaluations on regulator-issued warnings (black box, dear doctor,  
and public advisories) found that the intended effects were reported in 29 of  
52 cases (56%). Mixed impacts were found in 13 of 52 cases (21%). When 
unintended effects were assessed, they were almost always present (demonstrating 
the need to consider unintended effects) (Piening et al., 2012).
Black Triangle Scheme – EMA (European Union)
Description A small black triangle that appears at the top of communication documents  
for a given drug along with the words: “this medicinal product is subject to 
additional monitoring.”* 
Appears on the risk communication documents for a given drug  
(e.g., package leaflet).
Purpose To encourage the reporting of adverse reactions by indicating that a product is 
being monitored more intensively than other health products (e.g., because of 
uncertainty associated with a new-to-market drug).
Target Healthcare professionals, general public
Dissemination Appears on the package leaflet and summary of product characteristics.
Appears on the EMA website for the drug.
Examples of 
Evaluation
None identified.
* Text as it appears in the United Kingdom. 
Sources: (Wooler, 1995; EMA, 2006, 2009, 2014b, 2014c; FDA, 2006, 2007a, 2013; 
Health Canada, 2010, 2014d, 2014e; TGA, 2014d, 2014f)
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The most common document for presenting risk information is the package 
insert, some form of which exists in all jurisdictions. In Canada, all prescription 
drugs must either include a package insert or a statement on the packaging 
that the product information is available on request (Health Canada, 2014d). 
The EMA requires inserts for all medicines; the FDA requires them for certain 
medicines; and the TGA requires that they be “made available to consumers 
either in the pack or in another manner.” In the European Union, inserts 
(i.e., patient information leaflets) must be tested by MAHs (i.e., pre-testing 
evaluation) to ensure that they are effective at conveying information. 
EU regulations state that “the package leaflet shall reflect the results of 
consultations with target patient groups to ensure that it is legible, clear and 
easy to use” (European Parliament, 2001). Generally, an MAH undertakes 
face-to-face interviews with members of the general public to meet these 
requirements. Package inserts generally give risk information in qualitative 
terms, although in some cases quantitative ranges are given (e.g., a side effect 
is expected in 10 out of every 1,000 people who take a drug). Canada and the 
United States have no testing requirements (Edwards & Chakraborty, 2012).
While inserts generally present information in a similar way in all jurisdictions, 
there are a few notable exceptions. In EU member states, a small black triangle 
appears at the top of the package leaflet and summary of product characteristics 
to indicate that a product is being monitored more intensively than other 
health products because of the presence of uncertainty in the evidence (usually 
related to long-term effects of a drug that is new to the market) (EMA, 2014c). 
While the purpose of the triangle is to encourage the reporting of adverse 
reactions, it also serves as a simple visual cue to quickly convey a particular 
type of risk information (i.e., uncertainty). In “exceptional cases,” the EMA 
also has the option to propose the inclusion of a boxed warning (in bold) in 
the summary of product characteristics (in the section on special warnings 
and precautions for use) (European Commission, 2009). Black box warnings 
in the United States are also a simple visual cue to indicate a particular type 
of risk, in this case a serious warning. These warnings appear at the top of any 
document used to provide information on the drug (e.g., insert, promotional 
material) (FDA, 2013). 
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All jurisdictions post online a wide range of ongoing communication documents, 
which vary in length and in intended targets. Those intended for the general 
public (e.g., part 3 of Health Canada’s product monograph and the EMA’s 
EPAR for the public) are generally much shorter than those for other audiences 
and often do not include quantitative information. More detailed documents 
aimed at healthcare professionals, which are longer and contain more medical 
terminology, are also available online. 
In general, the Panel found few publicly available evaluations of ongoing 
communication tools (see Table 3.1 for examples). For all tools except black 
box warnings, evaluations primarily related to measuring either the quality of 
a tool’s content or whether users could understand content. These evaluations 
relied on either individual interviews or expert analysis and were mainly 
conducted at the end-stage, with the exception of evaluation of the package 
inserts in the European Union, which is conducted at the pre-testing stage 
by law. In the case of black box warnings, Piening et al. (2012) identified 
15 evaluation studies, all of which were outcome measures of use and impact. 
Common indicators for measuring effectiveness were prescription rates, new 
users, or overall drug use volume. 
3.2.2 Incident(s)-Based Communications
Incident(s)-based communications alert healthcare professionals and the 
public to newly discovered side effects, adverse drug reactions, or medication or 
device errors. This information often leads to an update to the risk information 
included in ongoing communication tools. The most common incident(s)-
based communication tools are advisories for the public and dear doctor 
letters for healthcare professionals. The risk information contained in them 
is largely from post-marketing pharmacovigilance. Table 3.2 summarizes select 
examples of these tools.
71Chapter 3 Health Product Risk Communication in Practice
Table 3.2 
Select Incident(s)-Based Communication Tools for Health Product Risks
Public Documents
Public Advisory – Health Canada
Description Memo-style document that contains information on a risk. 
Most salient points are listed at the top of the document as bolded bullets.
Quantitative risk information provided in some cases. 
Includes a link to the safety review summary when one is available.
Often includes references.
Generally less than two pages.
Purpose To “inform about a situation in which the use of, or exposure to, a product may 
cause adverse health consequences or where the probability of serious adverse 
health consequences is remote.”
Target General public
Dissemination Posting on the Health Canada and MedEffect™ Canada websites.
Distribution through Health Canada’s media listserv and the MedEffect™ 
mailing list.
Distribution to various relevant parties (e.g., healthcare professional associations).
Health Product InfoWatch.
Examples of 
Evaluation*
Canada: Standardized readability and Suitability Assessment of Materials (SAM) 
tests found that advisories required a post-secondary level of reading to 
understand and that new templates improved SAM scores but not readability 
(LeBrun et al., 2013).
U.S: Study of FDA safety advisories found that notices had variable effects,  
with some having significant impact, others having delayed effects, and some  
having no effect at all. In some cases, the effects were not consistent with  
the recommendations contained in the warnings (Dusetzina et al., 2012;  
Edwards & Chakraborty, 2012).
Review of evaluations on regulator-issued warnings (black box, dear doctor,  
and public advisories) found that the intended effects were reported in 29 of  
52 cases (56%). Mixed impacts were found in 13 of 52 cases (21%). When 
unintended effects were assessed, they were almost always present (demonstrating 
the need to consider unintended effects) (Piening et al., 2012).
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Drug Safety Communication – FDA (United States)
Description Memo-style document that contains information on a safety announcement. 
Most salient points may be bolded.
May include a section on additional information for patients,  
and for healthcare professionals. 
Quantitative risk information (in frequencies) sometimes provided.
Includes reference list. 
May summarize the results of a safety review.
May include images and graphs.
Purpose To “provide information and advice regarding an emerging drug safety issue  
or other important public health information.”
Target General public, healthcare professionals, patients
Dissemination Posted on the drug safety communication website.
Promotion of the FDA_Drug_Info Twitter feed.
Examples of 
Evaluation
*same as Public Advisory – Health Canada
Safety Review Summary – Health Canada
Description Text-based report that summarizes the results of a Health Canada safety review.
Qualitative risk information provided (e.g., increased risk).
Includes a reference list.
Generally about three pages.
Purpose To inform on the results of a safety review (i.e., is there evidence that there  
is a safety risk?).
Target General public, healthcare professionals
Dissemination Summaries of reviews posted on the Health Canada website.
Full safety reviews can be obtained by emailing the directorate, although  
“these reports are subject to redactions of personal and confidential information.”
Examples of 
Evaluation
None identified.
Question and Answer – FDA (United States)
Description Document with common questions and answers related to a drug  
safety communication.
Quantitative risk information often provided.
Purpose To provide a plain language overview of a potential safety issue associated  
with a medicine.
Target General public
Dissemination Posted on the FDA website. A link is included at the bottom of the 
corresponding drug safety communication.
Examples of 
Evaluation
None identified.
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Physician Warnings
Dear Health Care Professional Letter – Health Canada
Description Letter with information on a new health product warning(s). 
Most salient points are listed in the letter as bolded bullets.
Quantitative risk information provided in some cases. 
Generally two pages or less.
Purpose To “inform about time-sensitive issues regarding the safety or effectiveness  
(or both) of a marketed health product.”
Target Healthcare professionals
Dissemination Distribution by mail-out of printed copies (fax-out under exceptional 
circumstances).
Posting on MedEffect™ Canada, MAH, and association websites.
Distribution through the MedEffectTM email list.
Health Product InfoWatch.
Examples of 
Evaluation
None identified. 
Dear Health Care Provider Letter – FDA (United States)
Description Letter with information on a new health product warning(s). 
Generally includes quantitative risk information.
Generally includes reference list.
Generally two pages or less.
Purpose Inform about emerging data on a risk associated with a post-market medicine.
Target Healthcare professionals
Dissemination Mailed to physicians.
Examples of 
Evaluation
A highly publicized dear doctor letter sent in June 1998 led to a 58% decline  
in the concomitant dispensing rate with the contradicted drugs. An earlier letter 
with less publicity led to no measurable effect (Weatherby et al., 2002). 
A study of dear doctor letters sent to inform of a change in the warning section 
of the drug label found that they varied in where key information was placed, 
length, and formatting. Doctor ratings found that 25% were deficient in clarity, 
28% in readability, and 28% in overall effectiveness (Mazor et al., 2005).
continued on next page
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Direct Healthcare Professional Communication – EMA (European Union)
Description Letter with information on a new health product warning(s).
Quantitative risk information provided.
Summary appears at top of letter in bold.
Purpose Inform about emerging data on a risk associated with a post-market medicine.
Target Healthcare professionals
Dissemination Distributed to the national health service through the Central Alerting System 
(in the case of MHRA).
Posted on the national regulator website.
Commonly accompanied by an EMA press release or EMA public  
health communication.
Examples of 
Evaluation
Direct healthcare professional communications in the Netherlands were found 
to have greater impact when a template was used (emphasizing the main risk) 
and for high risks (e.g., death) (Reber et al., 2013).
Other Healthcare Professional Warnings
Health Product InfoWatch – Health Canada
Description Replaced the Canadian Adverse Reaction Newsletter.
Colour newsletter that includes a summary of all advisories (including  
notices to hospitals, summary safety reviews, etc.) and review articles on 
selected advisories.
Articles often provide quantitative risk information.
Published monthly.
Purpose To raise awareness of new health product safety information and provide  
a recap of health product advisories and summary safety reviews.
Includes information from other tools.
Target Healthcare professionals
Dissemination Posting on the MedEffect™ Canada website.
Emailed to a list of relevant stakeholders.
Examples of 
Evaluation
None identified.
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Drug Safety Update – MHRA (United Kingdom)
Description Monthly electronic colour newsletter that contains articles on recently  
identified risks (or new information on known risks). 
End of each article has a box with advice for healthcare professionals. 
Quantitative risk information provided.
Purpose To provide the “very latest information and advice to support the safer  
use of medicines.”
Target Healthcare professionals
Dissemination Posted on the MHRA website.
Sent out by email (to those who register).
Examples of 
Evaluation
None identified.
Australian Prescriber – TGA (Australia)
Description Bi-monthly colour journal that includes letters, articles, medicine safety update, 
and information on new drugs and diagnostic tests. 
Some articles include figures and graphs.
Some articles have detailed quantitative risk information; others include only 
qualitative risk information.
Articles include references.
Purpose To “provide expert, balanced, impartial, reliable and up-to-date information  
for its readers by reviewing recent evidence where therapy is evolving and 
updating readers on therapeutics in their own and other fields.”
Target Healthcare professionals
Dissemination Published in print and online. 
Physical copies sent to prescribing healthcare professionals in Australia,  
as well as medical schools and teaching hospitals.
Examples of 
Evaluation
None identified.
continued on next page
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Medicines Safety Update – TGA (Australia)
Description Newsletter that contains articles on recently identified risks (or new information 
on known risks) related to health products. 
Sometimes includes references.
Quantitative information sometimes provided.
Purpose To “[provide] practical information and advice on drug safety and information 
about emerging safety issues.”
Target Healthcare professionals
Dissemination Posted on the TGA website.
Appears in each edition of the Australian Prescriber.
Examples of 
Evaluation
None identified.
Source: (FDA, 2007a, 2011; Health Canada, 2008, 2014c, 2015; 
Australian Prescriber, 2014; MHRA, 2014a, 2014b; TGA, 2014g)
When the safety of a drug on the market comes into question, a regulator may 
undertake a safety review to determine whether there is a new risk that needs 
to be communicated. Recently, Health Canada announced that it will release 
summaries of its safety reviews. These summaries are generally about three pages 
long and include quantitative risk information and a reference list (Health 
Canada, 2014c). These documents are not linked to the Health Canada drug 
database, but can be found through the safety review website or a link given 
on the corresponding advisory. The EMA and FDA also publish summarized 
results of selected drug safety reviews using their public advisory platforms. 
The dear doctor letters used in Canada, the United States, and the European 
Union (including the United Kingdom) have similar layouts, generally containing 
a reference list and some quantitative risk information. As discussed in Chapter 2, 
Health Canada provides detailed guidance documents and templates to guide 
MHAs in the development of both dear doctor letters and public communications. 
The dissemination methods vary slightly, with letters mailed to physicians in 
Canada6 and the United States, but sent electronically in the United Kingdom 
(see discussion of the Central Alerting System in Section 3.3.2). In all cases, 
the letters are also posted online. Most jurisdictions publish a newsletter or 
journal for physicians that summarizes new risks. While Canada requires a 
corresponding public document to be released at the same time as a dear 
doctor letter (Health Canada, 2008), this is not the case in all jurisdictions. In 
the United Kingdom the majority of dear doctor letters do not appear to have 
a corresponding document intended for the general public, whereas in the 
6 In some cases letters in Canada are disseminated by fax.
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United States and Australia drug safety communication documents are aimed 
at the general public and healthcare professionals. In Canada, the documents 
intended for the general public are posted online (and linked through apps, 
social media, and other online tools).
Similar to ongoing communication, the Panel identified only a few publicly 
available evaluations of incident(s)-based communications (see Table 3.2 for 
examples). Two evaluations examined readability using either standardized tests 
or a survey. Health Canada carried out one of these studies, which demonstrated 
that its public advisories were rated as “requiring a college/university education 
comprehension level.” Recent changes to the template used by MAHs to create 
public advisories have improved their Suitability Assessment of Materials 
(SAM) scores, but not their readability (LeBrun et al., 2013). This evaluation 
demonstrates the utility in evaluating the templates used to develop a class of 
risk communication tools, as these evaluations can provide useful information on 
development (e.g., are templates based on evidence-informed communication 
practices) without examining each individual tool produced. The Panel identified 
several evaluations related to use and impact, which used similar indicators to 
evaluate ongoing communications, notably prescription and drug dispensing 
rates. Piening et al. (2012) conducted a systematic review of evaluations of 
health warnings (public health advisories, dear healthcare provider letters, 
and black box warnings) and found 52 studies in a period of 14 years. All 
of the studies involved warnings on antidepressants, third generation birth 
control, or cisapride and came to a range of conclusions on their effectiveness. 
In 9 of the 14 articles looking at warnings related to antidepressants and 9 of 
17 articles evaluating warnings about cisapride, the intended effects of the 
warnings were observed (i.e., decreased use in children or reduced drug use 
volume or contraindicated drug use respectively). About half of the studies 
also assessed and found unintended effects (e.g., increased drug use volume) 
in almost all cases (Piening et al., 2012). Similarly, Dusetzina et al. (2012), who 
authored a review of evaluations of FDA warnings (label changes, public health 
advisories, and dear healthcare provider letters), found that while some warnings 
did have strong effects, others had delayed or no effects. In some cases the 
effects observed were not consistent with the recommendations contained in 
the warnings; for example, while, in general, warnings recommending increased 
clinical or laboratory monitoring resulted in decreased usage, they led to only 
small short-term increases in monitoring (Dusetzina et al., 2012). The results 
of these reviews demonstrate the importance of considering both intended 
and unintended effects when developing and evaluating communication tools 
(Dusetzina et al., 2012; Piening et al., 2012). 
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3.2.3 Defect and Error Communications
Defect and error communications present information about risks associated 
with product defects and labelling errors. These risks are communicated 
to the public and healthcare professionals using recalls or some other alert 
(e.g., foreign product alert or natural health product advisory) and are usually 
identified by pharmacovigilance post-market monitoring or regular monitoring 
efforts carried out by manufacturers. Table 3.3 summarizes select examples of 
these tools.
Table 3.3 
Select Defect and Error Communication Tools for Health Product Risks
Health Product Recall – Health Canada
Description Memo-style document that includes information on the recall, how to identify 
the affected lots, who is affected, and what should be done with the product.
Purpose To inform about a recall and change behaviour (i.e., stop using a recalled product).
Target Can include healthcare professionals, general public, distributors, and hospitals
Dissemination Posting on the Health Product and Foods Branch Inspectorate website.
Posting on the MedEffect™ website (when deemed necessary).
Includes a public advisory if Health Canada deems one necessary. 
Examples of 
Evaluation
An external review of the Alysena™ 28 recall concluded that Health Canada 
could have issued a public communication sooner and the appropriate experts 
were not informed until too late in the process (RSI, 2013).
Foreign Product Alert – Health Canada
Description Memo-style document that includes information on the product, hazard,  
place of origin, and what should be done.
Purpose To communicate warnings about risks from the use of products that are not 
authorized for sale in Canada.
Target General public
Dissemination Posting on the Health Canada and MedEffect™ Canada websites.
Distribution of the message through Health Canada’s media listserv and  
the MedEffect™ e-Notice mailing list.
Health Product InfoWatch.
Examples of 
Evaluation
None identified.
continued on next page
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Public Notice About Drug or Medical Device Recalls – FDA (United States)
Description Press release-style document that includes information on the recall, how to identify 
the affected lots, who is affected, and what should be done with the product.
Purpose To inform about a recall and change behaviour (i.e., stop using a recalled product).
Target Can include healthcare professionals, general public, distributors, and hospitals
Dissemination Posted on the FDA website.
Released on the FDA recall RSS feed.
Press release may be issued.
Examples of 
Evaluation
None identified.
Drug Alert Letter – MHRA (United Kingdom)
Description Letter that includes information on the recall, how to identify the affected lots, 
who is affected, and what should be done with the product.
Purpose To inform about a recall and change behaviour (i.e., stop using a recalled product).
Target Healthcare professionals, (in some cases) patients
Dissemination Posted on the MHRA website.
Distributed through the Central Alerting System.
Examples of 
Evaluation
None identified.
Health Product Recall – TGA (Australia)
Description Letters, ads, or summaries that include written information on the recall, how to 
identify the affected lots, contact information, and what should be done with 
the product.
Purpose To inform about a recall and change behaviour (i.e., stop using a recalled product).
Target Can include healthcare professionals, general public, distributors, and hospitals
Dissemination Summaries posted on the TGA website. 
In some cases letters mailed to affected groups (e.g., hospitals).
Paid advertisements in daily print media when the recall is at a consumer level 
and the affected consumers cannot be identified.
Examples of 
Evaluation
None identified.
Source: (Health Canada, 2008; RSI, 2013; FDA, 2014b; TGA, 2014c; MHRA, n.d.)
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The most common defect and error communication documents are those 
that accompany recalls. In all jurisdictions, recall documents are almost always 
developed by industry (even where the regulator has the authority to order 
a recall) and contain similar information (e.g., affected lots, what should be 
done). Their layout, however, varies. In Canada, recall documents are written in 
a memo format (Health Canada has developed guidance for MAHs developing 
content), including headers and bulleted lists; in the United States they are 
written in a press release style; in the United Kingdom they are written as 
letters to healthcare professionals (it appears that there is no corresponding 
public document);7 and in Australia they present information in a table format. 
There does not appear to be any evaluation of which format is best at conveying 
information. For the most part, it is the prerogative of the media themselves to 
decide whether to report on a recall (as with other types of communications). 
However, the TGA requires that paid advertisements be placed in daily print 
media as part of a recall at the consumer level when the affected consumers 
cannot be identified. In Canada, the United States, the United Kingdom, and 
Australia, recall documents (or notices about recalls) are posted on the same 
website as advisories and have similar look and tone to them.
The Panel identified only one publicly available evaluation specifically related 
to health product error communication. The evaluation, which concerned the 
recall of the Alysena™ 28 (an oral contraceptive) in Canada, was a process/
implementation evaluation (see Chapter 4) based on expert analysis of the 
timelines associated with the recall and the associated media and public 
perception. It found that, while Health Canada’s process was followed, the 
regulator could have issued a public communication sooner than it did 
(RSI, 2013). 
3.2.4 Summary and Comments on Evaluation
Overall, the Panel found it challenging to characterize many health product 
risk communication tools because of a lack of readily available information 
summarizing and describing tools in use. In many cases, the information 
presented in Tables 3.1, 3.2, and 3.3 was deduced through reading several 
examples of the tool in question.8 Furthermore, in some cases, regulator 
documents reference an internal evaluation, but the Panel could not find any 
7 The recall information released publicly by the MHRA (or any national regulator in Europe) 
is often supplied by the EMA. 
8 Given that this exercise was not meant to be exhaustive, there are health product risk 
communication tools that exist in the different jurisdictions examined, which the Panel chose 
not to include due to space constraints or because information was difficult to locate. It is also 
possible that the information described under tool characteristics may need updating or revision 
as new information becomes available.
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concrete information on the nature of the study, timeframe, methods, or results. 
As this report is based on publicly available information, these evaluations 
could not be included in the summary tables. 
Although the Panel identified a range of established risk communication tools, 
several shared similar features. Many tools, for example, were primarily text-
based with few visuals and sparse colour. While some tools used images, these 
were generally illustrations or pictures rather than graphic risk presentations. 
The most common method of dissemination was through posting online 
(with the notable exception of leaflets), although some of the tools aimed at 
healthcare professionals were also disseminated by other methods such as mail. 
Occasionally, tools consisted of an addition or change to another established 
tool, such as a black box on a leaflet. Most of the tools that targeted the public 
often did not quantify risk, instead using terms such as “increased risk,” “rare,” 
or “chance of.” Detailed information about risk was generally available in some 
of the comprehensive ongoing communication documents (e.g., summary basis 
of decision documents), but these documents were also longer and written in 
more technical language. Many of these observations, however, do not align 
with the evidence-informed communication practices outlined in Chapter 2 
and Table 2.6.
For evaluation to be undertaken successfully, the goals of a risk communication 
need to be defined. Although the desired populations that a communication 
is intended to reach might vary, the goal of sending the communication in 
a timely and appropriate manner was constant in the identified evaluations. 
Generally, evaluations used individual interviews, surveys, standardized tests, 
or expert analysis to mostly measure the readability or clarity of a given tool. 
Importantly, these evaluations only provided evidence on the content of a 
communication tool and did not evaluate if it achieved broader goals such 
as whether it was understood and incorporated into the behaviours and 
decision-making of the targeted receivers of information.
In most cases of the evaluations reviewed by the Panel, the desired goals of the 
communication tools could be characterized simply as either informing select 
groups, changing their behaviour (and possibly seeking out more information), 
or both. For instance, a public recall has the goal of changing behaviour 
(i.e., stop using a product) while a product insert has the goal of informing 
patients about the risks and benefits associated with a medication. Some 
evaluations also explored broader goals such as enhancing the health of 
Canadians. The outcome evaluations that examined use and impact most 
often used medical or pharmacy data (e.g., prescribing rates, new users) as 
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indicators. There was no apparent evaluation of larger overarching goals related 
to relationship-building such as establishing trust with the public, empowerment, 
or becoming the go-to source for health information. 
Overall, the Panel found little publicly available and publicly conducted 
evaluation results on the effectiveness of health product risk communication 
tools or template documents. Of the evaluations identified, the majority related 
to tools used by the FDA. For example, Dusetzina et al. (2012) identified 
49 outcome evaluations of FDA dear doctor letters, public advisories, or black 
box warnings over a period of 20 years. However, most of these evaluations were 
done by independent researchers rather than the FDA and it is not clear how 
the regulator is applying the evaluation results. It seems that regulators have 
either not evaluated the effectiveness of their health product risk communication 
tools or used the results of external evaluations, and in any case have not made 
these results public or easily accessible. This gap could have implications for 
the quality of risk communication. 
Apart from the evaluation of specific health product risk communication tools, 
Health Canada has released some broader evaluations of programs with a range 
of communication activities, which demonstrate some learning (see Box 3.2). It 
has also discussed plans for specific evaluation and public engagement activities 
related to risk communication, but the results of these activities are either not 
yet completed or have not been released. For example, public consultations 
and public surveys have been identified as methods to engage receivers of 
information and other stakeholders and to “collect important data to inform 
the Department of the effectiveness of current methods used to communicate 
drug safety information and to identify areas where the Department needs to 
make improvements” (Health Canada, 2011a). The specific results of these 
activities, however, do not appear to be public and the Panel could only find 
limited evidence of similar surveys conducted between 2003 and 2007 that 
indicated a number of opportunities for improved awareness among the public 
and health professionals (Evaluation Directorate, 2014c).
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Box 3.2.  
Broader Health Canada Program Evaluations
Although there are few targeted evaluations of specific Health Canada communication 
tools, the regulator has included communication elements in the evaluations of broader 
health product programs including those relating to biologics, medical devices, and 
human drugs. These recent evaluations include assessment of all program activities 
(i.e., all ongoing, incident(s), and defect related tools were included in addition to all 
other Health Canada activities) and a range of outcome variables related to “relevance 
and performance (effectiveness, efficiency, and economy).” The studies were carried 
out by an external evaluation firm using literature, document (government) and 
administrative data reviews, case studies, surveys of industry and other stakeholders 
(patients, healthcare professionals), focus groups with manufacturers, and key 
informant interviews. These studies illustrate a comprehensive approach to reviewing 
regulatory activities.
With respect to communication-related findings, the program evaluations note that 
in the past decade Health Canada has implemented a number of new initiatives to 
improve communication, openness, and engagement. These initiatives include the 
publication of summary basis of decision documents, public consultations on proposed 
policies, and improvements to the MedEffect™ website (e.g., adding an advanced 
search option). While the evaluation states that Health Canada’s activities are 
expected to “lead stakeholders…to adopt safe behaviours” and “produce increased 
awareness and understanding…of risks and benefits,” it did not determine whether 
communication tools were actually achieving these outcomes or other communication 
goals related to development, reach, use, or impact. The evaluation also found no 
evidence of other evaluations that draw these types of conclusions, apart from a 
small number of limited public opinion surveys. 
In all of these more comprehensive program evaluation activities, it was noted 
that the “vast scope and complexity of the subject matter” was a challenge for 
document review as was locating all relevant internal documents, and that there 
were problems with very low survey response rates and difficulties in organizing 
interviews. These limitations highlight the opportunity for Health Canada to carry 
out more targeted evaluations of specific health product tools, which would better 
scope the subject matter, better explore communication specific goals, and better 
engage more specialized evaluation participants. 
(Evaluation Directorate, 2014a, 2014b, 2014c)
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Health Canada has also stated that it is working with experts in knowledge 
translation to help evaluate the effectiveness of its public advisory template 
in terms of “reducing the health literacy burden on Canadians,” carrying 
out readability tests on its public advisories template (see Section 3.2.2), 
and collecting data to establish whether prescribing patterns are influenced 
by dear healthcare professional letters (Health Canada, 2011a). The results 
of the evaluation on doctor letters have not yet been released. Finally, the 
Panel is aware that Health Canada is currently planning an evaluation of the 
effectiveness of risk communications. However, no results of this evaluation 
have been made public and no description of the types of activities that are/
would be included were available at the time of report publication (Evaluation 
Directorate, 2014a, 2014b, 2014c).
Ultimately, a health agency has a responsibility to the citizens it protects. The 
Panel identified clear instances where Health Canada has demonstrated its 
recognition of the importance of openness and evaluation (e.g., plain language 
initiative, public communication documents to coincide with communication 
documents for healthcare professionals, release of safety reviews, readability 
evaluations). These exemplars signify that Health Canada could position itself 
as a leader in the evaluation of health product risk communication. However, 
these evaluations must be publicly available if any agency wants to establish a 
long-term commitment to building and establishing trust with the people it 
intends to reach. The benefits, process, and challenges associated with evaluation 
are discussed further in Chapter 4.
3.3 EMERGING TOOLS FOR HEALTH PRODUCT  
RISK COMMUNICATIONS
Key Findings
• Promising developments that could shape the future of health product risk 
communication include refining how the message is presented, changing the 
conditions that shape behaviour, using multi-media approaches, taking advantage 
of new mediums, and improving dissemination. 
• Emerging tools provide new opportunities for communication and evaluation.
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In addition to established tools, the Panel identified several classes of emerging 
tools that are being used, or have been proposed, for communication of 
risks associated with health products. These new approaches tackle the 
challenges associated with risk communication, for example, through ongoing 
communication tools that refine how the message is framed or incident(s)-
based tools that use new mediums to improve reach. Some of them have been 
adopted by regulators while others have been developed by researchers. 
3.3.1 Ongoing Communications
Refining How the Message is Presented: Drug Fact Boxes
One of the criticisms of medication guides and drug labels is that they neither 
discuss the benefits of taking the drug nor prioritize or quantify side effects 
(Schwartz & Woloshin, 2013). This may make it challenging for physicians 
and consumers to determine the best treatment. This information is part of 
the documentation submitted during the review process for new drugs but is 
currently available only in relatively inaccessible formats (e.g., in Health Canada’s 
summary basis of decision documents). Drug fact boxes have been proposed as 
an alternative method to present the risk and benefit information associated 
with prescription drugs in a manner similar to nutrition labels. These boxes 
are one page and standardized across all prescription medications, with one 
version for physicians and one for consumers. As Schwartz and Woloshin (2013) 
describes, “the central feature of the box is a data table with the absolute risks 
of various outcomes with and without the drug.” To address the challenges 
associated with determining which data to present in the boxes, Schwartz and 
Woloshin have developed (and tested) a handbook (Schwartz & Woloshin, 2013). 
Figure 3.2 shows an example box for prescription drug aripiprazole (brand 
name Abilify®), designed for adults suffering from major depression that persists 
despite taking antidepressants. 
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Source: (Schwartz & Woloshin, 2013) 
Figure 3.2 
Drug Fact Box for Aripiprazole, an Antipsychotic
This drug fact box is designed to present the risks and benefits of aripiprazole to adults suffering from 
major depression who have symptoms that persist despite antidepressant therapy. Another version 
of the box would be used to present this information to healthcare professionals or patients taking 
the drug for another condition.
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Research has shown that most consumers can understand the risk-benefit data 
presented in drug fact boxes (Schwartz et al., 2009; Schwartz & Woloshin, 2011). 
Studies have also further improved their clarity (Schwartz & Woloshin, 2011; 
Woloshin & Schwartz, 2011). One surprising result of these studies was that 
presenting the prevalence of side effects using percentages alone was as good, if 
not better, than using percentages and frequencies (Woloshin & Schwartz, 2011). 
However, natural frequencies (which have been identified as the most 
understandable way to present probabilistic information (Akl Elie et al., 2011)) 
were not tested (Gigerenzer, 2011). These results demonstrate the importance 
of using all available data when developing a communication, as opposed to 
simply adopting a one-size-fits-all approach. 
As drug fact boxes are not radically different from currently used ongoing 
communication tools (e.g., based on the same information, text-based), they 
could be implemented more easily than some other innovations, and provide 
immediate benefit in terms of clarity and understandability. Currently, the FDA 
is considering implementing the boxes, but has stated that it needs three to 
five years to study the evidence (Schwartz & Woloshin, 2013). In the Panel’s 
opinion, although more research is needed on the real-world applicability 
of the tool for varying populations, drug fact boxes are the most promising 
innovation in the field of health product risk communication. 
Changing the Conditions that Shape Behaviour
Nudge approaches to changing behaviour (as popularized in Thaler & 
Sunstein (2008) and Sunstein (2014)) have potential for health product risk 
communication. They are based on the notion that indirect suggestions or 
imposed structures can encourage changes in people’s behaviours while 
preserving freedom of choice (e.g., encouraging healthy eating in cafeterias by 
placing the salad bar before other food options). These types of interventions 
have been used in the past, but have only recently been given a common 
name (nudge).
An example of such an approach applied to the health product field is illustrated 
through a recent RCT on the treatment of patients with acute respiratory 
infections (ARIs) at five outpatient primary care clinics in Los Angeles. The 
study found that simply displaying poster-sized commitments in exam rooms 
led to a decrease in antibiotic prescribing rates for ARIs where antibiotics 
were inappropriate (Meeker et al., 2014). This decrease was relative both to 
a control group and the intervention group’s previous prescribing rates. The 
commitment letters stated the physician’s pledge to avoid prescribing antibiotics 
for ARIs when they were not appropriate and also contained the physician’s 
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photo and signature. Nudge approaches could also be used to encourage 
physician-patient risk communication through reimbursement policies that 
incentivize these activities.
Using Multi-Media Approaches 
With the internet and social media available for disseminating risk information, 
regulators can use coordinated multi-media approaches to reach various 
populations. Different mediums are appropriate in different cases, and the 
selection of which, and how many, mediums to use depends on several factors, 
including time constraints, severity of the risk, and characteristics of the key 
receivers of information (such as age).
Two examples of coordinated initiatives that used different types of 
communication tools are Get Smart, a U.S. Centers for Disease Control and 
Prevention (CDC) campaign (CDC, 2006) and the Do Bugs Need Drugs? 
(DBND) program funded by the British Columbia ministry of health9 (Do 
Bugs Need Drugs?, 2014). Both initiatives aimed to educate the public and 
healthcare professionals on the risks associated with misuse of antibiotics, 
and included several tools that took advantage of different dissemination 
methods, including pamphlets, internet, print media, and television. DBND 
also collaborated with community partners and the education system to enable 
the teaching of specially developed public teaching programs to different age 
groups. The multi-media approaches enabled the communicators to target 
different segments of the public using different (and tailored) tools. For example, 
Get Smart used Spanish-language tools to target the Hispanic population 
(CDC, 2006), and DBND developed television advertisements that targeted 
children aged 2 to 11 and their mothers (Do Bugs Need Drugs?, 2014). 
There has been some evaluation of both programs. Evaluation activities of Get 
Smart focused on two dimensions: patient and provider educational materials 
(including community-based education) and a media campaign in selected 
communities (including posters and radio public service announcements) 
(CDC, 2006). Using program logs, sign-in sheets, and registration forms, the 
evaluations could assess reach, although the results were not published. In 
addition, a post-communication questionnaire was given to both providers 
and patients. Providers had a high level of satisfaction with the educational 
materials, but patients reported much lower levels. Interviews with patients 
revealed that their dissatisfaction stemmed from finding the materials overly 
complicated and lacking clear explanations of what to do when antibiotics were 
not necessary. In the case of the media campaign, program logs and media 
9 There is a similar program in Alberta, but the discussion here is limited to the British Columbia program.
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tracking demonstrated that “all media materials were developed as planned but 
that ad placement varied dramatically between communities”, with greater public 
exposure to ads in one of the communities as a result of outside partnerships 
(CDC, 2006). Despite this, however, demand for antibiotics (self-reported) did 
not change significantly.
Evaluation of DBND focused on the program’s reach and select outcomes 
(Do Bugs Need Drugs?, 2014). For example, the evaluation determined that 
in 2013 public transit advertisements were seen an estimated 30 million times and 
television advertisements reached at least 70% of the target audience (women 
aged 25 to 54) in all markets. An online survey to assess public knowledge found 
that 71% of respondents had seen DBND materials and that there was a high 
level of awareness around appropriate antibiotic use in the province (Do Bugs 
Need Drugs?, 2014). In addition, since the program has been implemented, 
the rate of antibiotic consumption for all age groups has decreased (with 
the greatest decrease observed in children10) (Do Bugs Need Drugs?, 2013). 
Although the evaluation did not attempt to assign causation, and acknowledged 
that there are many factors that affect antibiotic prescribing, it did state that 
DBND “likely contributed to some of the decrease” in antibiotic use (Do Bugs 
Need Drugs?, 2013).
3.3.2 Incident(s)-Based and Error Communications
Taking Advantage of New Mediums
Social media provide new opportunities to improve risk communication, and the 
Panel identified several examples of tools that take advantage of social media 
to disseminate risk information. These include Twitter feeds, Facebook pages, 
smartphone apps, podcasts, and YouTube videos. Social media have several 
benefits for dissemination, including speed and accessibility (Rutsaert et al., 2014). 
Although these tools take advantage of different media, they often present the 
health product risk information in the same manner as established tools. For 
instance, Health Canada’s recall app, Recalls and Safety Alerts, takes advantage 
of smartphone technology, but simply has links to public advisories and recalls 
already available on the Health Canada website. Similarly, the FDA’s Consumer 
Update YouTube videos describe a risk in a similar manner to the text of the 
corresponding consumer update document, either through a voiceover or an 
expert discussing the issue on-screen. 
10 In children, antibiotic prescriptions, rather than consumption, are used as a proxy for antibiotic 
usage (Do Bugs Need Drugs?, 2014). 
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Social media, however, are more than simply a new way to disseminate 
information. Used properly, social media can enable meaningful dialogue, free of 
any filter, between the senders and receivers of information (Veil et al., 2011). As 
Veil et al. (2011) explains, “the greatest reason for communication practitioners 
to use social media [...] is that stakeholders are already using social media to 
communicate.” Direct discussions with different groups receiving information 
allow communicators to monitor how these groups are feeling about and reacting 
to a particular risk and to respond quickly to rumours or misinformation 
(Waters et al., 2009). This type of dialogue can build trust and increase satisfaction 
in communicators. For example, the CDC encouraged a dialogue with the 
public during the H1N1 pandemic, even among people with beliefs counter to 
the CDC recommendations. This was associated with an increase in the CDC 
American Customer Satisfaction Index, with those who used social media giving 
CDC higher ratings than those that did not (Reynolds, 2010; Veil et al., 2011).
Improving Dissemination 
Some regulators are using different approaches to ensure that risk 
communications reach desired groups. In the United Kingdom, for example, 
communications meant for healthcare professionals are delivered via the Central 
Alerting System (CAS). The CAS is defined as, “a web-based cascading system 
for issuing patient safety alerts, important public health messages and other 
safety critical information and guidance” (U.K. Department of Health, 2015). 
Messages are delivered electronically to hospitals and other healthcare facilities, 
which can then distribute them further. The CAS, however, is only a delivery 
system, and the documents delivered are of the same type as those described 
above (e.g., recalls, dear doctor letters). In a survey of 1,800 respondents, 42% 
found CAS alerts “always relevant,” while receiving too many irrelevant alerts 
and the time of day when alerts were received were identified as problems 
(MHRA, 2013).
Alert (or message) fatigue occurs when people start tuning out risk messages 
because of the large amount of information to which they are exposed (much of 
which may be minor or irrelevant to their lives) (FDA, 2012; CBC News, 2014). 
Baseman et al. (2013) found, for example, that for each additional public 
health message to which healthcare providers are exposed (per week) there is a 
decrease in the odds that they will be able to recall the content of that message. 
This can lead to important warnings being missed. Emerging practices could 
help overcome the challenges of alert fatigue by directing communications at 
the point of care and decision-making. Requiring that all prescribing be done 
electronically, for example, would ensure that physicians see warnings when 
they make the initial prescription (CBC News, 2014). Other healthcare partners 
could also be used to amplify the dissemination of information beyond the 
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direct healthcare prescriber. For example, at the pharmacy level, software that 
cannot be disabled and requires a user to give a reason for overriding warnings 
could ensure that pharmacists consider all relevant advisories (CBC News, 2014). 
Furthermore, software could ensure that more serious warnings are given first 
and could distinguish them from minor risks in some way.
3.3.3 Summary and Comments on Evaluation
Although the emerging tools described above are not in widespread use, they 
have often been subjected to important evaluation efforts including using 
pre-testing data to improve reach and understandability and measuring the 
initial impact of tools to assess changes in health outcomes. Such new tools 
may be perceived as unproven and therefore in need of more evaluation than 
established tools. The developers may also wish to publish articles about them 
in peer-reviewed journals, which often require some type of evaluative evidence. 
Needs evaluation and pre-testing are especially important for emerging tools, 
as there is an opportunity, and even an expectation, that the tools can be 
improved. Similarly, process evaluation can be used to audit and improve the 
development and release plan. As many of these emerging tools are not yet being 
used on a wide scale, outcome evaluations will be limited but, as demonstrated 
by the evaluation results discussed above, important observations for a range 
of communication goals can be obtained with concerted efforts.
Emerging tools provide new opportunities for communication, and for evaluation. 
For example, online access opens the door to online surveys before and after 
a communication is released. Social media, in particular, allow collection of 
feedback from a wide range of populations and stakeholders quickly and directly 
(Rutsaert et al., 2013). This enables regulators to monitor public opinion on 
a risk before and after a communication is released. Online resources also 
provide new metrics that could be useful in evaluation, such as website hits, 
downloads, search terms, or retweets. The FDA has recognized the usefulness 
of social media for evaluation, and has recently requested proposals from 
companies to carry out social media monitoring (Anonymous, 2014). This 
monitoring will be used to evaluate the effectiveness of the FDA’s risk and 
benefit communications through social media listening (Anonymous, 2014).
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3.4 CONCLUSION 
The Canadian regulatory context for health product risk communication 
is similar to that in other jurisdictions, including the United States, United 
Kingdom, Australia, and Europe. Given these similar contexts, it is not surprising 
that Health Canada’s challenges in evaluating and enhancing health product 
risk communication are common. Health Canada can benefit from the lessons 
learned by other regulators and from innovations adopted in health product risk 
management. However, given the general lack of evaluation across jurisdictions, 
Canada has the opportunity to lead in implementing effective health risk 
communication evaluation efforts.
Regulators around the world use similar tools to communicate health product 
risk information. The tools identified by the Panel can be classified into three 
categories: ongoing communications, incident(s)-based communications, and 
defect and error communications. While many different individual tools were 
identified, in many cases information about their structure, target, dissemination 
methods, and purpose could not be found. However, the Panel found some 
important similarities across all tools. For example, most tools identified are 
almost exclusively text-based, and the most common dissemination method is 
posting online. Emerging tools or approaches include those that refine how the 
message is presented, change the conditions that shape behaviour, use multi-
media approaches, take advantage of new mediums, and improve dissemination.
Evaluation of health product risk communication is essential for determining 
whether a tool is achieving, or is likely to achieve, the desired outcomes, and for 
improving future communications. Although extremely limited, the evaluation 
literature on established tools has shed some light on useful approaches. 
Emerging tools seem to be subject to greater evaluation scrutiny and point to new 
evaluation opportunities. The range of tools identified by the Panel highlights 
that evaluation cannot be done in a one-size-fits-all fashion, or simply tacked on 
at the end of the risk communication process. Instead, it should be considered 
throughout all stages of a communication. Just as risk communication tools 
are tailored to varying goals and populations, so too must the corresponding 
evaluation activities be tailored. Furthermore, communication tools will evolve, 
and evaluation plans will need to be updated accordingly. The Panel expands 
on these points in Chapter 4.
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4 Evaluating the Effectiveness of Health Product  
Risk Communication  
Evaluation of health product risk communication is lacking in many jurisdictions, 
despite its integral role in risk communication and its demonstrated value in 
supporting communication goals and improvements to content, processes, 
outcomes, and resource use. Evaluation not only provides feedback on the 
effectiveness of risk communications, but also helps to design and re-design 
communications aligned with the needs of various populations, to account for 
and learn from past mistakes, and to continue or build on identified successes. 
This chapter explores the general principles of evaluation by examining how 
careful planning and the determination of evaluation questions can shape the 
choice and application of evaluation methods. It examines the unique information 
needs and communication attributes, including the four goals specific to health 
product risk communication, and how these can determine the most appropriate 
methods. Where possible, the Panel uses illustrative examples of actual evaluations. 
The chapter concludes with discussion of strategies for securing commitment 
and resources for evaluation efforts.
4.1 ALIGNING HEALTH PRODUCT RISK COMMUNICATION 
AND EVALUATION
Evaluation is central to developing effective risk communication tools, allowing 
communicators to learn from and improve upon new and existing communication 
efforts. It can therefore help maximize resources and opportunities to inform 
the behaviour of the receivers of information as well as avoid negative outcomes 
associated with certain health product risks. Evaluation can also help fulfil 
regulatory and fiduciary obligations and demonstrate commitment to transparency 
Key Findings
• Evaluation has tremendous value for effective risk communication since it can 
address a range of decision-making needs.
• Careful planning efforts determine relevant evaluation questions by identifying 
and integrating information needs and motivations, and the attributes of the risk 
communication tool, including the goals of risk communication.
• Different evaluation methods produce different kinds of evidence and require 
different levels of resources. They reveal the most meaningful information when 
they are an extension of well-developed evaluation questions. 
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and accountability, which can have positive implications for gaining trust and 
credibility. In general, evaluation is essential to understand the extent to which 
a communication is achieving its goals and to improve future communication 
and related decision-making. This focus on improving decision-making and real-
world applications distinguishes it as an applied form of research (CDC, 2006; 
DFID, 2012; Kreps, 2014). Evaluations therefore often focus on understanding 
the broader context and the relationships involved in communications among 
a range of other factors (Kasperson & Palmlund, 1989; Pawson & Tilley, 1997; 
Weiss, 1998; Mayne, 2011b; Berriet-Solliec et al., 2014). For example, beyond 
finding evidence of impact, an evaluation may also aim to understand why a 
communication had impact, determine if it will have similar impacts in other 
settings, make the results of an evaluation transparent and accessible, or build 
trust with the receivers of information and other stakeholders. As such, the 
range of evaluation goals and related questions is extensive.
Often those conducting the evaluation may quickly jump to the identification 
of methods without properly assessing the specific context and decision-making 
needs for a given situation. However, since different evaluation methods produce 
a range of knowledge and have varying strengths and weaknesses, they may 
be more or less applicable to the evaluation of a particular communication 
(Rothman & Greenland, 2005; Cartwright & Munro, 2010; Fischhoff et al., 2011; 
DFID, 2012; Mayne, 2012). Moreover, there is also no universal way to evaluate a 
communication tool. Different evaluation methods may be applied in different 
ways to address various situations, needs, motivations, and goals. A truly successful 
evaluation therefore depends on taking the necessary time to develop appropriate 
and feasible evaluation questions and a better understanding of why the 
evaluation is taking place, who is conducting the evaluation, and for whom it 
is being conducted (Kasperson & Palmlund, 1989). 
Given the varied attributes of most risk communication tools, evaluation 
planning can help identify the most salient factors to explore and situate the 
goals of a tool within the complex environment in which it exists. Detailed and 
thoughtful planning must start as soon as possible and can determine relevant 
evaluation questions by identifying and integrating information needs and 
motivations, and accounting for the attributes of the tool, including the goals of 
risk communication. Planning allows an evaluation to take stock of the situation, 
ensuring that methods become an extension and build on evaluation questions. 
This increases the likelihood that appropriate evidence is collected and that the 
evaluation will produce meaningful knowledge for the senders and receivers of 
information and other stakeholders. The following subsections explore some 
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of the key factors in determining meaningful evaluation questions and identify 
some of the more feasible evaluation methods for regulators responsible for 
health product risk communication. 
4.1.1 Determining Evaluation Questions 
Ultimately, there is no one-size-fits-all way to conduct an evaluation. Successful 
evaluations are structured around clear evaluation questions determined by 
(i) information needs and motivations of the senders and receivers of risk 
information, and (ii) the communication attributes of the tool used.
Information Needs and Motivations
Senders of Information
As discussed in Chapter 3, regulators around the world use a range of similar 
tools for communicating the risks associated with health products. These tools 
are important for demonstrating action in the public interest and proof of 
their commitment and competence as leaders in protecting and promoting the 
health and safety of the population (Kasperson & Palmlund, 1989). Evaluation 
can “serve the central purpose of solidifying, justifying, or extending” these 
tools by demonstrating that they work and that the regulator is committed 
to ensuring they continue to meet government goals and work in the public 
interest (Kasperson & Palmlund, 1989).
Most regulators are interested in demonstrating accountability: that 
is, the compliance of their risk communication tools with regulatory 
responsibilities or requirements established by external oversight mechanisms 
(Kasperson & Palmlund, 1989). For this purpose, they may want to prove that a 
risk communication followed internal protocols and contributed to the short-, 
medium-, and long-term goals established during program planning. Evaluations 
may focus solely on attributing a communication to a set of pre-determined 
goals, seeking to establish a relationship between a risk communication tool 
and desired outcomes, and proving that the tool worked at a given time in a 
given context (Shadish et al., 2002; Cartwright, 2007; DFID, 2012).
Evaluations may also be motivated by the need to improve future risk 
communication, answer questions about performance, address failures 
or criticisms, or make decisions about the allocation of scarce resources 
(Kasperson & Palmlund, 1989). In these situations, evaluations become broader 
in nature and should seek to explain “how” and “why” a risk communication 
tool led to desired outcomes. It is therefore about understanding the nature of 
the relationship between tools and outcomes and what factors may influence 
that relationship (Cartwright & Hardie, 2012; DFID, 2012). Evaluations may 
therefore be concerned with whether the risk communication tool is necessary 
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and/or sufficient for producing an outcome and with identifying the range of 
factors that also contribute to various outcomes (DFID, 2012). The complexity 
of risk communication (see Chapter 2) renders the relationship between a 
tool and an outcome non-linear — that is, very difficult to attribute a given 
tool to a particular outcome. As such, the evaluation literature points to the 
notion of contribution, recognizing that a given outcome is the product of 
many factors (Rothman & Greenland, 2005; Pawson, 2006; Cartwright, 2007; 
Mayne, 2011a; DFID, 2012).
Finally, evaluation can demonstrate a clear commitment to transparency. 
In these cases, “evaluation has not only a factual but also a symbolic role — in 
demonstrating interest in what went wrong, in seeking solutions, in making 
concessions to outside critics, and in allocating blame and responsibility” 
(Kasperson & Palmlund, 1989). Therefore, an evaluation must be seen as 
relevant and trustworthy. High-level, rigorous evaluations may be of limited use 
to regulators if the results are not relevant or are seen as biased and subject to 
conflict of interests. In these cases, the composition of the evaluation team and 
the evaluation process are most important (Kasperson & Palmlund, 1989). Lack 
of relevance may be due to inaccessible findings (e.g., too technical, narrowly 
communicated) or to lack of stakeholder engagement and involvement. The 
Panel considers it is critical for those conducting an evaluation to understand 
the receivers of information and other stakeholders, involving them in a 
transparent manner to build trust and ensure relevance. As discussed in Chapter 2, 
institutions can help build trust by providing accurate risk communications that 
take into account the information needs, capabilities, and feelings of affected 
populations; evaluation efforts are no different.
Receivers of Information 
The identification of individual and group information needs is an outstanding 
challenge in risk communication and for the social sciences more generally 
(Fischhoff & Manski, 1999; Glimcher & Fehr, 2013). In the Panel’s view, 
however, the central motivation specific to the receivers of information and 
other stakeholders is determining credibility and who to trust when making 
decisions about health product risk information. As discussed in Chapter 2, 
these needs can be supported by ensuring that affected groups feel engaged in 
the communication process and empowered to use the information provided 
(NRC, 1996; Lundgren & McMakin, 2013). Similarly, they need to feel that 
their involvement in evaluation will be taken seriously, with their needs and 
concerns fully acknowledged. In some cases, there may be a degree of mistrust 
of risk communicators or those conducting the evaluation among different 
groups, owing to a lack of transparency (Garcia-Retamero & Cokely, 2014; 
Löfstedt & Bouder, 2014), concerns over previous evaluations, or a general 
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mistrust of particular institutions (Löfstedt & 6, 2008; Victory et al., 2014). 
Ensuring that the receivers of information and other stakeholders are consulted 
in ways that are meaningful and sensitive to outside concerns requires those 
conducting the evaluation to be knowledgeable about appropriate evaluation 
methods; participatory techniques and strategies that are feasible given resource 
and time constraints; and particular population beliefs, values, and needs that 
are specific to receiving risk information, participating in evaluation projects, 
and being engaged in dialogue. 
Communication Attributes
The increasingly complex world in which communication tools are implemented 
creates many different attributes that need to be accounted for in establishing 
evaluation questions. To develop evaluation questions, the Panel concluded 
that differentiating health product risk communication tools across three main 
attributes was most salient for regulators and other government institutions: 
(i) type, (ii) stage, and (iii) goal.
Type of Health Product Risk Communication Tool
Chapter 3 highlights three main types of risk communication tools, which 
can be further grouped as ongoing communication and incident(s)-based 
communication.11 Ongoing communication involves those tools that present 
known information about health product risks, and they are neither immediately 
pressing nor time sensitive. Incident(s)-based communication, on the other 
hand, involves newly discovered information and is often related to crises or 
emergencies. This means that these tools are time sensitive and subject to the 
pressures of immediately getting information into the public realm, while taking 
the time necessary to establish the full extent of the risk and risk management 
strategy. In both situations, multiple sources of information are simultaneously 
competing for the attention of affected populations, and these sources can 
differ in how, and by how much, they influence reception of information 
and decision-making.
How an evaluation is carried out will be different depending on the type of tool. 
With ongoing communication tools, there will be more time to gain sufficient 
resources, conduct systematic assessments, use comprehensive methods, 
and fully engage the receivers of information prior to, during, and after the 
evaluation. It may be difficult, however, to justify an evaluation of a tool that 
has been in use for a number of years. Conversely, with the limited time for 
evaluation planning and implementation that results from incident(s)-based 
11 Recall that incident(s)-based communication tools share many similarities to errors and defects 
communication tools and are therefore grouped for the purposes of discussion in this chapter.
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communication, evaluations will likely be working with fewer resources, less 
comprehensive evaluation methods, and limited engagement opportunities. 
Alternatively, the ability to assess various goals using clear before and after 
comparison groups becomes more viable for incident(s)-based communication. 
Because incident(s)-based communications are delivered at a fixed point in 
time, there is a clear baseline from which to measure the distribution of a 
communication. In this sense, it is relatively straightforward to measure the 
effectiveness of specific distribution channels. In contrast, since ongoing 
communications are delivered in a continuous manner, it is difficult to identify 
a baseline start date and end date for analysis. 
Finally, the public is more likely to demand certain types of evaluation for high-
profile incident(s)-based communications that need to be done quickly and in 
full view of the public. In these situations transparency is critical. Regulators 
and other government institutions may be more interested in evaluations that 
demonstrate appropriate and proper processes were followed over demonstrating 
long-term impacts. To conduct a successful evaluation, those conducting the 
evaluation also need to be aware of other types of information on a given risk and 
how they may play out differently in ongoing versus incident(s)-based situations.
Health Product Risk Communication Stage 
The different stages in the risk communication process (i.e., planning, 
implementation, and assessment) translate into different types of evaluation 
(Rohrmann, 1992; Jardine, 2008; Downs, 2011). Ultimately, evaluation is 
integral to all stages and is not simply an end-stage task carried out after the 
risk communication is completed. The Panel selected the following categories 
to distinguish types of evaluation because they most clearly highlight the stages 
of health product risk communication and link to the information needs and 
goals of risk communication:
• Needs assessment: undertaken to identify the information needs of the 
senders and receivers of information and other stakeholders — why the 
communication is taking place, what needs to be communicated and the 
quality of that evidence, for whom the communication is intended, and the 
most appropriate communication tool. Its findings can increase the likelihood 
that a risk communication will be effective.
• Pre-testing: undertaken before the full implementation of a risk communication 
to preliminarily test the feasibility, appropriateness, and effectiveness of the 
identified communication tool in sub-groups of the population intended 
to receive the final communication. Its findings can lead to changes to 
the communication, which will further increase the likelihood that it will 
be effective. 
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• Process/Implementation: typically undertaken during the implementation 
of a risk communication to provide evidence that it is progressing as planned 
and that an organization is following its internal protocols and plans. It may 
also be done retrospectively to identify lessons learned. Its findings provide 
insight into potential revisions to implementation strategies and the need 
for reassessing goals and potential outcomes. It can also help identify the 
potential value of conducting outcome evaluations in the future. 
• Outcome: conducted after a risk communication has been disseminated and 
completed to link meaningful short-, medium-, and long-term outcomes to the 
tool in question. It is capable of producing various kinds of evidence, from 
largely descriptive findings to more rigorous explorations of the relationships 
between tools and outcomes, and the nature and factors that may influence 
those relationships. Although considered end-stage efforts, more rigorous 
evaluations will usually establish a baseline prior to the implementation of 
the communication followed by ongoing measurement. 
Health Product Risk Communication Goals
Defining risk communication goals implies that evaluation will be done to 
establish whether these goals have been met. Many of the evaluations identified 
by the Panel that were specific to certain tools had a limited focus and often 
only looked at singular components (e.g., readability) or singular goals 
(e.g., use) (see Chapter 3). However, it is important to establish a broad range 
of goals for proper testing. In Chapter 2, four goals for health product risk 
communication were introduced to capture the range of short-, medium-, and 
long-term outcomes to be assessed through evaluation: 
• Development: incorporating evaluation methods and learning into the steps 
involved in designing risk communications, including when characterizing 
and managing risk, creating messaging, and ensuring ongoing partnership 
and exchange.
• Reach: how and when the communication is sent and received and by whom. 
• Use: how the information is considered, its timeliness, and the reactions 
and actions taken as a result of the communication, thus exploring 
understandability, timeliness, informed decision-making, and behaviour.
• Impact: achieving a desired result with respect to various outcomes related to 
the senders and receivers of information and the relationship between them. 
These goals will ultimately align with information needs and motivations of 
decision-makers, as well as with other communication attributes, to shape 
evaluation questions and subsequent methods. For example, development 
aligns with needs assessment and pre-testing evaluations, reach and use align 
with process/implementation evaluation, and impact aligns with outcome 
evaluation. In addition, development and reach align with information needs 
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and motivations related to accountability, whereas use aligns better with program 
improvement motivations, and impact is an important goal to demonstrate in 
meeting transparency-oriented motivations. 
Research demonstrates that even with concrete goals and a clear idea of relevant 
and meaningful outcomes, it may be difficult to collect indicators that are 
sufficient proxies for these outcomes. Indicators must be reliable to the extent 
that they consistently represent the same outcome when repeatedly used across 
different situations and over time. Indicators must also be able to represent what 
they are intended to represent, and be precise, accurate, and comprehensive 
in scope. Based on the Panel’s review of available evaluations, it appears that 
for many outcomes related to behavioural change, and to development, reach, 
use, and impact more generally, there is little consensus on which indicators are 
truly valid, reliable, and comprehensive over time. Therefore, better knowledge 
involving measurement is needed in the field of risk communication; however, 
this is no excuse for limited evaluation. Rather, a range of methods can be used 
to more fully capture the range of communication goals. The dimensions and 
associated evaluation methods for each of the four communication goals are 
described in Sections 4.2 to 4.5.
4.1.2 Selecting Evaluation Methods
Evaluation methods can become an extension and build on the evaluation 
questions selected, thereby increasing the likelihood that the evaluation will 
produce meaningful results. A wide array of methods can be used, ranging from 
simple to complicated and from quantitative to qualitative. Each method can be 
applied in different ways for different situations, and provide different types of 
knowledge and carry different strengths and weaknesses. There are a number of 
ways to classify these methods in the evaluation literature (Fischhoff et al., 2011; 
DFID, 2012; McDavid et al., 2013; Kreps, 2014). The Panel organized available 
methods into five broad approaches that it determined to be the most relevant 
for health product risk communication and the most feasible for regulators 
and other government institutions to implement: 
• Synthesis: Methods include literature reviews, systematic reviews, 
and meta-analyses.
• Records-based: Methods include textual, archival, and administrative 
data analysis.
• Self-reported data: Methods include interviews, focus groups, and 
population-based surveys. 
• Experimental: Methods include quasi-experimental methods, natural 
experiments, and RCTs. 
• Mixed methods: This involves combining quantitative and qualitative methods 
from different approaches in the same evaluation.
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The list is not meant to be exhaustive and readers are encouraged to look to 
other sources for more detailed guidance (HM Treasury, 2011; Owen, 2011; 
DFID, 2012; McDavid et al., 2013; Lance et al., 2014; Web Center for Social 
Research Methods, n.d.). Appendix A provides a basic overview of the types of 
knowledge gained, advantages, and challenges associated with key approaches 
and constituent methods; this information is also summarized in Table 4.1. 
Sections 4.2 to 4.5 explore how various methods can be adapted across different 
communication goals and related evaluation questions.
Table 4.1
Overview of Approaches and Methods for Evaluation
Synthesis Approach
Methods Type of Knowledge Gained Advantages Challenges 
 • Literature and 
Systematic 
Reviews, and 
Meta-Analyses
 • Expert/scientific model of 
risk understanding
 • Understanding of health  
risk and associated factors
 • Suggests hypotheses, 
methodological challenges, 
and other evaluation issues 
 • Efficient 
 • Low cost 
 • Difficult to 
determine 
accuracy/quality 
 • Not always 
comparable/
relevant
Records-Based Approach
Methods Type of Knowledge Gained Advantages Challenges 
 • Textual 
Analysis 
 • Patterns in recorded 
presentation and language 
used in risk communication 
tools 
 • Efficient
 • Low cost 
 • Not generalizable 
 • Often limited 
quantitative data
 • Archival and 
Administrative 
Data Analysis
 • Background information
 • Data on program  
outcomes/impacts
 • Quantitative measures  
of health, economic,  
and social conditions 
 • Efficient 
 • Low cost
 • Sometimes 
incomplete/
inaccurate
continued on next page
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Self-Reported Approach
Methods Type of Knowledge Gained Advantages Challenges 
 • Interviews 
and Focus 
Groups
 • In-depth knowledge of 
population needs, beliefs, 
and behaviours 
 • Gain understanding of 
social meaning of risk  
and why people make  
the decisions they do 
 • Preferred wording  
and context of 
communication tools
 • Reliable 
 • Versatile
 • Focus on breadth 
and depth
 • Produces shared 
understanding  
as part of  
social context
 • Accuracy of 
responses 
 • No control group
 • Human resource 
requirements
 • Variable costs, 
ranging from low 
to high depending 
on design
 • Population-
Based Surveys
 • Superficial knowledge of 
population needs, beliefs, 
and behaviours 
 • Various types of quantitative 
and qualitative data and 
information, depending on 
evaluation needs
 • Allows comparisons 
across larger groups 
of individuals and is 
representative of 
more people
 • Varying sampling 
strategies
 • Variable costs, 
ranging from low 
to high depending 
on design
Experimental Approach
Methods Type of Knowledge Gained Advantages Challenges 
 • RCTs
 • Quasi-
Experimental 
Methods
 • Natural 
Experiments
 • Comparison of effects 
between those  
who receive 
communications and those 
who do not
 • Strength of attribution 
depends on strength of the 
research design
 • Allows comparisons 
across individuals 
and populations
 • Reliable comparison 
population can 
account for 
influencing factors
 • Varying sampling 
strategies
 • Generalizable and 
can be compared to 
other similar studies
 • Can be difficult  
to implement
 • Costly
 • Provides less 
information on 
context and larger 
social process
 • Ethical and 
acceptability 
issues involved in 
randomization
 • Normally limited 
participation from 
affected groups 
Mixed Methods Approach
Methods Type of Knowledge Gained Advantages Challenges 
 • Variable  • Range of evidence from 
information needs and 
beliefs/behaviours to valid 
causal inferences and 
in-depth understanding  
of communication results 
 • Diverse 
 • Versatile
 • Combines the  
best aspects of 
different methods 
 • Can be costly 
 • Human resource 
requirements
 • Time intensive
104 Health Product Risk Communication: Is the Message Getting Through?
4.2 DEVELOPMENT: MATCHING EVALUATION METHODS  
TO RELEVANT QUESTIONS
Key Findings – Development 
• Development refers to incorporating evaluation methods and learning into 
the steps involved in designing risk communications.
• The relevant evaluation questions and methods for dimensions of development 
are listed below.
Dimensions Evaluation Questions Methods
Characterizing and 
Managing Risk
 • Who needs to receive the risk communication?
 • Who wants to receive the risk communication?
 • What needs to be communicated?
 • Who is the source of the risk information?
 • What is the accuracy and credibility of the 
evidence base?
 • Literature review/
Systematic 
review/
Meta-analysis 
 • Textual analysis
 • Interviews and  
focus groups
 • RCTs
 • Mixed methods
Creating Messaging  • What are the communication wants and needs 
of the receivers of information?
 • How do the receivers of information  
make sense of risk?
 • Will they understand the content?
 • What will the content look like (e.g., text, 
images, colour)?
 • Does the content address wants and needs?
 • How will the risk communication be 
disseminated?
 • Are the communication channels appropriate for 
all groups receiving the information?
Ongoing Partnership 
and Exchange
 • What is the relationship between the sender and 
receiver of information?
 • How could that relationship change, stay  
the same, or be strengthened?
 • What is the best way to engage the receivers of 
information in the evaluation process?
 • How can the senders and receivers of 
information and other stakeholders be involved 
in the implementation of evaluation?
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Before launching a risk communication, evaluation methods can be used to inform 
its development, using evidence to increase the likelihood that it will lead to 
desired and meaningful outcomes (Jardine, 2008; Downs, 2011; Bruine de Bruin & 
Bostrom, 2013). This process can best be described by exploring needs assessment 
and pre-testing activities (see Section 4.1.1) and the risk communication 
dimensions discussed in Chapter 2: (i) characterizing and managing risk; 
(ii) creating messaging; and (iii) ongoing partnership and exchange. 
Evaluation can help establish what needs to be communicated; to whom it needs 
to be communicated; and the appropriate content, design, and delivery channels 
for those populations. Moreover, relationships between the senders and receivers 
of information, those conducting the evaluation, and other stakeholders can 
be fostered through engagement in evaluation planning and pre-testing as well 
as through participatory evaluation approaches. Sometimes communicators 
fail to conduct this type of evaluation because they are overconfident about 
understanding the needs of varying groups, they are unaware of leading 
methods, or they face resource constraints (Rohrmann, 1992; Bruine de Bruin 
& Bostrom, 2013; Fischhoff, 2013). However, even though assessing needs and 
pre-testing preliminary messages does not guarantee that a risk communication 
will be successful, it does reduce the chance of failure due to developmental 
flaws (Jardine, 2008). 
4.2.1 Dimensions and Evaluation Questions
Characterizing and Managing Risk
As discussed in Chapter 2, risk characterization involves considering a given 
hazard and its potential outcomes as well as identifying affected populations 
and their needs. Understanding the risks for a given health product is rarely 
straightforward (NRC, 1996). It requires assessing the state of knowledge 
possessed by experts and the public. Broadly speaking, expert understanding 
refers to the current scientific and technical knowledge about the nature 
and magnitude of a health product risk and approaches to its management 
(Morgan et al., 2002; Bruine de Bruin & Bostrom, 2013). Expert opinion can 
be drawn from risk and decision analysts, behavioural scientists, subject matter 
experts, and communication practitioners (Fischhoff, 2009). In contrast, the 
state of the public’s understanding refers to the general level of knowledge across 
individuals and groups, which is shaped by social and cultural values and 
individual risk perceptions (Kasperson et al., 1988; Slovic, 2000; Kahan, 2012). 
This process consists of identifying the receivers of information, the risk issues 
most in need of communication, and the quality of available evidence (source). 
As such, evaluations must explore the following questions:
• Who needs to receive the risk communication?
• Who wants to receive the risk communication?
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• What needs to be communicated?
• Who is the source of the risk information?
• What is the accuracy and credibility of the evidence base?
Creating Messaging
Creating messaging requires further understanding the traits of the receivers 
of information, their approaches to decision-making, and their information 
wants and needs. Understanding the information needs and expected reach, 
use, and impact of communications is facilitated by evaluation specific to the 
risk, to the communication, and to the demographic, socio-economic, and 
health characteristics of the populations involved. This approach helps ascertain 
how a communication responds to the “concerns, needs, perspectives, and 
communication styles” of different groups and whether the information will be 
personally relevant, comprehended, considered, and accepted (Kreps, 2014). 
It can identify the “relevant performance gaps between ideal and actual 
health outcomes that might necessitate development of targeted health 
risk communication[s]” and, ultimately, if there is enough demand for new 
communications that promote health (Kreps, 2014). This information is 
complemented by collecting data on health behaviours; how people communicate 
and their preferences (e.g., use of social media, preferences for communication 
channels, literacy, and language preferences); knowledge, attitudes, values, 
and emotions related to the communication topics across groups; “cultural 
habits and preferences; effective motivational factors; and potential barriers 
to accepting information and changing health behaviours” (Kreps, 2014). This 
information is then used to establish the most appropriate communication 
content, design, and channel, which can then be pre-tested in sub-groups of the 
population intended to receive the final communication. As such, evaluations 
must explore the following questions:
• What are the communication wants and needs of the receivers of information?
• How do the receivers of information make sense of risk?
• Will they understand the content?
• What will the content look like (e.g., text, images, colour)?
• Does the content address wants and needs?
• How will the risk communication be disseminated?
• Are the communication channels appropriate for all groups receiving 
the information?
Ongoing Partnership and Exchange 
The benefits of engaging the receivers of information and other potential 
stakeholders in evaluation planning are explained simply: “stakeholders are 
much more likely to buy into and support the evaluation if they are involved 
in the evaluation process in the beginning” (CDC, 2011). How engagement 
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takes place can vary based on a number of factors and there are many types of 
engagement (IRGC, 2014). Co-determination models, which engage stakeholders 
and members of the affected public to co-design policies and assist in making 
joint decisions (IRGC, 2014), hold promise for meaningful engagement strategies. 
The Panel notes that further research is needed on how best to engage, when 
to engage, and who to engage in the context of health product risk, specifically.
Undertaking engagement activities early in the planning process, enables 
those conducting an evaluation to dispel any misconceptions about the process 
(e.g., explain its limitations and quell any anxieties over the goals of an 
evaluation). In addition, ongoing engagement models can help prepare various 
populations for negative evaluation results (Bowen, 2012) and ensure that 
results are actually used in future decision-making. Receivers of information 
and other stakeholders that have a sense of ownership over an evaluation are 
more likely to consult and use its results in the future (Cargo & Mercer, 2008; 
Bowen, 2012). Establishing relationships between those conducting an evaluation 
and those sending and receiving information throughout planning can also 
benefit future communications. As with risk communication in general, an 
ongoing relationship builds trust over time, which can have long-term benefits 
for future evaluations. As such, evaluations must explore the following questions:
• What is the relationship between the sender and receiver of information?
• How could that relationship change, stay the same, or be strengthened?
• What is the best way to engage the receivers of information in the 
evaluation process?
• How can the senders and receivers of information and other stakeholders 
be involved in the implementation of evaluation?
4.2.2 Relevant Methods 
A range of methods can be used to evaluate the potential effectiveness of a risk 
communication before implementation, depending on the resources available. 
Conducting a literature review, systematic review, or meta-analysis (i.e., a synthesis 
approach) of the existing literature can accomplish several goals. It can 
highlight the risk information that needs to be communicated and the sources 
of risk communication to which the receivers of information may have access. 
Moreover, it can provide guidance on the most effective means of presenting 
and designing a risk communication. This is often the first step in the design of 
an effective risk communication. A slightly more labour-intensive method is to 
conduct a textual analysis of current and previously issued risk communications 
to understand common types of content, designs, and delivery channels. Taken 
together, the synthesis approach and textual analysis can provide an accurate 
risk characterization, understanding of risk decision-making, and overview of the 
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most essential features of an effective risk communication. With these benefits in 
mind, the generality of these methods provides limited guidance about a specific 
risk communication in a specific context.
Interviews and focus groups examine the information needs, beliefs, and behaviours 
of the receivers of information in the context of a specific health product risk 
communication. This provides an initial characterization of the information 
needed, including preferred wording and style of presentation (Jardine, 2008; 
Bruine de Bruin & Bostrom, 2013). Moreover, focus groups provide a relatively 
straightforward way to engage the receivers of information and other stakeholders. 
Once a risk communication has been designed, but before it is implemented, 
an evaluation using these methods can also test whether it will be effective by 
directly asking participants about the relevance of the communication content 
and how it may influence their decision-making and behaviour (Fischhoff, 2009). 
There are, however, a number of challenges associated with this type of testing. 
Participants may be unaware and/or unable to predict how information will 
inform their decision-making. It may also be difficult to determine the accuracy 
of responses and how they compare across individuals. Finally, these methods 
do not provide a means to compare the decision-making of individuals who 
receive a risk communication with those who do not.
At this stage, RCTs can be used by randomly assigning individuals to receive 
different types of information by altering the content, design, or delivery of risk 
communications. For example, as described in Chapter 3, Schwartz et al. (2009) 
conducted two RCTs to test the effectiveness of drug fact boxes relative to direct-
to-consumer drug ads. One trial involved information related to a drugs ability 
to alleviate allergy or heartburn symptoms (symptom drug boxes), while the 
other focused on a drugs ability to prevent cardiovascular events (prevention 
drug boxes). In both trials, the control groups received two actual drug ads that 
consisted of a front page and a summary while the treatment group received 
the same ads with the summary replaced by a drug fact box. In the trial using 
symptom drug boxes, 68% of the treatment group chose the superior drug 
(compared to 31% in the control group) while in the trial using prevention drug 
boxes, 72% of the treatment correctly identified the drug benefit (compared 
to 9% in the control group) (Schwartz et al., 2009). This study provides clear 
evidence that a drug fact box is an effective risk communication tool. RCTs are 
an effective method for conducting controlled tests of various content, design, 
and delivery channels across the receivers of information; however, these 
results are specific to a given setting and cannot be easily generalized to other 
situations (Cartwright & Munro, 2010; DFID, 2012). Of the methods described 
in this section, RCTs are the most resource intensive and difficult to conduct.
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With sufficient resources and commitment, mixed methods provide the most 
comprehensive way to identify the appropriate populations, sources, content, 
design, and delivery channels for a risk communication, ultimately informing 
its development. Box 4.1 provides a case study of one such evaluation. 
Box 4.1 
Developing Risk Communication Tools with Mixed  
Methods Evaluation  
A study of the beliefs of adolescent girls related to sexual behaviour provides 
an example of how mixed methods evaluation can inform risk communication 
development. Bruine de Bruin et al. (2007) note, based on a literature review, 
that adults and teens view sexual health risks differently, and that the former 
group may make erroneous assumptions about why teens engage in risky sexual 
behaviour. To develop a more effective risk communication tool about sexual health 
and use of related health products (e.g., condoms), needs assessment and pre-
testing were carried out using mental models (Morgan et al., 2002). This process 
involved examining the available scientific model and the model of a sample of 
adolescent girls. To develop the adolescent girl model, engagement with this group 
was needed. This was achieved through in-depth individual interviews using non-
directive questions and increasingly specific prompts (to explore understanding, 
including intuitive theories), followed by written surveys to “[measure] the prevalence 
and correlates of potentially critical beliefs, as identified by the interviews” 
(Bruine de Bruin et al., 2007).
Based on the gap between the scientific and adolescent models, an interactive video 
format on DVD (What Could You Do?) was developed to empower young women 
in making sexual health decisions (Bruine de Bruin et al., 2007).  As the authors 
describe, “empowering [young women]…means helping them to understand their 
world and work it to their best advantage. Given the complexity of sexual decisions, 
young women need a broad perspective to create and evaluate options, adapt to 
unanticipated obstacles and opportunities, and consider the broader context that 
gives meaning to their lives and relationships.” Further evaluation methods that 
used think-aloud protocols helped to make the content realistic, compelling, and 
understandable (Bruine de Bruin et al., 2007). 
continued on next page
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4.3 REACH: MATCHING EVALUATION METHODS  
TO RELEVANT QUESTIONS
Evaluating the reach of a risk communication requires gathering evidence on how 
the risk communication was distributed and whether the affected populations 
received it (Chen, 2005; Montague & Porteous, 2013). This information 
allows the senders of information to modify processes and procedures during 
implementation to ensure that the messages are reaching affected groups 
through the selected channels (Jardine, 2008; Downs, 2011). While this approach 
Key Findings – Reach
• Reach refers to how and when the communication is sent and received and by whom.
• The relevant evaluation questions and methods for dimensions of reach are 
listed below.
An evaluation to measure the effectiveness of the DVD was then undertaken. In an 
RCT, the researchers evaluated the communication’s effects on 300 female urban 
adolescents’ knowledge about sexually transmitted infections, self-reported sexual 
risk behaviour, and acquisition of sexually transmitted infections (Downs et al., 2004b; 
Bruine de Bruin et al., 2007). The interactive DVD was compared with two control 
groups: one that received the same content in book form, the other in commercially 
available brochures. After three months, self-reports revealed that those in the DVD 
group were significantly more likely to be abstinent than those in either control 
group. After six months, those in the DVD group were significantly less likely to 
report having had a condom break, leak or fall off, or to have been diagnosed with 
a sexually transmitted infection (Downs et al., 2004b; Bruine de Bruin et al., 2007). 
This highlights the power of evaluation for developing effective risk communication 
tools that engage with the receivers of information.
Dimensions Evaluation Questions Methods
Delivery  • Was the risk communication sent  
and to whom specifically?
 • Administrative data analysis
 • Interviews and focus groups
 • Population-based surveys
Receipt  • Did those groups receive the  
risk communication?
 • Are those groups aware of the  
risk communication?
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to evaluation is closely linked to process/implementation evaluation, delivery 
and receipt can be evaluated retrospectively as part of an outcome evaluation. 
Although this type of evaluation cannot ensure that a communication is 
achieving use and impact, it can provide evidence that a risk communication 
is implemented as intended, on track, and on time, and whether the budget is 
sufficient (Jardine, 2008; Downs, 2011). The findings of such an evaluation also 
provide insight into potential revisions to communication goals and strategies.
4.3.1 Dimensions and Evaluation Questions
Evaluating reach is relatively straightforward and involves two main dimensions: 
delivery and receipt. This can include describing the program, documenting the 
steps for implementing it, and identifying who will deliver (e.g., the regulator) 
and who will receive the communication (e.g., particular patient groups, 
professionals, other stakeholders) (Downs, 2011). A data collection plan is 
then developed to observe the outcome of interest (Downs, 2011), such as 
the volume of communications sent and received. Although they can be done 
retrospectively, these evaluations are particularly valuable for assessing how well 
procedures follow the communication plan conceived during development, and 
how they may need to be adapted during implementation. Reach evaluations 
should be tailored to the internal needs of the organization(s) implementing 
the risk communication. As such, they must explore the following questions: 
• Was the risk communication sent and to whom specifically?
• Did those groups receive the risk communication?
• Are those groups aware of the risk communication?
4.3.2 Relevant Methods
While there are numerous ways to evaluate reach, the Panel notes three methods 
that align with these evaluation questions. Administrative data analysis consist 
of collecting basic descriptive statistics from program records that provide 
indicators such as: posting on the organization’s website or social media, 
number of website hits or read tweets, press releases, number of pamphlets or 
posters, number of package inserts, and letters sent to physicians. It explores 
the channels of risk communication distribution and can effectively answer the 
question: was the risk communication sent and to whom specifically? In general, 
this provides an overall picture of the degree to which a risk communication was 
distributed and requires relatively few resources. However, it does not capture 
if affected populations received it. For example, in the evaluation of the Do 
Bugs Need Drugs? (DBND) program discussed in Chapter 3, administrative 
data in the form of distribution numbers and estimated transit ridership 
were used to demonstrate that 75,000 print materials were distributed across 
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British Columbia, 14,700 books were distributed to healthcare professionals, 
and public transit advertisements were viewed an estimated 30 million times 
(Do Bugs Need Drugs?, 2014). 
Interviews and focus groups, while requiring more resources and time than 
administrative data analysis, allow evaluation teams to more accurately, and with 
a higher degree of confidence, evaluate whether affected populations actually 
received and are aware of the distributed risk communication, and which 
channels of distribution were the most effective. Interviews can be carried out at 
one point in time or used to further refine and enhance the evaluation process. 
For example, Chakraborty and Löfstedt (2012) conducted 70 interviews across 
two major U.S. metropolitan areas considered to be representative for assessing 
public perceptions, to assess the FDA Adverse Event Reporting System (AERS). 
The interviews were modified based on analysis from preliminary findings, and 
revealed that awareness of AERS was low and it was viewed as inaccessible or 
confusing. Interviews do not have to strictly involve the public; they may also 
explore perceptions of risk communicators, regulators, industry, and others 
involved in risk communication dissemination.
Population-based surveys randomly sample the receivers of information or other 
relevant stakeholders to explore both delivery and receipt. Overall, the large 
sample inherent in these surveys can provide confidence in results; however, 
this method is resource and time intensive. Many surveys are conducted by third 
party market research companies to provide regulators and other government 
institutions with an independent assessment of reach. For example, the DBND 
program contracted an independent market research firm to assess program 
activities with an emphasis on awareness of the DBND media campaign related 
to antibiotic use. Based on an online survey of 1,002 B.C. residents, 71% of 
respondents were aware of promotional material, and 54% had seen a television 
advertisement about the program (Do Bugs Need Drugs?, 2014). Similarly, 
in 2003 and 2006, Health Canada commissioned surveys of healthcare 
professionals and the general public to assess the reach of certain health 
product risk communication tools, such as those related to drugs (Evaluation 
Directorate, 2014c).  Among the healthcare professionals who responded, 
54% were very or somewhat familiar with manufacturer-issued Dear Health 
Professional Letters (DHPLs, includes Dear Health Care Professional Letters 
and Notice to Hospitals) compared with 42% with Health Canada-issued DHPLs 
and 38% with Health Canada’s online drug safety advisories. Across respondents 
from the public, only 36% were aware of Health Canada’s website as a source of 
new safety information about drugs while 62% were aware of public advisories 
issued through the media (Evaluation Directorate, 2014c). 
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4.4 USE: MATCHING EVALUATION METHODS TO  
RELEVANT QUESTIONS
Key Findings – Use
• Use refers to how the information is considered, its timeliness, and the reactions 
and actions taken as a result of the communication.
• The relevant evaluation questions and methods for dimensions of use are listed below.
Dimensions Evaluation Questions Methods
Understand- 
ability
 • What are the barriers (facilitators) that might prevent 
(support) understanding the message? 
 • Was information sent in a way that overcomes barriers  
and leverages facilitators to understanding?
 • How does the information align with evidence-informed 
practices in communication and health literacy?
 • Is the information understood by those receiving  
the information?
 • Was awareness of the risk increased in the receivers  
of information?
 • Textual analysis
 • Interviews and 
focus groups
 • Population-based 
surveys
 • Quasi-experiments
Timeliness  • How much time has elapsed between identification  
and dissemination?
 • What is the justification for this amount of time and  
is it based on reasonable grounds?
 • Did the senders and receivers of information and other 
stakeholder groups consider the risk communication 
timely to inform their decision-making and behaviour? 
How do expectations compare across these groups? 
Informed 
Decision-
Making
 • Did the receivers of information, both among the public 
and among healthcare professionals, seek the risk 
communication out?
 • Did the receivers of information feel that the 
communication provided meaningful information? 
 • Did the risk communication contain messages that the 
receivers of information believe they can successfully 
carry out and were those messages believed to be 
successful for averting any harm?
 • Did the risk communication influence shared  
decision-making between healthcare professionals  
and the receivers of information?
Behaviour  • Did the risk communication change the risk perceptions  
of the receivers of information?
 • Were there any changes in the preferences of the receivers 
of information (e.g., patients, healthcare professionals)?
 • Was information used by healthcare professionals  
and the groups that they work with?
 • Did the receivers of information change their behaviour  
or continue recommended desirable behaviour?
 • Was the risk minimized by actions based on specific 
recommendations from the risk communication?
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Evaluating the use of a risk communication requires gathering evidence on 
whether it influences the decision-making and behaviour of populations 
receiving the message (DFID, 2012; Mayne, 2012; McDavid et al., 2013). It 
involves exploring many dimensions related to how the communication is 
understood or considered, its timeliness, and the reactions to and actions 
taken as a result of it. This kind of evaluation most closely matches process/
implementation and outcome evaluation. Therefore, although it may be 
valuable to explore use retrospectively, it is most meaningful when undertaken 
during the implementation of a risk communication to provide insight into 
program fidelity and potential revisions to communication activities and goals. 
It is difficult to assess decision-making and behaviour, particularly informed 
refusal, and the subjective nature of dimensions such as timeliness. It follows 
that evaluating use mostly involves qualitative methods that explore the beliefs, 
values, and behaviours of the receivers of information (although quantitative 
approaches can be useful when there are clear indicators of behaviour change 
such as prescribing rates or drug use).
4.4.1 Dimensions and Evaluation Questions
Understandability
It is important to determine whether the messaging of the communication 
is understood by the receivers of information and other stakeholders. In the 
evaluations of health product risk communication tools identified in Chapter 3, 
understandability was one of the most common goals. Generally, these kinds 
of evaluations use interviews, surveys, and expert analysis to mostly measure 
indicators such as readability, clarity, and literacy. They assess both the tools 
themselves and the levels of comprehension of different groups receiving the 
information. As such, evaluations must explore the following questions:
• What are the barriers (facilitators) that might prevent (support) understanding 
the message? 
• Was information sent in a way that overcomes barriers and leverages facilitators 
to understanding?
• How does the information align with evidence-informed practices in 
communication and health literacy?
• Is the information understood by those receiving the information?
• Was awareness of the risk increased in the receivers of information?
Timeliness
Timeliness refers to the degree to which an organization communicated relevant 
information within a suitable timeframe after a risk incident. It depends on the 
urgency, severity, probability, and uncertainty associated with a risk and the need 
to balance the speed of dissemination with establishing quality information. 
While timeliness can be measured as the elapsed time between a risk event 
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(identification) and a communication release (dissemination), timeliness can 
largely be a subjective notion for the senders and receivers of information and 
other stakeholders. As such, evaluations must explore the following questions: 
• How much time has elapsed between identification and dissemination?
• What is the justification for this amount of time and is it based on 
reasonable grounds?
• Did the senders and receivers of information and other stakeholders consider 
the risk communication timely to inform their decision-making and behaviour? 
How do expectations compare across these groups? 
Informed Decision-Making
An effective risk communication enables the receivers of information to make 
informed choices, including informed refusal, based, in part, on the information 
in a risk communication. This requires that the receivers of information seek out 
the risk communication and are able and willing to use that information in their 
personal risk management decision-making and self-care strategies. Informed 
decision-making can be assessed by exploring the beliefs and behaviours of 
the public and sub-populations that are affected by the messaging in question; 
however, it may also involve assessing other stakeholders who influence the 
shared decision-making process related to healthcare. As such, evaluations 
must explore the following questions:
• Did the receivers of information, both among the public and among healthcare 
professionals, seek the risk communication out?
• Did the receivers of information feel that the risk communication provided 
meaningful information? 
• Did the risk communication contain messages that receivers of information 
believe they can successfully carry out and were those messages believed to 
be successful for averting any harm?
• Did the risk communication influence shared decision-making between 
healthcare professionals and the receivers of information?
Behaviour
As described in Chapter 2, risk behaviour depends on a range of factors. 
Fundamentally, a risk communication can induce behaviour change (or reinforce 
existing behaviour) if it influences the risk perceptions or knowledge of those 
receiving the information since both factors can change the way an individual 
understands the risk (relative to the benefit) of health product use. This can be 
observed directly by looking at rates of health product use or prescription rates 
for example, or by asking the receivers of information how a communication 
influenced their risk perceptions and subsequent behaviour. As with informed 
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decision-making, various populations (e.g., patients, healthcare professionals) 
that are affected by the risk communication are important to include when 
evaluating use. As such, evaluations must explore the following questions:
• Did the risk communication change the risk perceptions of the receivers 
of information?
• Were there any changes in the preferences of receivers of information 
(e.g., patients, healthcare professionals)?
• Was information used by healthcare professionals and the groups that they 
work with?
• Did the receivers of information change their behaviour or continue 
recommended desirable behaviour?
• Was the risk minimized by actions based on specific recommendations from 
the communication?
4.4.2 Relevant Methods 
Of the numerous ways to evaluate use, the Panel noted four methods that vary 
in the evaluation questions answered and the resources required. Textual analysis 
evaluates understandability, by exploring the degree to which the content and 
design of a risk communication is accurate, clear, and well-presented in alignment 
with evidence-informed risk communication practices (recall Table 2.6). 
It typically involves experienced individuals using standardized tests or tools 
to compare various components related to understandability. For example, 
LeBrun et al. (2013) undertook Suitability Assessment of Materials (SAM) and 
readability tests on 46 Health Canada public advisories to determine the school 
grade reading equivalent needed to understand the advisories. In the end, it 
was determined that all of the assessed public advisories required “college/
university education comprehensive” (LeBrun et al., 2013). Similar methods can 
track improvements in the content and presentation of information over time 
in response to feedback. Although this method requires relatively few resources, 
they are also limited to expert analysis with little engagement opportunities 
with the people actually receiving the information.
Interviews and focus groups are the primary method to explore how a risk 
communication influenced decision-making. This is accomplished by asking the 
receivers of information about their understanding of a risk communication, 
its effect on their risk perceptions and knowledge, and its role in shaping 
their subsequent behaviour. Although this method typically involves fewer 
participants, a major advantage of well-conducted focus groups is that they 
generate rich in-depth data by providing a context in which the claims that 
people make about various issues, topics, or events (risk related or otherwise) 
are challenged and shaped collectively. This better represents the social and 
interactional ways through which people come to make sense of risks in their 
lives. These findings can then be combined with information from individual 
117Chapter 4 Evaluating the Effectiveness of Health Product Risk Communication                   
interviews to provide a comprehensive assessment of how differing groups receive, 
make sense of, and use risk information. For example, Driedger et al. (2013) 
examined how First Nations and Métis perceived and responded to the public 
health management of pandemic H1N1. Focus groups were used to explore 
First Nation and Métis views around the identification of groups most at risk 
for H1N1, the safety and effectiveness of the H1N1 vaccine, and identification 
of priority groups to receive the vaccine. Different health decision-makers 
(e.g., public health officials, communicators, representatives from First Nations 
and Métis self-governing organizations) were also interviewed to understand and 
align their intentions with focus group findings. The evaluation demonstrated 
that risk communication practices have improved, but that one-size-fits-all 
communications are not effective, particularly when communicating to the 
groups most at risk. This underscores the need for communicators to account 
for “specific socio-economic, historical, and cultural contexts” of affected 
populations when planning, implementing, and managing communications 
(Driedger et al., 2013).
Population-based surveys can explore self-reported use of risk information in 
decision-making and behaviour as well as perceptions around understandability 
and timeliness. The large sample allows evaluation teams to explore existing 
risk perceptions and knowledge and how they may change as a result of 
the communication. For example, Garbutt (2010), mailed a survey to 
105 pediatricians and had 1265 parents complete a self-administered survey 
during a medical visit to evaluate the use of a 2008 FDA public advisory noting 
the dangers of using over-the-counter cough and cold products for children 
under 2 years old. Using both descriptive statistics and logistic regression, 
they found that among surveyed physicians, 100% were aware of the advisory, 
75% agreed with the content, and post advisory, 35% were less likely to prescribe 
cough and cold products. In addition, across parents, 73% were aware of the 
advisory, 68% did not believe the products were dangerous, and post advisory, 
21% of parents were more likely to request antibiotics in place of cough and 
cold products (Garbutt, 2010). Similarly, Bhatia et al. (2008) conducted a 
survey of 1521 prescribing clinicians to evaluate the effectiveness of 2004 FDA 
black box warning on SSRIs. They found that 97% were aware of the warning 
and that 16% and 37% decreased their prescribing frequency for children and 
adolescents, respectively (Bhatia et al., 2008).
Quasi-experimental methods, using techniques, such as matching estimation and 
time-series analysis, to create statistical control groups enables the comparison 
of the receivers of information without needing to randomize the delivery of the 
communication (Gertler et al., 2011). These methods can be used to assess behavioural 
changes in various populations (e.g., healthcare professionals, the public), using 
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metrics such as prescribing rates and actual drug use; however, their usefulness 
as an engagement tool is limited. Box 4.2 describes the use of quasi-experimental 
methods to assess use of risk communications involving SSRIs over time. 
Box 4.2 
Using Quasi-Experimental Methods to Assess Behaviour Changes   
The link between use of SSRIs and the increased risk of suicide in young people has 
been debated for more than a decade (Breggin, 2004; Lu et al., 2014). There has 
been conflicting evidence about the magnitude of such a link, but in the early 2000s 
regulators around the world deemed the risk great enough to warrant warnings. The 
MHRA in the United Kingdom first advised that children should not take the SSRI 
paroxetine (Cheung et al., 2004) and later extended this advisory to all SSRIs, with the 
exception of fluoxetine. Health Canada (and the MAHs for these drugs) and the FDA 
released their own warnings that extra vigilance should be taken for children taking 
antidepressants (Breggin, 2004; Health Canada, 2004). A year later, the FDA issued 
another advisory and made it mandatory to include a black box warning outlining 
the risk in all communication materials for SSRIs (Breggin, 2004; Cheung et al., 2004). 
Research has been done in both Canada and the United States on the effectiveness of 
these risk communications on prescribing of SSRIs to children. In Ontario, a population-
based, time series analysis of new prescriptions dispensed by the Ontario Drug Benefits 
plan (only available to low-income Ontarians) over a seven-year period found that 
the number of new prescriptions for all SSRIs did not change after the release of the 
warnings (Kurdyak et al., 2007). This was true for all age groups (under 20 years old, 
20 to 65 year-olds, and older than 65). The rate of prescriptions for paroxetine (the 
specific antidepressant named in the initial U.K. warning) did decrease by 54% for 
people under the age of 20 (Kurdyak et al., 2007). A study of Manitoba youth found 
that following the advisories, the rate of prescriptions of antidepressants decreased 
for children and adolescents (aged 17 and under) and for young adults (aged 19 to 24) 
(Katz et al., 2008). In the United States, there have been several studies on the impact of 
the FDA advisories and black box warnings on SSRI prescriptions. One quasi-experimental 
study found that after the FDA warning, relative changes in antidepressant use were 
negative in all groups (although the percentage of young adults and adults taking 
antidepressants remained relatively constant and there was only a slight initial decrease 
in the percentage of adolescents taking the drugs) (Lu et al., 2014). An earlier study had 
also found that the percentage of children diagnosed with depression being prescribed 
antidepressants decreased after the advisories (Libby et al., 2007). The number of 
pediatric diagnoses of depression also decreased following the warnings.
continued on next page
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With sufficient resources and commitment, evaluation of the use of a health 
product risk communication and/or the process involved in its implementation 
can improve the future timeliness of the communication, its potential effect on 
decision-making and behaviour, and understanding of public expectations and 
confidence. The most successful evaluations of use typically involve combining 
the knowledge gained through the range of methods identified above, as 
demonstrated by Box 4.3.
It is difficult to link any changes observed to one regulator’s specific advisory, given 
the media attention garnered by these warnings, which crossed borders. Even in 
cases where relationships can be observed (e.g., prescription rates going down after 
the warning), the nature of those relationships is very difficult to determine. While it 
may be the result of the warning, it may also be the result of reduced incidence of a 
disease, a change in consumer preferences, or economic factors. Greater understanding 
and learning comes from comparing and considering the study results together. The 
different studies, based on different outcome variables, were often confirmatory, and 
enriched the picture of what happened after the warning.
Box 4.3 
Evaluating Use to Improve Risk Communication     
In 2013, Apotex sent notices of a recall of a single lot of Alysena™ 28, an oral 
contraceptive, to its wholesalers and distributors (RSI, 2013). The recall was in 
response to the identification of a problem in the packaging of the drug (i.e., more 
placebos pills than usual). Health Canada posted notice of the recall on its website 
five days later. The delays were due to Apotex initiating the recall before notifying the 
regulator, Health Canada’s internal review process being interrupted by a weekend, 
and other factors. There was significant public concern about multiple dimensions of 
the recall, including the number of women at risk of becoming pregnant, the efficacy 
of the drug in general, and Health Canada’s handling of the situation. These concerns 
were driven by media coverage of the recall, some of which contained only partial 
information (RSI, 2013).
continued on next page
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The criticisms and concerns spurred an investigation into Health Canada’s handling 
of the recall and subsequent risk communication activities. Health Canada contracted 
a third party to carry out an evaluation of the events that occurred during the recall 
(RSI, 2013). The evaluation used a combination of methods: an archival analysis 
provided an understanding of the responsibilities and processes of industry and 
regulator groups during a recall and demonstrated what information was available 
from both industry and regulator groups, how it was presented, and when it was 
released; a textual analysis enabled an understanding of public reaction, confusion, 
and how information of the recall spread; and the individual interviews (anonymous) 
provided a timeline of when recall events occurred and regulator perceptions of 
the causes of public and media concerns (RSI, 2013). The use of different methods 
established a more complete picture of the events surrounding the recall and the 
challenges encountered, including the views and perceptions of Health Canada 
employees who were part of the process. Coordination of information from all risk 
communication players (e.g., Health Canada, industry, and the media) also enabled 
a more thorough evaluation of the situation. 
The evaluation identified multiple areas where Health Canada could improve risk 
communication processes. For example, given that public expectations of performance 
and accountability exceeded the powers of Health Canada to regulate industry 
behaviour, better communication of the roles and responsibilities of different players 
and limitations facing Health Canada surrounding recalls could be useful. Other 
lessons involved clarifying/modifying the timing of recall notification requirements, 
and properly considering the social concerns surrounding a particular recall.
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4.5 IMPACT: MATCHING EVALUATION METHODS  
TO RELEVANT QUESTIONS
Key Findings – Impact
• Impact refers to achieving a desired result with respect to various outcomes related 
to the senders and receivers of information and the relationship between them.
• The relevant evaluation questions and methods for dimensions of impact are 
listed below.
Dimensions Evaluation Questions Methods 
Outcomes for 
Receivers of 
Information
 • What individual and population health  
outcomes have improved as a result of the risk 
communication in the groups receiving the 
information and other stakeholders?
 • What individual and population health outcomes  
have worsened (i.e., unintended impacts) as  
a result of the risk communication in those  
same groups?
 • Have knowledge, attitudes, and perceptions 
advanced or changed as a result of the  
risk communication?
 • Archival and 
administrative data 
analysis
 • Population-based 
surveys
 • Interviews and 
focus groups
 • Quasi-experiments
 • Natural 
experiments
 • Mixed methods
Outcomes for 
Senders of 
Information
 • What organizational constraints hindered the risk 
communication? Did the risk communication make 
efficient use of financial and human resources?  
How did the organization overcome these constraints?
 • Did the receivers of information and other 
stakeholders trust the risk communication and  
how has it affected general perceptions of trust?
 • What was the effect of the risk communication  
on the credibility of the organization?
 • Did the receivers of information and other 
stakeholders view the risk communication as 
transparent and how has it affected general 
perceptions of transparency?
Outcomes Related 
to Relationships 
Between Senders 
and Receivers
 • Were there opportunities for those receiving 
information and other stakeholders to provide 
feedback? How were the receivers of information  
and other stakeholders engaged?
 • Did the sender of information receive that  
feedback and make use of it to improve the  
risk communication?
 • Did the receivers of information feel empowered  
by the risk communication?
 • How has the risk communication contributed  
to future communications and opportunities  
for cooperation?
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Impact or outcome evaluation is fundamentally intended to link the risk 
communication to particular short-, medium-, and long-term impacts and to 
explain how and/or why these impacts were achieved (DFID, 2012; Mayne, 2012; 
McDavid et al., 2013). Evaluations thus generally explore questions such as 
“How much of the impact can be attributed to the intervention? [...] Did 
the intervention make a difference? [...] How has the intervention made a 
difference? [...] [And] will the intervention work elsewhere?” (DFID, 2012). The 
information needs and motivations of decision-makers most clearly shape the 
selection of a particular method for assessing impact (Kasperson & Palmlund, 
1989). For example, an evaluation motivated by accountability may be more 
focused on demonstrating program fidelity and finding simple indicators that 
a risk communication worked. In such instances, archival or administrative 
data analysis or quasi-experimental methods are most applicable. However, 
evaluations motivated by transparency or program improvement would likely 
focus more on methods to build trust with the receivers of information and 
other stakeholders as well as gain more detailed and nuanced understanding of 
context and influencing factors. As such, drawing more heavily on interviews, 
focus groups, and population-based surveys may be more appropriate in these 
cases. Given the paradigm shift of modern risk communication (recall Chapter 2), 
which focuses on multi-way communication and the relationship between 
senders and receivers of information, the Panel concluded that dimensions 
for impact evaluation should also include relationships between these groups.
4.5.1 Dimensions and Evaluation Questions
Outcomes for the Receivers of Information 
Outcomes related to the receivers of information comprise a range of individual- 
and population-level indicators of health status, exploring both quantitative 
and qualitative aspects, such as reported adverse events related to health 
products, hospitalizations, perceived wellness, and mortality and morbidity 
rates (CDC, 2006; Fischhoff et al., 2011; Dusetzina et al., 2012; Kreps, 2014). 
These outcomes are determined by a wide number of factors, many of which 
are outside both the sphere of control and the sphere of direct influence of 
a risk communication (Montague & Porteous, 2013). Factors such as lifestyle, 
demographics, socio-economic characteristics, and pre-existing risk perceptions 
will influence health outcomes in ways that are complex and difficult to predict. 
This makes the relationship between an outcome and a risk communication, 
and the nature of that relationship, difficult to fully establish and understand. In 
some cases, some methods can control for these factors (e.g., quasi-experimental 
methods); however, often evaluations need to articulate spheres of influence 
123Chapter 4 Evaluating the Effectiveness of Health Product Risk Communication                   
and identify the contribution of a risk communication to outcomes in relation to 
other factors (Mayne, 2012; Montague & Porteous, 2013). As such, evaluations 
must explore the following questions: 
• What individual and population health outcomes have improved as a result 
of the risk communication in the groups receiving the information and 
other stakeholders?
• What individual and population health outcomes have worsened 
(i.e., unintended impacts) as a result of the risk communication in those 
same groups?
• Have knowledge, attitudes, and perceptions advanced or changed as a result 
of the communication?
Outcomes for the Senders of Information 
Outcomes related to the senders of information build on the information 
needs and motivations of the regulators and other government institutions: 
accountability, program improvement, and transparency. These institutions have 
a responsibility to the citizens they protect and want to be seen as a credible 
and respected information source. Beyond questions of internal efficiencies 
and improvement, assessing various organizational and corporate outcomes, 
such as trust, transparency, and credibility, over time and across a range of 
communication activities and events, can provide a clearer picture of success, 
failure, and opportunities for future improvement. This kind of self-reflection 
also contributes to a learning culture (Section 4.6.2) and can further position 
regulators and other government institutions as global leaders in the evaluation 
of health product risk communication. As such, evaluations must explore the 
following questions:
• What organizational constraints hindered the communication? Did the risk 
communication make efficient use of financial and human resources? How 
did the organization overcome these constraints?
• Did the receivers of information and other stakeholders trust the risk 
communication and how has it affected general perceptions of trust?
• What was the effect of the risk communication on the credibility of 
the organization?
• Did the receivers of information and other stakeholders view the risk 
communication as transparent and how has it affected general perceptions 
of transparency?
Outcomes Related to Relationships Between Senders and Receivers 
The most effective risk communications often include multi-way and multi-
level dialogue whereby the receivers of information and other stakeholders 
provide feedback, which is used by communicators to improve future risk 
communication. Communication is approached as a learning experience 
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where all parties involved interact and come away with new understandings 
and better connections to support future communication needs. Indicators of 
good relationships and functioning include: outcomes that relate to evidence 
of active listening and opportunities for feedback; empowerment of affected 
groups and stakeholders; and engagement, exchange, and cooperation. As 
such, evaluations must explore the following questions: 
• Were there opportunities for those receiving information and other 
stakeholders to provide feedback? How were the receivers of information 
and other stakeholders engaged?
• Did the sender of information receive that feedback and make use of it to 
improve the risk communication?
• Did the receivers of information feel empowered by the risk communication?
• How has the risk communication contributed to future communications and 
opportunities for cooperation?
4.5.2 Relevant Methods
As the International Initiative for Impact Evaluation (2008) notes, “[r]igorous 
impact evaluation studies are analyses that measure the net change in outcomes 
for a particular group of people that can be attributed to a specific program 
using the best methodology available, feasible and appropriate to the evaluation 
question that is being investigated, and to the specific context.” As argued 
throughout this chapter, evaluation should be tailored to evaluation questions 
and employ a range of methods, building on the relative strengths of each. 
Although a method on its own may not be sufficient to establish a relationship 
between the risk communication and a given outcome, combining the findings 
of several methods can lead to more comprehensive knowledge. It also helps 
better understand why an evaluation has impact, how meaningful it is to various 
groups, and the importance of contextual factors. 
Archival and administrative data analysis can be used to evaluate outcomes 
for various senders and receivers of information. They can provide relevant 
information for accountability, improvement, and transparency; however, 
engagement is limited. The cost and human resources vary depending on 
the methods used to analyze data. Statistical methods range from simple 
descriptive statistics to more complex interrupted time series analysis, to link 
these outcomes to risk communications (Dusetzina et al., 2012). This type of 
analysis can answer evaluation questions about whether a communication has 
led to improvements or identify unintended consequences when it results in 
negative outcomes over time (Piening et al., 2012). 
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Population-based surveys can be used to evaluate all three dimensions of impact. 
They can be administered to the receivers of information, other stakeholders, 
and experts to collect information on health status and opinions on aspects 
related to credibility, transparency, empowerment, engagement, and trust 
(Evaluation Directorate, 2014c). The potentially large sample can lead to 
greater confidence in results; however, increasing sample sizes requires greater 
financial and human resources. 
Interviews and focus groups can also evaluate all three dimensions of impact. 
Interviews or focus groups with the receivers of information, other stakeholders, 
and experts can explore how and why a risk communication led to health status 
outcomes, enhance credibility and transparency, and foster relationships. They 
can also provide information about why a communication was not successful. 
For example, Richardson et al. (2007) conducted focus groups with 35 health 
care professionals to evaluate the effectiveness of a 2004 FDA black box warning 
on depression treatment. They found that since treatment was constrained 
by “lack of availability of mental health resources in the community, feeling 
responsible for helping based on long-standing relationships with patients and 
families, and patient and family beliefs and preferences regarding treatment” 
most health care professionals were unable to change treatment options in line 
with the black box warning (Richardson et al., 2007). Essential for improving 
future risk communications, these methods can be a key engagement strategy 
and the cost and human resources vary depending on the number of interviews 
and the size of focus groups. 
Quasi-experimental methods can be useful because of their ability to enable the 
comparison of different groups without needing to randomize the delivery of 
the communication (Gertler et al., 2011). These methods are most applicable 
for evaluating outcomes in the populations receiving information and provide 
evidence of impact that is relevant for accountability, improvement, and 
transparency purposes. For example, research has been done on the impact 
of SSRIs warnings (see Box 4.2) on several health-related indicators such as 
attempted and completed suicides and healthcare utilization in children and 
youth. A study of Manitoba youth found that following SSRI advisories, there 
was a decrease in the rate of ambulatory visits and an increase in the rate of 
completed suicides for children and adolescents (Katz et al., 2008). Another 
quasi-experimental study found that after a similar FDA warning, there were 
relative increases in the psychotropic (i.e., mood altering) drug poisonings 
among adolescents and young adults, but no change in the number of completed 
suicides per 100,000 people for any age group (Lu et al., 2014). These studies 
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also highlight the importance of acknowledging the limitations of empirical 
estimates, including data challenges and the reliability and validity of indicators 
chosen to measure real-world outcomes. For example, there was significant 
controversy around the results of Lu et al. (2014) because psychotropic drug 
poisoning was used as a proxy for attempted suicide (BMJ, 2014). While the 
author stated that this proxy was validated, several researchers questioned that 
conclusion and therefore the legitimacy of the study’s findings (BMJ, 2014). 
The debate on this issue demonstrates the importance of being clear on the 
limitations of proxies used and, when relevant, the debate about their validity. 
Natural experiments have gained popularity as method to evaluate public health 
interventions in general (Gertler et al., 2011; Craig et al., 2012; DFID, 2012). 
In the context of health product risk communication, natural experiments 
require situations where either aspects of the risk communication (e.g., content, 
design, and delivery) or the risk itself vary naturally across sub-populations, 
allowing for the creation of treatment and control groups. For instance, if 
different risk communications about the same risk were disseminated to affected 
populations in different provinces, an evaluation could compare outcomes for 
receivers of information in a naturally controlled manner. This provides strong 
evidence of impact and helps to account for factors that may influence the 
relationship between a communication and certain outcomes. This method is 
useful for accountability and to improve future risk communications. Box 4.4 
provides examples of natural experiments based on variation in a risk and in 
risk communications. 
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Box 4.4 
Using Natural Experiments to Evaluate the Impact of  
Risk Communications      
Body mass index (BMI) screening with parental notification of weight status is a 
potential means of reducing pediatric obesity; however, there is disagreement on the 
merits of such communication (Institute of Medicine, 2005; U.S. Preventative Services Task 
Force, 2005). Madsen (2011) explored the effectiveness of these risk communications with 
a natural experiment. In California, while annual BMI screening is conducted in the fifth, 
seventh, and ninth grades by the majority of public schools, parental notification of the 
results is optional. This creates the treatment and control groups, screened/notified and 
screened/not notified, respectively. Administrative data from the California Department 
of Education (e.g., enrollment, BMI status, sex, ethnicity) was supplemented by structured 
telephone interviews with school districts, which provided data on notification rates and 
delivery channel: mailing a notification letter or sending it home with children. Using these 
data, Madsen (2011) tested whether notification in a given year impacts BMI z-scores 
two years later using a mixed-effects linear regression.* The researchers found that prior 
parental BMI notification in fifth and/or seventh grade did not lead to a change in the 
BMI of those children when they reached seventh or ninth grade and that there was no 
difference between the two delivery channels or across ethnicities. While these results may 
not be generalizable with other jurisdictions, this study provides evidence that parental 
notification of BMI screening results is a largely ineffective form of risk communication in 
California (Madsen, 2011).
Another example of the use of a natural experiment to evaluate the effectiveness of a risk 
communication is provided in Johnson and Luke (1987), who examined the impact of the 
Maine Medical Center (MMC) radon information pamphlet on both perceived risks and 
household mitigating behaviour. In this case, the differentiation between the treatment and 
control groups — both of whom received the pamphlet — was made on the basis of radon 
exposure level (i.e., objective risk). The treatment group consisted of households with high 
radon exposure while the control consisted of households with various radon exposure levels. 
Based on data collected through telephone interviews on pamphlet understandability, risk 
perceptions, risk mitigation, health and socioeconomic status, the study found: a statistically 
insignificant correlation between objective and perceived risk, with respondents understating 
the former by orders of magnitude; and no relationship between objective risk and the 
decision to mitigate/mitigation expenditure level. Together, these findings underscore that 
communicating “fairly technical information on health risk” will neither induce “accurate 
perceptions . . . [n]or protective measures” in the general public (Johnson & Luke, 1987).
*  Body mass index z-scores are measures of relative weight adjusted for sex and age. The mixed-effect 
includes a random effect for district “to account for repeated measures within districts over time 
and clustering of students within districts” (Madsen, 2011).
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4.6 ENSURING EVALUATION HAPPENS
While evaluation can help organizations achieve a wide range of objectives, 
the value of an evaluation is often the knowledge that it provides on how to 
improve future risk communication and build on proven success. Employing 
a range of methods helps ensure that the evidence collected is meaningful, 
useful, and transparent. Evaluation of this variety, however, demands institutional 
commitment, and sufficient financial and human resources. 
4.6.1 Securing Institutional Commitment and Resources
There are at least two challenges to gaining commitment and resources: 
institutional resistance and organizational mandate. An evaluation may provide 
evidence that risk communications are ineffective, raising a quandary: should an 
organization be willing to show that it is committed to evaluation by revealing 
that it is falling short in its risk communication activities? Indeed, institutional 
resistance, apathy, and other characteristics have been identified as among the 
most common reasons for failing to evaluate (Jardine, 2008). Apathy towards 
evaluation often stems from concerns that a specific evaluation will assign 
blame if a communication did not meet its objectives (Interagency Task Force 
on Environmental Cancer and Heart and Lung Disease, 1991). This view of 
evaluations as tools for blame, rather than for learning, may contribute to 
them only being done when the results are likely to be positive or in cases 
of significant public outcry.
The extent to which evaluation is identified in an organization’s mandate may 
either encourage or hinder its practice. For example, gaining commitment and 
resources is more challenging if a regulator has a mandate to communicate 
about health product risks, but no clear mandate to gather evidence about its 
effectiveness. As discussed in Chapter 3, this is partially the case in Canada. 
Key Findings
• Ensuring that evaluation evidence is meaningful, useful, and transparent demands 
institutional commitment, and sufficient financial and human resources — the biggest 
challenge to evaluation overall. 
• Securing institutional commitment is a function of fostering and supporting a 
learning culture, demonstrating the value of evaluation relative to other spending 
priorities, standardizing communication appraisal tools, and encouraging learning 
and sharing of experiences from other jurisdictions.
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Evaluation is explicitly recognized in Health Canada’s communication framework, 
but there is no clear set of objectives, standards, or best practices for evaluation. 
Similarly, Health Canada provides guidance to industry about when and how 
to issue various risk communications (Health Canada, 2014d, 2014e), but 
not on how to collect data or evaluate these efforts. Regardless of whether 
the regulator or industry is responsible for initiating a health product risk 
communication, it may not be entirely clear whether it has an obligation 
to perform an evaluation of its effectiveness. The segmentation of health 
responsibilities between different government agencies and levels of government 
in Canada can also lead to confusion over who has responsibility for evaluation 
of health product risk communication.
4.6.2 Supporting and Fostering Evaluation
Fostering a Learning Culture 
Developing a learning culture within organizations can help secure institutional 
commitment and resources (Barrette, 2012). In a learning culture, continuous 
learning is encouraged and facilitated to help the organization improve. To 
support a learning culture, a number of factors must be considered when 
evaluating, including the type of knowledge to be gained, the relevance of the 
evaluation, and the meaningfulness and credibility of evaluation results. Research 
on what leads to institutional resistance to evaluation, the consequences of this 
resistance on communication planning and implementation, and the value of 
establishing a learning culture can help to identify factors that will facilitate or 
hinder organizational commitment to evaluation in the future.
Demonstrating the Value of Evaluation 
Governments face many competing demands and should show good value 
for money when using public dollars. With several spending priorities, some 
of which lead to short-term, visible, and politically advantageous effects, 
it is critical to demonstrate a return on public investments of any kind. In 
the case of evaluation, as noted, institutional resistance and organizational 
mandate can serve to undermine its perceived value (Interagency Task Force 
on Environmental Cancer and Heart and Lung Disease, 1991; Jardine, 2008). 
Even when value and responsibility are evident, undertaking evaluation is 
often perceived as too costly. Furthermore, finding appropriate evaluation 
experts for a given communication, whether internal or external, may be 
difficult (Interagency Task Force on Environmental Cancer and Heart and 
Lung Disease, 1991). Even if the necessary human resources are available, 
ensuring sufficient time for evaluation is important. For instance, undertaking 
an outcome evaluation after the completion of a risk communication may be 
seen as prohibitive, especially when an organization’s focus has shifted to the 
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next risk to be communicated. Fischhoff et al. (2011) have classified a range 
of evaluation options according to their cost, showing that some evaluations 
are feasible even under constrained resources.
Improved knowledge and sharing experiences that demonstrate the value 
of evaluation can provide the foundation for sufficient and stable funding of 
evaluation as an integral part of risk communication. Specifically, evidence 
of the cost-benefit of various types of evidence and evaluation methods will 
enable decision-makers to determine the most appropriate and cost-effective 
evaluation to meet their needs.
Standardizing Risk Communication Appraisal Tools and Checklists
Recognizing that each evaluation will be different, standardizing appraisal 
tools or checklists can ensure that all risk communication tools meet certain 
minimum standards, but can also be more efficient and less resource intensive, 
thereby encouraging evaluation. While regulators have developed guidelines 
for the development of many of the established communication tools discussed 
in Chapter 3 (e.g., product monographs (Health Canada, 2014e)), there does 
not appear to be any widespread standardization of communication appraisal 
tools or checklists.
Standardized appraisal tools that promote minimum-quality criteria are 
in development in other health fields and may offer important lessons 
for communication of health product risk. For instance, research into 
a checklist of potential certification criteria for patient decision aids has 
been ongoing for some time (Elwyn et al., 2006; Joseph-Williams et al., 2013; 
Volk et al., 2013). Patient decision aids are evidence-informed communication tools 
(e.g., pamphlets, videos, web-based information) that help individuals engage 
in decision-making about healthcare options. They are used when more than 
one medically reasonable option is apparent and the best choice depends on 
a patient’s personal preferences (Stacey et al., 2014). Generally, a decision aid 
helps people to: recognize that a decision needs to be considered and that the 
best choice depends on what matters most to them; understand their health 
condition, the available options, associated benefits, harms, probabilities, and 
scientific uncertainties; and implicitly or explicitly clarify the value placed on 
specific harms, benefits, and uncertainties.
Joseph-Williams et al. (2013) have identified criteria for preparing a checklist 
to evaluate decision aids by building on quality criteria previously established 
(Elwyn et al., 2006, 2009) and refining these by consulting expert groups. The 
criteria are grouped into three categories: qualifying criteria that demonstrate 
that an intervention can be considered a decision aid; certification criteria that 
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demonstrate that a decision aid can be classified as less likely to be biased; and 
quality criteria that demonstrate that a decision aid can be considered strong 
(Joseph-Williams et al., 2013). This type of checklist does not rate the science 
being communicated, but rather the communication effort itself. As Joseph-
Williams et al. (2013) explains, “the proposed standards are designed to rate 
the quality of the development process and shared decision-making design 
elements, not the quality of the [patient decision aid’s] clinical content.” 
The checklist approach could be modified for evaluation of the health product 
risk communication tools of regulators or other government institutions by 
drawing on the considerable scientific research on health risk communication 
practices (see Table 2.6 for examples). Checklists centred around effective 
communication practices (Fischhoff, 2011; Volk et al., 2013) could help regulators 
to ensure that their communication tools are less likely to be biased and clearly 
present risk information using the practices supported by scientific research 
(e.g., using numbers instead of words). These checklists could be incorporated 
into the guidance documents and templates provided by Health Canada, and 
used to facilitate the approval of specific tools (e.g., a tool could be automatically 
rejected if it does not conform to the checklist). As the checklist would be 
standardized and relevant for all communication efforts, it could be implemented 
easily, with less time and fewer human and financial resources. The use of 
checklists also provides a way to compare different risk communications and 
tools and, when applied consistently, to support a learning culture.
Encouraging Peer Learning
As highlighted in Chapter 3, most jurisdictions share a similar set of risk 
communication tools. Given these similarities, there is potential for learning 
when evaluations use different methods to evaluate similar tools. A jurisdiction 
can take advantage of the diversity of knowledge and consistency of results 
without necessarily having to undertake mixed methods or multiple evaluations 
themselves. Moreover, comparing cases where the health product risk is similar, 
but the context or the communication is different, roughly creates natural 
experiments that provide the variation needed to draw more fulsome information 
on the relationships between a communication and certain outcomes. In general, 
since all jurisdictions face similar evaluation challenges, bringing together 
evaluation experts, risk communication researchers, regulators, and affected 
populations can help identify examples of strong evaluations and leading 
evaluation practices. Indeed, strong relationships and cooperation between 
different governance bodies and other groups, along with good planning that 
considers complicated governance structures, can more effectively support 
the development and dissemination of effective risk communications and 
their evaluation.
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4.7 CONCLUSION
Effective risk communication requires understanding the nature of a risk, 
including how perception of the risk differs across various populations. This 
is complicated by the fact that the risk decision-making and information 
needs of varying groups are governed by a range of cognitive, demographic, 
and socio-economic factors that are difficult to understand, let alone control. 
A given risk communication exists within a surplus of additional information 
sources and disparate stakeholder concerns, and involves various institutions 
both inside and outside of government. Evaluating the effectiveness of a risk 
communication requires navigating through this complexity to determine if a 
single communication leads to change. There are many benefits of performing 
evaluation activities throughout the risk communication process and evaluation 
overall contributes to effectiveness of communication efforts.
The Panel found a limited number of publicly available evaluations of health 
product risk communication from which to glean best practices. Of the evaluations 
identified, all attempted to provide evidence that a risk communication was 
achieving certain goals (e.g., reach, use), but there was limited consistency in 
the measures of these goals and the application of methods to assess them. 
Effectiveness was sometimes measured using simple indicators like downloaded 
communication materials or changes in prescription rates, and other times 
measured using more complex qualitative explorations of timeliness or trust. 
In general, measurements were therefore specific to a given evaluation and 
varied greatly across evaluations. The story was similar for the application of 
different evaluation methods. There was no universal approach, and evaluations 
employed methods ranging from basic descriptive statistics to quasi-experimental 
methods and from a small number of interviews to extensive focus groups and 
population-based surveys. Ultimately, there is therefore no single approach 
to evaluation; different approaches and methods produce different kinds of 
evidence and require different levels of resources.
Given this relative dearth of evidence and the need for a tailored approach, the 
Panel suggests an overarching strategy for the evaluation of health product risk 
communications whereby evaluation methods are an extension of evaluation 
questions that take into account information needs, attributes, and goals. In 
general, the most valuable evaluations consider more than just the relationship 
between risk communications and their eventual outcomes. Rather, they 
also account for the information needs and motivations of regulators and 
government institutions communicating risk, receivers of risk information, and 
other stakeholder groups. Moreover, the right evaluation questions consider the 
attributes of the risk communication, including the type of communication tool, 
its stage of development, and most importantly, the goals of risk communication: 
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development, reach, use, and impact. Instead of jumping straight to a method, 
evaluations should ensure methods are an extension of evaluation questions 
that account for these information needs and risk communication attributes. 
Selecting an evaluation method then becomes a function of the evidence 
required to answer an evaluation question and the level of available resources. 
Evaluation conducted according to this premise will reveal the most meaningful 
information. Overall, a strong and dedicated focus on evaluation is needed 
throughout all stages of the risk communication process. Evaluation is most 
effective with sufficient resources and when embedded into the organizational 
culture of those communicating health product risk and when it engages 
relevant populations in appropriate aspects of the design, implementation, 
and use of the evaluation.
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• What Types of Instruments/Tools Are Currently 
Available for Health Risk Communication? 
• What Methodological Best Practices Can Be 
Used to Evaluate the Reach, Use, and Benefit  
of Health Risk Communication? 
• What Research Could Be Done to Inform  
the Measurement of the Effectiveness of  
Risk Communications? 
• What are the Existing Barriers to Effective Risk 
Communications and What Best Practices Exist 
to Address These Challenges? 
• Final Reflections
5
Conclusions 
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5 Conclusions 
Despite the barriers that can make the evaluation of health product risk 
communication challenging, the evidence is clear that there is tremendous value 
in undertaking such efforts. Proper evaluation is integral to risk communication 
activities and can aid in fulfilling regulatory and fiduciary obligations, demonstrating 
a commitment to transparency and accountability, and attaining an understanding 
of the strengths and weaknesses of risk communication efforts. Evaluation activities 
can improve decision-making and real-world applications of a communication 
and ultimately help to ensure the health and safety of the population. They can 
also help to improve content and processes, build trust and relationships, assess 
whether communications have achieved their objectives, and identify who is 
paying attention, what they are learning, and what impacts are occurring across 
a range of different groups. Without adequate study, not only is there potential 
for mistakes, but there is also the risk of missing opportunities to continue or 
build on proven successes. With dedicated resources, careful planning, and well 
executed evaluations, even the most complex communications can be evaluated 
in a meaningful way. 
This chapter summarizes the evidence reviewed in Chapters 2 to 4, to answer the 
main charge to the Panel: How can the effectiveness of health risk communications be 
measured and evaluated? It is organized across the four sub-questions that make 
up the charge (Section 1.2), and provides the Panel’s conclusions and final 
reflections. Although the report’s focus is health products, the Panel intends 
lessons on evaluation and risk communication to apply to other types of risks. 
5.1 WHAT TYPES OF INSTRUMENTS/TOOLS ARE CURRENTLY 
AVAILABLE FOR HEALTH RISK COMMUNICATION?
Health Canada’s regulatory responsibilities and monitoring activities for health 
products are similar to that of the FDA (United States), MHRA (United Kingdom), 
TGA (Australia), and EMA (European Union). However, the authority granted 
to these regulators varies. For example, Health Canada has greater authority over 
regulation of natural health products than other regulators, but only recently 
gained the authority to issue a recall or demand a label change, like the TGA and 
MHRA. All five regulators have or are developing communication frameworks 
relevant for the communication of health product risks. The frameworks generally 
emphasize two-way communication, engagement with affected populations, 
and meaningful and accessible messaging for a range of groups. Some have 
even gone so far as to establish advisory councils and ongoing consultation 
mechanisms. Most frameworks also explicitly or implicitly discuss the importance 
of establishing quality relationships with the various populations receiving health 
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risk communications and other affected stakeholders as well as related objectives 
such as trust. While the frameworks recognize the importance of evaluating risk 
communication, the level of detail or guidance provided varies greatly. Based 
on the Panel’s review of the evidence, it is unclear how evaluation and related 
outcomes are actually defined and how (if) evaluation is being carried out in 
practice across jurisdictions.
Given the similar communication frameworks and regulatory authority, it is 
not surprising that regulators have adopted similar tools for communicating 
health product risks. In general, health product risks involve known side 
effects, medication/medical device errors, product defects, and uncertainty 
in information. Tools used to communicate these risks can be classified as 
(i) ongoing communication, which disseminates information on known risks 
about a product; (ii) incident(s)-based communication, which disseminates 
information on newly discovered risks (or new information on known risks); 
and (iii) defect and error communication. Established risk communication 
tools aimed primarily at the public tend to describe risk in qualitative or 
general quantitative terms, use text exclusively, and lack colour and graphics 
showing risk, thereby ignoring important aspects of evidence-informed risk 
communication practices. The most common dissemination method is posting 
online, with the exception of inserts, which are included in the packages of many 
patent-protected medications (although not required in Canada). Tools aimed 
at healthcare professionals often contain more quantitative information than 
those aimed at the public and messages are disseminated in a greater variety 
of ways (e.g., mail, online, inclusion in journals or newsletters). 
There are few publicly available and publicly conducted evaluations of established 
health product risk communication tools in any jurisdiction. Of the evaluations 
identified, most relate to the tools used by the FDA but, for the most part, they 
were done by academic researchers. The majority of the evaluations identified 
for ongoing communication focused primarily on indicators of understandability 
(e.g., readability) and user surveys, expert analysis, and public consultations. 
There does not appear to be any systematic needs assessment or pre-testing 
evaluations for any of the established tools. Most of the evaluations identified for 
incident(s)-based communication examined effectiveness in terms of use and 
impact after implementation and completion of the communication (outcome 
evaluations). These studies most often used medical or pharmacy claims 
(e.g., prescribing rates, new users) as indicators.
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There are promising developments in risk communication that could shape the 
future of health product risk communication. These include work that is refining 
how the message is framed, changing the context in which risk communication 
is done, taking advantage of multi-media approaches and new mediums, and 
improving dissemination and access to data and evidence. Of these emerging 
tools, the Panel identified drug fact boxes, which refine the framing of the 
message, as the most promising. More research is needed, however, on their 
real-world applicability for varying populations.
Evaluation is important in the process of communicating health product risks, but 
done differently for different tools and purposes. For example, pre-testing data 
and measuring the initial impacts are important for emerging tools to optimize 
their design and delivery, and for established tools to see if they are ready for more 
outcome-oriented evaluation. Outcome evaluation is most suitable for established 
tools that are likely to be successful based on these initial evaluation efforts.
5.2 WHAT METHODOLOGICAL BEST PRACTICES CAN BE 
USED TO EVALUATE THE REACH, USE, AND BENEFIT  
OF HEALTH RISK COMMUNICATION?
Evaluation is essential to understand the extent to which a risk communication is 
achieving its goals, to improve future risk communication and related decision-
making, to foster transparency, and to improve engagement with affected 
populations and other stakeholders. Sometimes evaluation methods are selected 
without properly understanding the context of a risk communication and the 
information needs and motivations of regulators and government institutions 
communicating risk, receivers of risk information, and other stakeholders. 
However, different evaluation methods produce a range of knowledge and have 
varying strengths and weaknesses, and therefore may be more or less applicable. 
There is also no universal way to evaluate a communication; different methods 
may be applied in different ways to address various situations, needs, and goals. 
It follows that careful planning efforts are therefore necessary to first determine 
the most relevant evaluation questions before choosing an evaluation method. 
The best questions result from identifying and integrating information needs 
and motivations and the attributes of the risk communication tool, including the 
communication goals. Selecting evaluation methods then becomes a function of 
the evidence required to answer an evaluation question and the level of available 
resources. Evaluation conducted on this premise and involving appropriate 
stakeholders will reveal the most relevant and meaningful information. 
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Evaluations should be shaped by the information needs and motivations of the 
senders and receivers of information. Regulators and other government institutions 
communicating health product risks may be interested in accountability, program 
improvement, or transparency. Alternatively, receivers of information may need 
to determine credibility and who to trust, feel engaged in the communication 
process, and feel empowered to use the information provided. Evaluation 
questions should also consider three main attributes of risk communication 
tools: type, stage, and goal. 
Evaluations are influenced by the type of tool. For ongoing communication 
there is potential to conduct more systematic and comprehensive evaluation and 
engage affected populations and other stakeholders before, during, and after 
the evaluation. The time sensitivity of incident(s)-based communication implies 
that evaluation is often undertaken with less planning, is less comprehensive, and 
faces additional challenges in engaging different groups. Since it is delivered at a 
fixed point in time, there is a clear baseline from which to measure various goals 
and to use before and after comparison groups. This is not generally the case 
for ongoing communication tools since they are delivered in a more continuous 
manner. Finally, evaluation is more likely to be demanded for high-profile 
incident(s)-based communication. In these cases, transparency is critical, with 
regulators and other government institutions more interested in demonstrating 
that proper processes were followed than with measuring long-term impacts. 
Evaluation varies across the stages of risk communication and is integral to 
the entire process. It is not simply an end-stage task following the completion 
of a communication. Four types of evaluation highlight the stages of risk 
communication and link to information needs and goals of risk communication:
• Needs assessment: undertaken to identify the information needs of the 
senders and receivers of information and other stakeholders. Its findings can 
increase the likelihood that a risk communication will be effective.
• Pre-testing: undertaken before the full implementation of a risk communication 
to preliminarily test the feasibility, appropriateness, and effectiveness of 
the identified communication tool in sub-groups. Its findings can lead to 
changes to the communication, which will further increase the likelihood 
that it will be effective. 
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• Process/implementation: typically undertaken during the implementation of 
a risk communication to provide evidence that it is progressing as planned. Its 
findings provide insight into potential revisions to implementation strategies, 
the need for reassessing goals and potential outcomes, and the potential 
value in conducting outcome evaluations in the future. 
• Outcome: conducted after a risk communication has been disseminated and 
completed to link meaningful short-, medium-, and long-term outcomes to the 
tool in question. Although these are considered end-stage efforts, more rigorous 
evaluations usually establish a baseline prior to the implementation of the 
communication followed by ongoing measurement throughout implementation. 
Different types of evaluation should be undertaken for different risk 
communication goals. These goals will ultimately align with information needs 
and motivations as well as other communication attributes to shape evaluation 
questions and determine appropriate methods. Goals are defined here and 
various dimensions for each goal are described in Table 5.1: 
• Development: incorporating evaluation methods and learning into the steps 
involved in designing risk communications, including when characterizing 
and managing risk, creating messaging, and ensuring ongoing partnership 
and exchange.
• Reach: how and when the communication is sent and received and by whom. 
• Use: how the information is considered, its timeliness, and the reactions 
and actions taken as a result of the communication, thus exploring 
understandability, timeliness, informed decision-making, and behaviour.
• Impact: achieving a desired result with respect to various outcomes related to 
the senders and receivers of information and the relationship between them. 
Once evaluation questions have been established, approaches, and then specific 
methods, can be chosen that best provide the required evidence to answer 
those questions. This increases the likelihood that the evaluation will produce 
meaningful results. Numerous approaches can be employed in evaluation, 
ranging from simple to complicated and from quantitative to qualitative. The 
Panel identified the following approaches, and related methods, as feasible for 
regulators and other government institutions and highly relevant for health 
product risk communication:
• Synthesis: Methods include literature reviews, systematic reviews, 
and meta-analyses.
• Records-Based: Methods include textual, archival, and administrative 
data analysis.
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• Self-reported data: Methods include interviews, focus groups, and 
population-based surveys. 
• Experimental: Methods include quasi-experimental methods, natural 
experiments, and RCTs. 
• Mixed Methods: This involves combining quantitative and qualitative methods 
from different approaches in the same evaluation.
Table 5.1 summarizes the relevant evaluation questions and methods (ordered 
from simpler to more complex) across the four goals of risk communication. 
The Panel found no clear best methodological practices to evaluate health 
product risk communication. There are, however, many promising methods, 
which if tailored to the type, stage, and goal of a risk communication, can 
provide strong evidence of effectiveness. Taken together, they can help design 
and re-design communications that are aligned with the needs of various affected 
populations, to account for and learn from past mistakes, and to continue or 
build on identified successes. Employing a range of methods to ensure that 
evaluation evidence is meaningful, useful, and transparent, however, demands 
institutional commitment and sufficient financial and human resources — the 
biggest challenge to evaluation overall.
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Table 5.1 
Key Points for Matching Evaluation Questions and Methods
Goal Dimensions Evaluation Questions Methods
Development: 
incorporating 
evaluation methods 
and learning into 
the steps involved 
in designing risk 
communications
Characterizing 
and Managing 
Risk
 • Who needs to receive  
the risk communication?
 • Who wants to receive  
the risk communication?
 • What needs to be communicated?
 • Who is the source of  
the risk information?
 • What is the accuracy and 
credibility of the evidence base?
 • Literature 
review/
Systematic 
review/
Meta-analysis
 • Textual 
analysis
 • Interviews and 
focus groups
 • Randomized 
controlled 
trials
 • Mixed methods
Creating 
Messaging
 • What are the communication 
wants and needs of the 
receivers of information?
 • How do the receivers of 
information make sense of risk?
 • Will they understand the content?
 • What will the content look like 
(e.g., text, images, colour)?
 • Does the content address wants 
and needs?
 • How will the risk communication 
be disseminated?
 • Are the communication channels 
appropriate for all groups 
receiving the information?
Ongoing 
Partnership  
and Exchange
 • What is the relationship 
between the sender and receiver 
of information?
 • How could that relationship 
change, stay the same, or  
be strengthened?
 • What is the best way to engage 
the receivers of information  
in the evaluation process?
 • How can the senders and 
receivers of information  
and other stakeholders be 
involved in the implementation 
of evaluation?
Reach:
how and when  
the communication 
is sent and received 
and by whom
Delivery  • Was the risk communication 
sent and to whom specifically?
 • Administrative 
data analysis
 • Interviews and 
focus groups
 • Population-
based surveys
Receipt  • Did those groups receive the risk 
communication?
 • Are those groups aware of the 
risk communication?
continued on next page
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Goal Dimensions Evaluation Questions Methods
Use:
how the 
information is 
considered, its 
timeliness, and  
the reactions and 
actions taken as  
a result of the 
communication
Understandability  • What are the barriers (facilitators) 
that might prevent (support) 
understanding the message? 
 • Was information sent in  
a way that overcomes barriers 
and leverages facilitators  
to understanding?
 • How does the information  
align with evidence-informed 
practices in communication  
and health literacy?
 • Is the information understood by 
those receiving the information?
 • Was awareness of the risk 
increased in the receivers  
of information?
 • Textual 
analysis
 • Interviews and 
focus groups
 • Population-
based surveys
 • Quasi-
experiments
Timeliness  • How much time has elapsed 
between identification and 
dissemination?
 • What is the justification for this 
amount of time and is it based  
on reasonable grounds?
 • Did the senders and receivers  
of information and other 
stakeholder groups consider  
the risk communication timely to 
inform their decision-making and 
behaviour? How do expectations 
compare across these groups?
Informed 
Decision-Making
 • Did the receivers of information, 
both among the public and 
among healthcare professionals, 
seek the risk communication out?
 • Did the receivers of information 
feel that the communication 
provided meaningful information? 
 • Did the risk communication 
contain messages that the 
receivers of information believe 
they can successfully carry out 
and were those messages 
believed to be successful for 
averting any harm?
 • Did the risk communication 
influence shared decision-making 
between healthcare professionals 
and the receivers of information?
continued on next page
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Goal Dimensions Evaluation Questions Methods
Behaviour  • Did the risk communication 
change the risk perceptions of  
the receivers of information?
 • Were there any changes in the 
preferences of the receivers of 
information (e.g., patients,  
healthcare professionals)?
 • Was information used by 
healthcare professionals and the 
groups that they work with?
 • Did the receivers of information 
change their behaviour or 
continue recommended  
desirable behaviour?
 • Was the risk minimized by 
actions based on specific 
recommendations from  
the risk communication?
Impact: 
achieving a  
desired result with 
respect to various 
outcomes related  
to the senders  
and receivers of 
information and  
the relationship 
between them
Outcomes for 
Receivers of 
Information
 • What individual and population 
health outcomes have  
improved as a result of  
the risk communication in the 
groups receiving the information 
and other stakeholders?
 • What individual and population 
health outcomes have worsened 
(i.e., unintended impacts) as a 
result of the risk communication 
in those same groups?
 • Have knowledge, attitudes,  
and perceptions advanced  
or changed as a result of  
the risk communication?
 • Archival and 
administrative 
data analysis
 • Population-
based surveys
 • Interviews and 
focus groups
 • Quasi-
experiments
 • Natural 
experiments
 • Mixed methods
continued on next page
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Goal Dimensions Evaluation Questions Methods
Outcomes for 
Senders of 
Information
 • What organizational constraints 
hindered the risk communication? 
Did the risk communication make 
efficient use of financial and 
human resources? How did  
the organization overcome  
these constraints?
 • Did the receivers of information 
and other stakeholders trust  
the risk communication and  
how has it affected general 
perceptions of trust?
 • What was the effect of the risk 
communication on the credibility 
of the organization?
 • Did the receivers of information 
and other stakeholders view  
the risk communication as 
transparent and how has it 
affected general perceptions  
of transparency?
Outcomes 
Related to 
Relationships 
Between Senders 
and Receivers
 • Were there opportunities for 
those receiving information and 
other stakeholders to provide  
feedback? How were affected 
populations and other 
stakeholders engaged?
 • Did the sender of information 
receive that feedback and  
make use of it to improve  
the risk communication?
 • Did receivers of information  
feel empowered by the  
risk communication?
 • How has the risk  
communication contributed  
to future communications and 
opportunities for cooperation?
145Chapter 5 Conclusions                    
5.3 WHAT RESEARCH COULD BE DONE TO INFORM  
THE MEASUREMENT OF THE EFFECTIVENESS OF  
RISK COMMUNICATIONS?
It is clear that evaluations need to explore a range of outcomes to inform risk 
communication, across development, reach, use, and impact goals. While this 
is sometimes done for risk communication in general, there is a big gap in 
health product specific studies. Health product risk communication has unique 
challenges (e.g., multi-jurisdictional responsibility, the need for ongoing and 
incident(s)-based communication) that could provide valuable knowledge to 
the larger field of risk communication. Conducting health product specific 
studies more regularly in the future would build the evidence base and confirm 
whether the general learning from other relevant fields (e.g., decision science, 
public health evaluation) is indeed transferable. 
Evaluation is not simply about establishing metrics; often a detailed understanding 
of context and qualitative elements is needed. With this in mind, there are 
several gaps in the measurement of effectiveness, related to outcomes and 
indicator development, which could benefit from future research and guidance:
• Standardization and application: The evidence indicates that many complex 
ideas could be a part of a risk communication evaluation including shared 
decision-making, informed decision-making, empowerment, quality 
relationships, cooperation, trust, and credibility. However, the literature is 
unclear on the best ways for regulators to effectively measure these complex 
ideas in the case of health products and health product communication. 
There is also a need for further prioritization and standardization of these 
key concepts. Even in cases where standardization may be clearer, how to 
best operationalize and apply those concepts in the evaluation process is 
still a major challenge.
• Reliability and validity of indicators: Research demonstrates that even with 
concrete goals and a clear idea of relevant and meaningful outcomes, it may 
be difficult to collect indicators that are sufficient proxies for these outcomes. 
Indicators must be reliable to the extent that they consistently represent the 
same outcome when repeatedly used across different situations and over time. 
They must also be able to represent what they are intended to represent, and 
be precise, accurate, and comprehensive in scope. It appears that for many 
outcomes related to behavioural change, and to development, reach, use, 
and impact more generally, there is little consensus on which indicators are 
truly valid, reliable, and comprehensive over time, particularly in the context 
of health product risk communication.
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• Integration across disciplines: Multiple theories exist in the literature around 
how people make decisions in risky situations. Some literature attempts to 
combine the learning from these fields into evidence-informed communication 
practices; however, better measurement and integration of key concepts 
from across disciplines would ensure interdisciplinary learning and better 
communication and evaluation practices.
Across different evaluations, when measuring health product specific outcomes, 
those conducting the evaluation must work with a range of administrative data, 
and often with very personal health information. While new forms of media 
including Facebook, Twitter, and other forms of social media present new 
opportunities for communication and evaluation, they also create a wealth of 
new privacy concerns. Ethical standards relating to the use of big data, sharing 
of personal health information, and privacy can also vary across jurisdictions 
(e.g., in Canada across provinces and territories and among federal bodies). 
In the future clear ethical standards are needed to enable evaluations to use 
such information while maintaining individual privacy. This guidance must be 
dynamic and responsive to changes over time.
Similarly, further research is needed on practices for engaging the various 
populations that receive health product information and other relevant 
stakeholders, and in fostering transparency in both communication and 
evaluation. Future evaluation attempting to engage different groups would 
benefit from definitive research that explores how best to engage, when to 
engage, and who to engage in the context of health products specifically. 
Answers to these questions would enable those doing risk communication 
and evaluation to better empower the receivers of information and develop 
meaningful, long-lasting relationships. In addition, examining ways to share 
results to foster transparency and trust would improve the use of evaluation 
findings in decision-making. This is closely linked to the communication of 
uncertainty. Further research is needed on promising ways to communicate 
uncertainty, when it matters, and when it can be harmful.
5.4 WHAT ARE THE EXISTING BARRIERS TO EFFECTIVE RISK 
COMMUNICATIONS AND WHAT BEST PRACTICES EXIST 
TO ADDRESS THESE CHALLENGES?
Risk communication has evolved, from initial formulation as educating the 
public with accurate scientific information, to paternalistic persuasion, to 
a paradigm shift that recognizes ongoing partnership and exchange. All 
three views inform contemporary risk communication and demonstrate that 
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there is no one-size-fits-all approach to communication or its evaluation. 
Recognizing this diversity, evidence-informed practices related to effective risk 
communication typically involve:
• characterizing risk with larger context and population needs in mind;
• focusing on the importance of presentation and employing strategies for 
making information accessible and clear, accounting for literacy and numeracy, 
and addressing influence of framing effects, emotional responses, core values, 
and the ways that individuals process information;
• ensuring ongoing partnership and multi-level/multi-way communication 
that takes into account multiple concerns, factors, and needs at varying 
socio-economic levels; 
• committing to sustained communication and relationships that evolve and 
change when new information is available; 
• developing communications to be open, transparent, and honest about the 
level of (un)certainty and the evidence that is guiding decisions; and
• embedding evaluation in the planning and implementation of risk 
communication and not leaving it as an end-stage task.
Recognition of the importance of an ongoing and strong relationship between 
the senders and receivers of risk communication and other stakeholders has led 
to an emerging paradigm that builds on the learning from the past to address 
new challenges relevant for evaluation of health product risk communication: 
• Governance: addressing the challenges that stem from shared responsibility 
within the risk management and communication environment.
• Complexity: navigating the inherent complexities of the risk and the 
communication environment that comprises multiple players and priorities.
• Uncertainty: communicating uncertainty and multiple interpretations of 
the evidence.
• Empowerment: moving from providing prescriptive statements to enabling 
solutions and empowerment. 
• Timeliness: ensuring timely and proactive responses that build trust over time. 
• Transparency: ensuring reasoned transparency that increases the public’s 
access to and ability to understand health information.
The complicated governance around health products in Canada includes all 
three levels of government, industry, and many other groups. This shared 
responsibility for risk communication and evaluation demands establishing 
roles and responsibilities for the exchange of information, planning and 
coordination of communications, and strong relationships and cooperation 
between different senders and receivers of information and other stakeholders. 
It also means navigating the sometimes competing motivations of regulators 
and other groups. Depending on the nature of the situation, regulators 
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must facilitate cooperation and coordination between groups while at other 
times compel and act independently of those groups. Within such shared 
governance structures it can be challenging to gain institutional commitment and 
resources for evaluation. Factors that could address this key challenge include: 
(i) fostering a learning culture; (ii) demonstrating the value of evaluation relative 
to other spending priorities; (iii) standardizing communication appraisal tools 
and checklists to limit resources needed, improve comparability, and make 
evaluation more routine; and (iv) encouraging peer learning and sharing of 
experiences across jurisdictions.
Risk communication is an inherently complex exercise. Beyond the involvement 
of multiple players and mediums for communication that may play dual roles of 
sender and receiver of information at any given point, there are also inherent 
complexities associated with risk itself. This complexity stems from the hazards, 
the probabilities and uncertainties in the effects, the interactions between 
effects, and other political, ethical, economic, and social dimensions. The 
complicated environment for health product risk communication therefore 
requires coordination, collaboration, and ongoing dialogue between many 
different groups. Furthermore, the complexity associated with risks themselves 
needs to be considered and acknowledged when developing and disseminating 
risk communications.
Although there is sometimes debate about the best way to present uncertainty, 
it is an important consideration for any risk communication. It depends on the 
type of uncertainty and the objectives of the communication. Communicators 
must therefore distinguish the type of uncertainty associated with a given risk 
and present uncertainties in a manner that supports decision-making. Although 
further research is needed on best practices (i.e., when it matters and when it 
can be harmful), evidence suggests that communicating uncertainty can often 
help get the message through and build the trust and relationships needed 
for ongoing exchange. Improved evaluation can help reduce the challenges 
associated with uncertainty by creating a strong evidence base. Evaluations that 
integrate and use different data sets and methods would improve reliability 
and reduce uncertainty of the evidence. 
Empowerment of individuals to make informed decisions (i.e., to support 
existing behaviours in line with recommendations, to change behaviour, or to 
make an informed refusal) involves messaging appropriate for understanding 
and comprehension as well as for effective and meaningful dialogue. It is an 
important way to mitigate or avoid negative responses from populations receiving 
information. Within the context of communication this means collaborating 
with and empowering individuals, communities, and various affected groups 
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to act as platforms for further coordinated communication efforts. Within 
the context of evaluation, this involves engaging affected populations and 
other relevant stakeholders as members of the decision-making process at all 
stages of a continuous and ongoing evaluation process, thereby focusing on 
long-term relationships. Those sending and evaluating a risk communication 
must also respect informed individual decisions that may go against messaging. 
Empowerment during evaluation can help build strong relationships over time, 
which can support the proactive and timely delivery of future communications 
in the face of new risks.
While what is considered timely will be different for each risk communication 
situation, communicators can lay the groundwork to ensure that they are 
able to respond to risks quickly. Having clear guidelines and established 
relationships can enable organizations to act proactively in the face of new 
risks. In addition, using new communication sources such as social media to 
strengthen relationships and engage with affected populations can help set a 
strong foundation to deal with future risk situations. Similarly, the public and 
policy-makers around the world are increasingly recognizing the importance 
of transparency for governments, industry, and other communicators of risk. 
Reasoned transparency moves beyond simply releasing large amounts of data 
and increases the public’s ability to access and understand health information. 
It can build empowerment, trust, and relationships between the senders and 
receivers of information. When done effectively, it can also lay the groundwork 
for timely communication efforts by striking a balance between openness, on 
the one hand, and urgency and confidentiality, on the other.
5.5 FINAL REFLECTIONS
The evaluation of health product risk communication is rare. The complexities 
associated with health products, and the scarcity of dedicated resources, make this 
type of evaluation challenging. It is, however, no more difficult than the evaluation 
of other health interventions, which also have a unique set of challenges. That 
the Panel found a dearth of publicly available evaluations should not be taken 
as evidence that these evaluations lack real-world importance. In fact, failing 
to evaluate can be a dangerous oversight since ineffective communication 
may lead to negative health outcomes and erosion in the credibility and trust 
of those who communicate. Moreover, the lack of guidance and consensus 
does not diminish the need for evaluative efforts using available principles 
and knowledge. 
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Like other regulators and government institutions around the world, Health 
Canada has the opportunity to conduct and publicly release more evaluations 
on health product risk communication and to engage relevant stakeholders 
in the process. While this assessment has outlined a range of methods, some 
of which require significant time and resources, the Panel firmly believes 
that even a minimal evaluation can provide benefits. With commitment and 
sufficient resources, however, Health Canada could become a world leader in 
the area, conducting relevant, well-planned, comprehensive, systematic, and 
rigorous evaluations that apply appropriate and best available methods. A 
commitment to publicly accessible and publicly conducted evaluations would 
put Health Canada ahead of the curve on open government policy, which is 
an apparent global trend. Overall, the Panel believes that there is significant 
room for improvement in the volume and quality of evaluations on health 
product risk communication, conducted both in Canada and elsewhere. While 
there are numerous challenges, even when taken together, they are far from 
insurmountable. Evaluation can fundamentally improve the health of Canadians, 
now and in the future. Engaging in the challenges associated with evaluation 
is therefore worth the effort.
151Appendix A Relevant Evaluation Approaches for Health Product Risk Communication
Appendix A 
Relevant Evaluation Approaches for Health 
Product Risk Communication
152 Health Product Risk Communication: Is the Message Getting Through?
Appendix A   Relevant Evaluation Approaches for 
Health Product Risk Communication 
This appendix provides a basic overview of the types of knowledge gained, 
advantages, and challenges associated with key evaluation approaches, and 
their constituent methods. As Chapter 4 notes, the Panel categorized evaluation 
methods in five broad approaches: 
• Synthesis: Methods include literature reviews, systematic reviews, 
and meta-analyses.
• Records-based: Methods include textual, archival, and administrative 
data analysis.
• Self-reported data: Methods include interviews, focus groups, and 
population-based surveys.
• Experimental: Methods include quasi-experimental methods, natural 
experiments, and RCTs.
• Mixed methods: This involves combining quantitative and qualitative methods 
from different approaches in the same evaluation.
These approaches vary in complexity and in how data is collected and used 
(i.e., employing qualitative and quantitative methods). They also vary in the 
extent to which receivers of information and other stakeholders participate 
in data collection (e.g., self-reporting the effects of risk communication or 
acting as participants in a controlled RCT). The Panel organized the numerous 
available methods based on what they felt was feasible for regulators and other 
government institutions and relevant for health product risk communication. 
The list is therefore not meant to be exhaustive and there are numerous 
classification schemes in the literature that interested readers are encouraged 
to consultant (Fischhoff et al., 2011; HM Treasury, 2011; Owen, 2011; DFID, 2012; 
McDavid et al., 2013; Kreps, 2014; Lance et al., 2014; Web Center for Social 
Research Methods, n.d.). 
Synthesis Approaches 
A synthesis of the relevant literature enables the evaluation team to use previous 
research to provide valuable insight into the communication being evaluated 
(DFID, 2012; Dusetzina et al., 2012; Piening et al., 2012; Stacey et al., 2014). In 
general, a literature review consists of reviewing academic and grey literature for 
past research associated with a risk communication. This may suggest testable 
hypotheses, methodological challenges, and pertinent evaluation issues. Overall, 
a literature review is an economical and efficient way of collecting the initial 
evidence that can inform the development and implementation of an effective 
risk communication. Other more detailed methods include systematic reviews 
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and meta-analyses. While synthesis related methods can help provide the evidence 
about a given risk communication or its evaluation, it may not be relevant for a 
particular context given they are inherently retrospective.
Records-Based Approaches 
Records-based approaches consist of: textual, archival, and administrative data 
analysis. Textual analysis examines language, numbers, symbols and non-verbal 
cues through observational research methods (e.g., content analysis, rhetorical 
criticism, interaction analysis, discourse analysis) in order to describe and 
interpret the features of visual or auditory messages (Frey, 2000; Kreps, 2011). 
Evaluation using textual analysis is usually conducted with existing texts, such as 
archival records, books, newspapers, videos, and websites that are not produced, 
or inﬂuenced by the evaluation team (Hoff & Witt, 2000; Kreps, 2011). This 
implies that the data generated from textual analysis is unlikely to suffer from 
response bias (Kreps, 2011). Nonetheless, evaluations should carefully gather 
representative texts, and establish coding strategies that are valid and reliable 
(Frey, 2000; Kreps, 2011). 
Archival and administrative data analysis consists of using statistical tools to 
present and interpret data that are collected for and about a communication. 
An evaluation can review program files that provide information on scope 
and cost of the communication, characteristics of participants, outcomes of 
participants, and project management. A review of program files can provide 
valuable background data on the program design, context, and results, and offer 
a useful starting point for further data gathering. In some cases, the data needed 
to accurately evaluate may not be available or practical to collect. In emergency 
risk communication situations, for example, the communication and its success 
depend on the rapidity of disseminating the message, precluding the ability to 
collect baseline data from participants, and limiting the choice of indicators to 
assess its effectiveness (Interagency Task Force on Environmental Cancer and 
Heart and Lung Disease, 1991). Policies that limit an organization’s ability to gather 
information from the public may also be a barrier to collecting data (Interagency 
Task Force on Environmental Cancer and Heart and Lung Disease, 1991). This 
is an issue of particular relevance in the health field, as sensitive patient health 
data are confidential and may be made available only in certain circumstances, 
constraining the data available for evaluations (CCA, 2015). Finally, there may 
also be uncertainty in the data or incomplete datasets as a result of constraints 
in the data collection mechanism.
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Self-Reported Data Approaches 
Self-reported data approaches consist of population-based surveys (which can be 
qualitative or quantitative), focus groups, and interviews. Surveys are a systematic 
way of collecting data on the attitudes, beliefs, and activities of varying populations 
at various time points in a risk communication. There are several types of 
surveys described in the literature, including face-to-face and telephone-based 
interviews, and paper-and-pencil and computer-delivered questionnaires. The use 
of computer-assisted telephone interviewing equipment (CATI) provides access 
to populations over a large geographical area, and helps to automate entry and 
analysis of data (Kreps, 2011). However, diminishing response rates to telephone 
surveys threaten the representativeness of data gathered (U.S. Cancer Statistics 
Working Group, 2004 as cited in Kreps, 2011).
Focus groups (and qualitative methods generally) do not strive for reliability 
in the manner of quantitative research, but rather are more concerned with 
questions of validity (King et al., 2004; Ulin et al., 2004). Although this typically 
involves fewer participants, a major advantage of well-conducted focus groups is 
that they generate rich in-depth data by providing a context in which the claims 
people make about various issues, topics, or events (risk related or otherwise) 
are challenged and shaped collectively. This better represents the social and 
interactional ways through which people come to make sense of risks in their 
lives. Individual interviews provide the best mechanisms for eliciting a rich, deep 
understanding because there are better opportunities for exploring nuances in 
a more fulsome way, but the trade-off is that even fewer people can be engaged 
and it loses the socially contingent nature of how people make sense of risk 
issues. Surveys, by comparison do not necessarily probe the social dimensions 
of risk decision-making nor provide the deep contextual understanding of focus 
groups and individual interviews. The advantage of surveys however is that they 
often reach a greater number of participants and can be representative of a 
larger group of perspectives; although, these data tend to be fairly superficial 
and often do not explain why people respond the way they do. Surveys require 
samples to be more carefully constructed than focus groups and individual 
interviews, particularly if it is aiming for a random representative sample as 
opposed to a purposive sample. All of these different data collection methods 
involve significant human resources and complex data analysis, although the 
resource intensity and analysis complexity can vary depending on the needs of 
those conducting the evaluation.
Experimental Approaches 
Experimental approaches assign participants to a treatment or control group. 
In principle, the only difference between these two groups should be the 
communication (TBS, 1998; Gertler et al., 2011). These approaches typically 
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measure both the baseline and the final outcomes, ultimately seeking to show 
a causal link between the communication and its outcomes. One such method, 
RCTs, are very popular in impact measurement studies in international public 
health interventions (Gertler et al., 2011; DFID, 2012) and elsewhere (CCA, 2013). 
In practice, it is difficult to create perfect equivalence between the treatment and 
control group given there are always some differences because of natural variation 
among participants (Cartwright & Munro, 2010). Three types of randomized 
control group designs are discussed in the literature. Classical randomized 
comparison groups consist of randomly assigning participants to treatment 
and control groups and taking measurements before and after the intervention 
(TBS, 1998; Shadish et al., 2002). Post-program randomized comparison groups 
also consist of randomly assigning participants to treatment and control groups; 
however, measurements are taken only after the intervention. While this minimizes 
testing bias, there may be differences between treatment and control groups 
before the intervention. Lastly, randomized block and Latin square entails 
dividing the population into treatment and control groups by at least one control 
variable that is expected to influence the impact of the intervention (e.g., gender, 
urban-rural) (TBS, 1998). This approach can be used for small samples, but 
there is the possibility of selection bias (Shadish et al., 2002).
Quasi-experimental methods use comparison groups to make causal inferences; 
however, unlike RCTs, they do not use randomization to create treatment and 
control groups (Grimshaw et al., 2000; Shadish et al., 2002; Gertler et al., 2011; DFID, 
2012; CCA, 2013; Penfold & Zhang, 2013). Instead they use statistical approaches 
to create a control group that matches the treatment group as much as possible. 
Two quasi-experimental methods are discussed here: matching estimation and 
regression discontinuity design (RDD). Matching estimation finds non-participants 
that are statistically similar enough to participations to create a reliable control 
group using information on individual characteristics (e.g., demographic, socio-
economic, cultural) (Gertler et al., 2011). This technique can be used to evaluate 
almost many different kinds of interventions including risk communications 
(Dehejia & Sadek, 1999); however data requirements are significant (Todd, 2008). 
RDD ranks individuals according to criteria, usually individual characteristics, 
and uses a threshold to create a control group (Gertler et al., 2011; CCA, 2013). 
It is assumed that around this threshold, individuals have enough similarity that 
it mimics randomization.
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Natural experiments require capturing the experience of implementing a risk 
communication that affects some individuals but not others (Gertler et al., 2011; 
Craig et al., 2012; DFID, 2012). For instance, it could involve monitoring the 
experience of implementing a similar risk communication in two communities 
that differ from one another or it could involve capturing how two different 
communications compare if implemented in similar communities. Natural 
experiments therefore do not control what groups get what communications, or in 
other words, there is no random assignment. In many cases, the communication 
affects only a sub-group of individuals (Gertler et al., 2011; CCA, 2013). 
Mixed Methods Approaches 
No single approach or method can answer all evaluation questions and each will 
have their own particular strengths, weakness, and knowledge gained (DFID, 2012). 
Mixed methods refers to combining several of the methodological tools described 
in this section (that are both quantitative and qualitative) in the same evaluation 
(King et al., 2004; Ulin et al., 2004; Lieberman, 2005; Creswell & Clark, 2010). 
Mixed methods is an extremely relevant approach when evaluating complex 
health interventions and risk communications because it combines two or 
more of the other methods (e.g., RCT and survey, textual analysis and focus 
groups) therefore providing the greatest range and diversity of evidence. When 
the evidence collected from different approaches is consistent, confidence in 
the findings increases. When the evidence is inconsistent across the different 
approaches, this helps identify gaps and sources of error in the evaluation. Mixed 
methods evaluation can create a more comprehensive picture of the influence 
of a communication on subsequent outcomes over time. 
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